Application Process

Graduate Studies in Pathology at UBC

Get ready to change the future. Through the Department of Pathology & Laboratory Medicine Graduate Program you’ll be immersed in a world of discovery and opportunity . By working and studying with our esteemed faculty, grad students at UBC make a real difference in the world.

The training and experience you’ll acquire at the master’s or doctoral level will give you tools to drive change and excel in virtually any industry—whether you go on to teach and do research at a university, take a role in government, start a private enterprise, or embark on a professional career. Our research-driven graduate programs will help guide you through a lifetime of intellectual study, opportunity, and challenge.

APPLY NOW!

Congratulations to the Recipients of the 2024 Graduate Program Awards!

Student Supervisor Award(s)
Portrait photo of Cyril Helbling Cyril Helbling Mari DeMarco Four Year Fellowship
Michael Lane David Granville Four Year Fellowship
Hesam Karimi Qezeljeh Meydan Honglin Luo Four Year Fellowship
Portrait photo of Mohammad Ghodsi Mohammad Ghodsi Cheryl Wellington BC Graduate Student Award

PALM Alumni Reunion May 16, 2024

You’re Invited! Mingle and reconnect at the UBC PALM Graduate Program Alumni Reunion – May 16th

Our Graduate Studies Program and UBC Faculty of Medicine Alumni Engagement are excited to invite you to the PALM Graduate Program Alumni Reunion! Alumni, current graduate students, faculty and staff of the PALM Graduate Program are all welcome to attend this engaging evening filled with networking, discussions, and reconnection with former colleagues and mentors.

Don’t miss out on this evening of delicious food, reuniting with familiar faces, and making new connections! We currently have over 52 registrants – Register now!

Date: Thursday, May 16, 2024
Time: 5:30 – 7:30 pm
Location: UBC Medical Student & Alumni Centre – 2750 Heather St., Vancouver, BC
Cost (includes all food and one beverage): $20.00 Alumni/Faculty/Staff/Guests

Registration is free for current PALM Graduate Students!

We will show the Hockey Game at 7pm.

This venue is situated on the unceded ancestral territories of the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and səlilwətaɬ (Tsleil-Waututh) Nations.

Thank you to the 2024 Alumni Program Partners MNP LLP & Scotiabank Healthcare+

Welcome 2024 PALM Graduate Students!

Student Photo StudentSupervisorProgramBio
Alana BarrettoDr. Ramon Klein GeltinkPhDMy name is Alana Barretto and I’ve just started my first year in the PhD program at the Klein Geltink laboratory. I am currently looking at metabolic pathways and T cell therapy to improve tumour infiltration and T cell function to better treat pediatric cancer. I previously did my masters at National Taiwan University where I studied cancer immunology and the effects of GABA on the peripheral nervous system to reduce cancer formation in the pre-tumour environment. In the future I hope to be able to continue working in the research field because I am really interested in everything that I have studied and I love the busy lab environment. I choose UBC because my childhood dog lives in Vancouver and I was really interested in joining my current lab to learn more about T cell functions.
Aakar ChathaDr. Ying WangMScMy name is Aakar and I am a Master’s student in Pathology and Laboratory Medicine joining the Wang Lab at St Paul’s Hospital. I graduated from the University of British Columbia with a Bachelors of Science in a combined major in chemistry and biology. After my undergrad, I worked in administration at Vancouverr General Hospital for two years before joining the PALM Master’s program. I am researching the effect of shear stress on blood vessels and how different layers interact when exposed to shear stress of blood. As for my professional interests, I’d like to keep my options open but I intended to apply to medical school after completing my Master’s or pursue a PhD if I enjoy what I am doing! Outside of school, I enjoy playing badminton and competing provincially. I chose to apply to UBC because I live in Vancouver and enjoyed my undergraduate experience at UBC. Furthermore, the department of PALM is very well established and I believe I can gain a lot of experience through working with researchers and professors in this department.
Jesse ChiuDr. Jay KizhakkedathuPhDI chose UBC for my Ph.D. studies because of its global reputation for excellence in teaching and research. UBC’s high academic standards and commitment to cutting-edge research align perfectly with my goals. Additionally, the quality of education in Canada and the forward-looking environment in Vancouver make it an ideal place for my professional and personal growth. I earned my Master’s degree from National Taiwan University, where I studied the interaction between proteins and mRNA during the translational stage using single-molecule techniques. My passion lies in discovering new treatments for illnesses that can positively impact human health. This passion led me to join Dr. Kizhakkedathu’s lab for my Ph.D., where I will focus on researching immune complex destabilizing polyanion-binding inhibitors for the prevention and treatment of HIT.
Fabian FrontzekDr. Christian SteidlPhDI come from a smaller city in the Western part of Germany in North Rhine-Westphalia. From 2009 to 2016 I studied medicine at the University of Muenster. Afterwards, I started my training in Internal Medicine, Hematology, and Oncology at the University Hospital in Muenster where I had the great opportunity to combine my clinical training with basic research in the field of aggressive lymphomas. My previous work as translational clinician scientist focused in particular on the molecular characterization of aggressive lymphoma subtypes to contribute to a better molecular understanding of disease and to finally unravel potential novel therapeutic targets. The PhD program in Pathology and Laboratory Medicine at UBC will allow me to pursue the molecular characterization of specific aggressive B-cell lymphoma subtypes in a world-leading scientific environment at the Centre for Lymphoid Cancer (CLC) in Vancouver. In the working group of my supervisor Professor Dr. Steidl, novel sophisticated techniques are applied and will allow me to become proficient in relevant state-of-the art methodologies at the highest level. In my free time I enjoy hiking, paddle boarding, and exploring the area around Vancouver.
Craig IvanyDr. Lucy PerronePhDA Laboratory services strategist with over 37 years of experience influencing healthcare. My depth of practice includes leadership across Canada, including executive roles with DynaLIFE Alberta, Dynacare Ontario, Eastern Ontario Regional Laboratory Association, Alberta Precision Laboratories, and Provincial Laboratory Medicine Services British Columbia. I am a Certified Health Executive with the Canadian College of Health Leaders, hold an ICD.D with the Institute of Corporate Directors, and am an Adjunct Professor, Dept. of Pathology and Laboratory Medicine, University of British Columba.
My academic interests in health services research are rooted in my exposure to the academic perspective of laboratory medicine services which emerged during my career and was focused most importantly, by the privilege of serving as an Adjunct Professor in our department.
The objective of my research is to investigate, identify, evaluate, and understand the underlying operating model conditions and the effectiveness of the provincial integrative efforts in aligning the multiple interests of laboratory operators to advance system-level objectives.
UBC is a natural fit for me, beyond my affiliations with the Department and the local healthcare community, UBC is a place of innovation and embraces those who want to explore ideas and concepts that transform and build the future.
Hesam Karimi Qezeljeh MeydanDr. Honglin LuoPhDI’m Hesam Karimi, a PhD student in the Luo lab, diving deep into the world of cancer treatment through oncolytic viruses and cutting-edge vaccine development. I hold a bachelor’s in biology and a master’s in medical virology, with over five years of hands-on experience as a technical manager in virology labs.
When I’m not in the lab, you’ll probably find me out in nature—whether it’s trekking up mountains, playing football or tennis, or getting lost in a good book, a movie, or even the kitchen.
My passion lies in finding innovative ways to treat cancer, and I believe harnessing the power of oncolytic viruses and creating effective vaccines is key. That’s why I chose to pursue a PhD in Pathology and Laboratory Medicine at UBC, one of Canada’s top research medical universities.
At UBC, I’m excited to work alongside world-renowned faculty members in a top-ranked institution, where I believe I can sharpen my research skills and make significant strides in the fight against cancer. My goal is to emerge as a standout researcher, ready to contribute to groundbreaking advancements in this critical field.
Ethan KenmuirDr. Natalie PrystajeckyMScHello, my name is Ethan Kenmuir. I’m a Master’s student in the Prystajecky Lab at the BC CDC. My project aims to investigate amplicon-based sequencing approaches for the genetic characterization of large DNA viruses. Specifically, I’m working on the genetic characterization of Infectious Laryngotracheitis virus in poultry as part of a collaborative One Health project with the Ministry of Agriculture.
 I completed my BSc in Biochemistry at the University of Victoria where I researched molecular diagnostic techniques to enhance routine necropsies at the Plant and Animal Health Centre with the Ministry of Agriculture. I believe that using plant, animal and environmental samples provides valuable insights into the study disease transmission and control.
 I’m interested in continuing to gain more experience using next-generation sequencing techniques to further contribute to the study of disease prevention and control. When I’m not in the lab I enjoy reading, cooking and staying active (preferable outside, weather permitting). I chose to study at UBC because of the resources available and the diverse research opportunities they offer.
Cecilia LeeDr. Christian SteidlMScHello! My name is Cecilia, and I will be working on uncovering molecular mechanisms driving B cell lymphoma pathogenesis under the supervision of Dr. Christian Steidl at the BC Cancer Research Institute. I hold a BSc from UBC in Integrated Sciences, where I studied Genetics and Physiology. During my undergraduate degree, I had the opportunity to work in the Center for Lymphoid Cancers through a Directed Studies project. This sparked my interest in lymphoma research, and the incredible training environment at the CLC inspired me to return here for graduate studies. Having gone to UBC for my undergraduate degree, the world-class researchers, state-of-the-art facilities, and supportive teaching that I experienced made it a very easy decision to come back to for my MSc. When I’m not in the lab, I enjoy looking through bookstores, going to the gym or grabbing delicious food (there is plenty on West Broadway)! I look forward to meeting new people and learning lots of cool science in the coming years.
Zoe LofftAngela DevlinPhD
(Transfer)
I study how high levels of the B vitamin folate, and its synthetic form folic acid, affect the function and development of insulin-producing cells in the pancreas. 
Before coming to UBC, I completed my Master of Science at the University of Toronto in Dr. Elena Comelli’s Food and Gut Microbiome Lab. I studied how a polyphenol in the skin of cranberries, and its gut-derived microbial metabolites, affect the expression of microRNAs in the intestine, then predicted their functional implications using computational bioinformatics. Before that, I did my undergraduate degree in Health Sciences and Nutrition at Western University (London, Ontario).
When I am not in the lab, I enjoy being outside hiking, skiing, and road biking. I am also an avid reader and frequent visitor of the Vancouver Public Library. After graduating, I hope to explore roles in the biotech industry.
I chose UBC because I wanted to gain more perspectives by studying at a different university than where I did my MSc that also had a highly regarded reputation for research. Dr. Angela Devlin’s research platform stood out to me due to my background in studying molecular mechanisms in nutrition. 
Asha SubramaniamWill LockwoodMScMy name is Asha Subramaniam. I just moved from Toronto to Vancouver to start my Master’s in Pathology and Laboratory Medicine. I will be conducting my research in the Lockwood lab, where my project focus will be on exploring integrative strategies directed towards lung cancer biology. I completed my Bachelor’s of Health Science in Biochemistry and Biomedical Sciences with a Research Specialization and Concurrent Certificate in Immunology, Microbiology and Virology at McMaster University. My previous research projects have focused on infectious diseases and antimicrobial resistance. I studied the molecular mechanism of Ku-mediated DNA double strand break repair by LigD in Pseudomonas aeruginosa and Mycobacterium tuberculosis in order to inform the development of novel antibiotics against multi-drug resistant bacteria. My long-term goals are to complete my graduate studies in preparation for a career in academia. I chose UBC for the opportunity to conduct research with the BC Cancer Research Institute. Outside of research I enjoy swimming, playing piano and I am trying to get into hiking. I have always lived in Ontario and thought a move out to the west coast would be a life experience. Just need to buy a good raincoat now!
Abbey Sugars-KeenEd ConwayMScI’m thrilled to be joining Dr. Edward Conway’s lab at the Centre for Blood Research, where I will be exploring the interconnections between blood coagulation and insulin resistance in type II diabetes and obesity. My research will build on previous work at the lab showing the tissue factor-mediated cross talk between these two pathways. Having completed my undergrad in biomedical sciences at the University of Ottawa, I am so excited to be moving out here to the west coast to explore all that grad school has to offer! Outside of my studies, my hobbies range from voracious bibliophile (I’ll read just about anything I can get my hands on!) to amateur thespian and classical music nerd. I also enjoy trail running and am looking forward to getting more into hiking here in BC. Besides its reputation as an excellent institution for education and research, one of the many reasons why I chose UBC is the beautiful nature and scenery it has to offer. I can’t wait to meet my fellow students in the program and discover the graduate student experience!
Grace (Longyijie) WeiDavid HuntsmanMScI am a Master of Pathology and Laboratory Medicine student at the University of British Columbia (UBC), with a deep interest in the molecular mechanisms driving cancer progression, particularly ovarian cancer. My research focuses on understanding how microenvironments influence ovarian cancer, with the ultimate goal of improving prognosis, treatment, and early detection. I previously earned a Bachelor of Science at UBC, majoring in Biochemistry and Chemistry, which provided a strong foundation for my current research.
My academic journey has been enriched by hands-on research experiences at institutions like the British Columbia Cancer Research Center and Lanzhou University, where I explored the roles of key enzymes in cancer progression. These experiences have fueled my passion for cancer research and inspired me to pursue further study in this field.
I chose UBC for its vibrant research community, the opportunity to collaborate with leading experts, and the beautiful, inspiring environment the campus offers. Additionally, I believe UBC’s strong faculty and comprehensive training will equip me to make meaningful contributions to cancer research and help me develop a clear path for my future career.
Jenny ZhaoLeandro VenturuttiMScMy name is Jenny Zhao and I am a MSc. student in Dr. Leandro Venturutti’s lab at BC Cancer, studying the pathogenesis of Diffuse Large B-cell Lymphoma. I am working on uncovering the determinants granting malignant B cells to acquire loss-of-function mutations in TMEM30A , a gene that encodes a subunit of membrane phospholipid transporters. I hold a Bachelor’s degree in Pharmaceutical Sciences from UBC, where I studied drug development, drug delivery and pharmacoepidemiology to name a few. Throughout my undergraduate degree, I have worked in academic labs in the areas of solid and liquid tumours as well as in atopic diseases. I also have experience in the private sector, having interned at a biotechnology company to develop rapid infectious disease test kits. With a profound interest in the pathogenesis of immune malignancies, I look forward to honing my expertise in this field during my graduate studies in the Pathology and Laboratory Medicine graduate program. Ultimately, I aspire to work in the therapeutic development space and transform the current landscape of cancer treatments. UBC as an institution housing world-renowned faculty and alumni to connect and collaborate with provides an enriching space for me to grow as a scientist.

Congratulations to the 2024 Graduates in Pathology & Laboratory Medicine!

  Student Degree Thesis/Dissertation Title
Moones Yadegari MSc Developing a platform to monitor and target cancer-specific cell surface proteoforms
Danilo Tali Gordon Romero MSc Association between neurological blood biomarkers with baseline neuroimaging and cognitive assessments in adults with moderate to severe congenital heart disease
Josie Setiawan MSc Mutation of tryptophan residues in the binding site of novel therapeutics for prostate cancer
Lauren Denault MSc The role of cysteine residues in the binding of novel therapeutics for prostate cancer
Raneen Abdul-Rahman MSc Characterizing the neuronal expression of neuronal PAS-domain containing protein 4 and aryl hydrocarbon receptor nuclear translocator 2 in multiple sclerosis related inflammatory settings in vitro
Sau Ching Honor Cheung MSc Using light sheet microscopy to investigate the role of apolipoprotein e4 in traumatic vascular injury
Madeline Lauener PhD Characterization and expansion of regulatory natural killer cells for the therapy of chronic graft-versus-host disease
Emel Islamzada PhD Deformability based cell sorting enabling quality control of donated red blood cells
Marie-Soleil Rouleau Smith PhD Cellular and mitochondrial toxicity of integrase strand transfer inhibitors in human embryonic stem cell models
Yu Li PhD Functional characterization of recurrent mutations in the NF-κB and JAK-STAT signaling pathways in B cell lymphomas
Tseday Zewdu Tegegn PhD Mechanisms of dengue virus-mediated thrombocytopenia through virus-encoded protein synthesis and induction of selective host proteins in megakaryocytes and platelets
Amirhossein Bahreyni PhD Development of a safe treatment for breast cancer using an oncolytic Coxsackievirus B3
Li Ling PhD Integrin alpha6 mediates the invasion and metastasis of breast cancer cells

Zhao, Jenny

Zhao, Jenny

Degree Program:

MSc

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

BCCRC

Supervisor:

Leandro Venturutti

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Wei, Grace

Wei, Grace

Degree Program:

MSc

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

BCCRC

Supervisor:

David Huntsman

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Sugars-Keen, Abbey

Sugars-Keen, Abbey

Degree Program:

MSc

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

UBC

Supervisor:

Ed Conway

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Subramaniam, Asha

Subramaniam, Asha

Degree Program:

MSc

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

BCCRC

Supervisor:

Will Lockwood

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Lofft, Zoe

Lofft, Zoe

Degree Program:

PhD

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

BCCHRI

Supervisor:

Angela Devlin

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Lee, Cecilia

Lee, Cecilia

Degree Program:

MSc

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

BCCRC

Supervisor:

Christian Steidl

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Karimi Qezeljeh Meydan, Hesam

Karimi Qezeljeh Meydan, Hesam

Degree Program:

PhD

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

St. Paul’s Hospital

Supervisor:

Honglin Luo

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Ivany, Craig

Ivany, Craig

Degree Program:

PhD

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

UBC

Supervisor:

Lucy Perrone

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Frontzek, Fabian

Frontzek, Fabian

Degree Program:

PhD

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

BCCRC

Supervisor:

Christian Steidl

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Dehghani, Zahra

Dehghani, Zahra

Degree Program:

PhD

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

VGH

Supervisor:

David Granville

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Chiu, Jesse

Chiu, Jesse

Degree Program:

PhD

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

UBC

Supervisor:

Jay Kizhakkedathu

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Chatha, Aakar

Chatha, Aakar

Degree Program:

MSc

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

St. Paul’s Hospital

Supervisor:

Ying Wang

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Barretto, Alana

Barretto, Alana

Degree Program:

PhD

Date of Entry:

2024-05-01

e-mail:

Basic Info
OpenClose

Location:

BCCHRI

Supervisor:

Ramon Klein Geltink

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Kenmuir, Ethan

Kenmuir, Ethan

Degree Program:

MSc

Date of Entry:

2024-09-03

e-mail:

Basic Info
OpenClose

Location:

VGH (BCCDC)

Supervisor:

Natalie Pryztajecky

Short Bio

Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Congratulations to the Recipients of the 2024 CIHR and Affiliated Awards!

  Student Supervisor Award(s)
Razieh Sadat Banijamali Dr. Honglin Luo Vanier Canada Scholarship
Lucy Li Dr. David Huntsman CIHR Masters Award
Kidus Achalu Dr. Cheryl Wellington CIHR Masters Award
Abbey Sugars-Keen Dr. Ed Conway CIHR Masters Award
Vivian Zhu Dr. Jacqueline Quandt Guenter and Cordula Paetzold Affiliated Award

Venturutti, Leandro

Dr.

Venturutti, Leandro

PhD

e-mail:

lventurutti@bccrc.ca

Lab Website

Basic Info
OpenClose

Academic Rank:

Associate Professor

Affiliation(s):

BC Cancer Agency

Location:

BC Cancer Research Institute

Short Bio

Dr. Leandro Venturutti began his scientific career at the Faculty of Pharmacy and Biochemistry (University of Buenos Aires, Argentina), where he studied the structure and function of a protein lost in the hereditary neurodegenerative disease Friedreich Ataxia. Pursuing his profound interest in biomedical sciences and mechanisms of disease, he moved on to the cancer research field for his PhD studies. He devoted a significant part of his thesis work to exploring pathways of metastatic dissemination, identifying clinically useful predictive biomarkers, and developing novel therapeutic tools for breast and gastric tumors. Dr Venturutti completed his training working as a postdoctoral researcher at the Division of Hematology and Oncology (Weill Cornell Medicine, USA), where he investigated how recurrent mutations in aggressive B-cell lymphomas alter the epigenome and contribute to the early stages of malignant transformation.
Dr. Venturutti was recruited to the BC Cancer Research Institute in 2021 to start his own research group. His goals are to identify and understand the mechanisms driving the progression and dissemination of B-cell lymphomas, as a means to develop minimally invasive diagnostic tools, and novel prophylactic and curative treatments. His group exploits modern high-parameter technologies to study clinical specimens and develops sophisticated models of disease to tackle profound biological questions with great translational potential.

Academic
OpenClose

Academic Backgrounds

  • Postdoctoral Associate in Medicine, Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, USA
  • Ph.D., Biological Chemistry, Faculty of Natural and Exact Sciences, University of Buenos Aires, Buenos Aires, Argentina
  • B.Sc., Biotechnology and Molecular Genetics, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina.
     

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Cancer research
  • Solid tumour microenvironment
  • Hypoxia
  • Metastasis research
  • Pre-metastatic niche
  • Targeting hypoxic tumour cells in therapy
  • Radiation biology
  • 2013-present, National Mentor, The Terry Fox Foundation Strategic Initiative for Excellence in Radiation Research for the 21st Century (EIRR21) at CIHR.
  • This integrated Radiation Medicine training program for graduate students and post-doctoral fellows is based out of the University of Toronto, with 32 “local” mentors from Toronto, 3 national mentors from across Canada, and 3 international mentors. I am the national mentor representing the province of British Columbia.
Cancer
Teaching
OpenClose

Teaching

Zhu, Vivian (Yuchan)

Zhu, Vivian (Yuchan)

Degree Program:

MSc

Date of Entry:

2023-09-05

e-mail:

Basic Info
OpenClose

Location:

UBC (UBC Hospital)

Supervisor:

Jacqueline Quandt

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Zama, Julliet

Zama, Julliet

Degree Program:

MSc

Date of Entry:

2023-07-04

e-mail:

Basic Info
OpenClose

Location:

UBC (UBC Hospital)

Supervisor:

Helene Cote

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Wu Wu, Fabiola

Wu Wu, Fabiola

Degree Program:

MSc

Date of Entry:

2023-09-05

e-mail:

Basic Info
OpenClose

Location:

BCCH (BC Children’s Hospital Research Institute)

Supervisor:

Kirk Schultz

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Wang, Zhihan

Wang, Zhihan

Degree Program:

MSc

Date of Entry:

2023-09-05

e-mail:

Basic Info
OpenClose

Location:

SPH (Centre for Heart Lung Innovation)

Supervisor:

Honglin Luo

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Piradi Rad, Amir Parham

Piradi Rad, Amir Parham

Degree Program:

MSc

Date of Entry:

2023-09-05

e-mail:

Basic Info
OpenClose

Location:

VGH (iCORD)

Supervisor:

Babak Shadgan

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Nouri Zadeh, Armin (Mehdi)

Nouri Zadeh, Armin (Mehdi)

Degree Program:

MSc

Date of Entry:

2023-01-03

e-mail:

Basic Info
OpenClose

Location:

VGH (iCORD)

Supervisor:

Babak Shadgan/Kishore Mulpuri

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Lin, Bob (Peisi)

Lin, Bob (Peisi)

Degree Program:

MSc

Date of Entry:

2023-09-05

e-mail:

Basic Info
OpenClose

Location:

SPH (Centre for Heart Lung Innovation)

Supervisor:

Honglin Luo

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Li, Lucy (Yuqin)

Li, Lucy (Yuqin)

Degree Program:

MSc

Date of Entry:

2023-09-05

e-mail:

Basic Info
OpenClose

Location:

VGH (BC Cancer Research Centre)

Supervisor:

David Huntsman

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Golesorkhi, Parisa

Golesorkhi, Parisa

Degree Program:

MSc

Date of Entry:

2023-01-03

e-mail:

Basic Info
OpenClose

Location:

UBC (Centre for Blood Research)

Supervisor:

Dana Devine, Jay Kizhakkedathu

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Cheng, Melody (Wan Hei)

Cheng, Melody (Wan Hei)

Degree Program:

MSc

Date of Entry:

2023-09-05

e-mail:

Basic Info
OpenClose

Location:

SPH (Centre for Heart Lung Innovation)

Supervisor:

Ying Wang

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Byrne, Liam

Byrne, Liam

Degree Program:

MSc

Date of Entry:

2023-05-01

e-mail:

Basic Info
OpenClose

Location:

Vancouver General Hospital (BCCDC)

Supervisor:

Natalie Prystajecky

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Banijamali, Razieh Sadat

Banijamali, Razieh Sadat

Degree Program:

PhD

Date of Entry:

2023-09-05

e-mail:

Basic Info
OpenClose

Location:

SPH (Centre for Heart Lung Innovation)

Supervisor:

Honglin Luo

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Achalu, Kidus

Achalu, Kidus

Degree Program:

MSc

Date of Entry:

2023-09-05

e-mail:

Basic Info
OpenClose

Location:

UBC (Djavad Mowafaghian Centre for Brain Research)

Supervisor:

Cheryl Wellington

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Anwer, Mehwish

Anwer, Mehwish

Degree:

PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Postdoctoral Fellow

Affiliation(s):

Djavad Mowafaghian Centre for Brain Health

Location:

UBC

Supervisor:

Cheryl Wellington

Short Bio

Hello everyone! I joined the Wellington lab for my Postdoctoral fellowship in January 2021 where I am investigating the aftermath of Traumatic brain injury using techniques such as tissue clearing (making brains transparent!). I have completed my PhD (in March 2020) from University of Eastern Finland through the Marie Curie PhD Fellowship awarded by the European Union. My research interest includes studying Brain and Spinal cord injury using new methods (tissue clearing and spatial transcriptomics) to answer longstanding questions. In my free time, I like to paint and go on long drives with my husband to enjoy the beautiful scenery in BC.

Academic
OpenClose

Academic Backgrounds

PhD Molecular Medicine – University of Eastern Finland (2020)

Mphil Molecular Medicine

MSc Molecular Medicine

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

I am investigating the aftermath of Traumatic brain injury using techniques such as tissue clearing (making brains transparent!).

Teaching
OpenClose

Teaching

Cheng, Wai Hang (Tom)

Cheng, Wai Hang (Tom)

Degree:

PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Postdoctoral Fellow

Affiliation(s):

Location:

UBC

Supervisor:

Cheryl Wellington

Short Bio

Academic
OpenClose

Academic Backgrounds

PhD – University of British Columbia (2018)

MPhil – Biochemistry, Chinese University of Hong Kong (2009)

BSc (Hons)– Biochemistry, Chinese University of Hong Kong (2007)

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

My research focus is on studying the relationship between traumatic brain injury and neurodegenerative diseases. By using pre-clinical models, we study how traumatic brain injury can trigger neuroinflammation, axonal injury, and protein aggregation.

Teaching
OpenClose

Teaching

Kulka, Michaël

Kulka, Michaël

Degree:

PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Postdoctoral Fellow

Affiliation(s):

Location:

UBC

Supervisor:

Jayachandran Kizhakkedathu

Short Bio

I studied chemistry (BSc. and MSc.) at the Radboud University in Nijmegen (The Netherlands). In my bachelor thesis I worked on the total synthesis of ladderane molecules, in my master thesis I worked on an attrition-enhanced deracemization method for the enantiopure synthesis of pharmaceutically relevant isoindolinones. After my MSc. I started my PhD in the Haag group at the Free University of Berlin. Here I focussed on the development of linear polyglycerol-based antifouling coatings for the prevention of biomaterial-induced thrombosis in ventricular assist devices. My PhD work was in collaboration with Berlin Heart GmbH, which is one of the world leading producers of ventricular assist devices. During my PhD I got acquainted with polymer synthesis and material science characterization methods. After my PhD, I worked at Celares GmbH in Berlin, which is a small privately owned company that mainly focuses on the development of antibody-drug-conjugates. Here I was responsible for the GMP-like development of PEG-based dendrimers for the coupling of small molecules to antibodies. After one year, I decided to join the Kizhakkedathu group at UBC, to start a project in collaboration with Avivo Biomedical Inc. In my current project, I focus on the development of hemocompatible enzyme-capturing filter materials for the creation of universal blood. My core expertises; small molecule synthesis, polymer synthesis, material characterization, and the development of hemocompatible materials.

Academic
OpenClose

Academic Backgrounds

PhD – Free University of Berlin, Germany

MSc Chemistry – Radboud University, Nijmegen, Netherlands

BSc Chemistry – Radboud University, Nijmegen, Netherlands

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

In my current project, I focus on the development of hemocompatible enzyme-capturing filter materials for the creation of universal blood. 

Teaching
OpenClose

Teaching

Barnabas, Georgina D.

Barnabas, Georgina D.

Degree:

PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Postdoctoral Fellow

Affiliation(s):

Location:

BCCHR

Supervisor:

Philipp Lange

Short Bio

Academic
OpenClose

Academic Backgrounds

PhD Cancer Proteomics – Tel Aviv University

MSc integrated in Biomedical Sciences – Bharathidasan University

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Aiming to identify biomarkers for precision therapies using quantitative proteome profiling in pediatric leukemias and neuroblastoma

Teaching
OpenClose

Teaching

Ji, Haifeng

Ji, Haifeng

Degree:

PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Postdoctoral Fellow

Affiliation(s):

Location:

UBC

Supervisor:

Jayachandran Kizhakkedathu

Short Bio

Academic
OpenClose

Academic Backgrounds

PhD – Sichuan University, Chengdu, China (Jointly trained at UBC from 2019-2021)

BSc – Sichuan University, Chengdu, China

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

My research focuses on the behavior of proteins at the interface between material surfaces and blood. Based on this, I am working on developing functional materials with good hemocompatibility, specifically, developing materials with self-anticoagulation function or preventing the material surface-induced contact activation to reduce the bleeding risk induced by anticoagulant administration.

Teaching
OpenClose

Teaching

Rana, MD Mohosin

Rana, MD Mohosin

Degree:

PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Postdoctoral Fellow

Affiliation(s):

Location:

UBC

Supervisor:

Jayachandran Kizhakkedathu

Short Bio

Academic
OpenClose

Academic Backgrounds

PhD Biomedical Engineering – University of Calgary (2022)

MEng Materials Science (Nanotechnology Specialization) – University of Tsukuba

BSc with Distinction & MSc Biotechnology – Bangladesh

Awards & Recognition

MEXT Scholarship (Japan)

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

As a Biomedical Scientist, I am always keen to bridging the gap between Biology and Materials Science. Currently, I am exploring the potential of immunomodulatory polymer-based organ engineering approaches to prevent transplant rejection. I have extensive experiences in soft materials engineering and cell biology techniques.

Teaching
OpenClose

Teaching

Hamden, Jordan

Hamden, Jordan

Degree:

PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Postdoctoral Fellow

Affiliation(s):

Location:

SPH

Supervisor:

Mari DeMarco

Short Bio

Academic
OpenClose

Academic Backgrounds

PhD in Zoology – University of British Columbia

BSc in Biology – Radford University

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Clinical Chemistry – Focus on development of clinical assays for dementia (Recipient of Postdoctoral Fellowship funded by the Michael Smith Foundation for Health Research BC Foundation and the CLEAR Foundation)

Teaching
OpenClose

Teaching

Mohamud, Yasir

Mohamud, Yasir

Degree:

PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Postdoctoral Fellow

Affiliation(s):

Centre for Heart Innovation

Location:

SPH

Supervisor:

Honglin Luo

Short Bio

Academic
OpenClose

Academic Backgrounds

PhD – University of British Columbia (2021)

MSc – University of Ottawa (2015)

BSc – University of Ottawa (2012)

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

RNA viruses, viral-host interactions, viral pathogenesis, translational virology

Teaching
OpenClose

Teaching

Jassem, Agatha

Dr.

Jassem, Agatha

PhD, (D)ABMM, FCCM

Basic Info
OpenClose

Academic Rank:

Clinical Assistant Professor, UBC, Clinical Microbiologist at The British Columbia Centre for Disease Control

Affiliation(s):

BC Centre for Disease Control

Location:

BC Centre for Disease Control

Short Bio

Dr. Agatha Jassem, PhD, (D)ABMM, FCCM (UBC Pathology and Laboratory Medicine Clinical Assistant Professor; Head, Virology/Molecular Diagnostics Lab, BCCDC PHL) is an accredited Clinical Virologist. She oversees diagnostic services and has extensive expertise in developing and implementing molecular- and serological-based tests for several organisms, including respiratory pathogens and those causing sexually transmitted and blood-borne infections. She is the BC Lab Lead for the Canadian Sentinel Practitioner Surveillance Network, which is monitoring SARS-CoV-2 and influenza vaccine effectiveness. During COVID-19 pandemic, Dr. Jassem secured funding to characterize the immune response after infection and vaccination, which involved validation and operationalization of novel multiplex serology, neutralization, and infectivity methods to support cohort-based studies across BC. Her current focus couple’s viral genomics and immune correlates of protection to understand the impacts of SARS-CoV-2 evolution under vaccine pressure. Other research led by Dr. Jassem includes utilization of novel phage immunoprecipitation sequencing technologies to link viral exposures to chronic illness and the validation and implementation of dried blood spot samples for diagnosis of HCV and HIV in hard to reach populations. She is the Vice President of the Canadian Association for Clinical Microbiology and Infectious Diseases (President-elect for 2022) and President of the British Columbia Association of Clinical Scientists.

Academic
OpenClose

Academic Backgrounds

  • American Board of Medical Microbiology (ABMM) Diplomate. 2016
  • Clinical Microbiology Fellow, Laboratory Medicine, National Institutes of Health Clinical Center. 2015
  • PhD, Pathology & Laboratory Medicine, University of British Columbia. 2012
  • BSc (Hons), Biology, York University. 2006

Awards & Recognition


Selected Publications

 
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include

 

Research

  • Infectious Diseases
Teaching
OpenClose

Teaching

Aparicio, Sam

Portrait photo of Sam Aparicio

Dr.

Aparicio, Sam

BM BCh PhD FRCPath FRSC

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

Faculty member, UBC Genome Science and Technology Graduate Program, Associate member, Head Single Cell Genomics, BC Cancer Genome Sciences Centre, Associate member, UBC CIHR/MSFHR Bioinformatics Program, Associate member, Michael Smith Genome Sciences Centre

Location:

BC Cancer Agency

Short Bio

The Aparicio lab studies the genomic and phenotypic behaviour of breast and other cancers. Integrating leading edge technologies with patient-derived xenograft models of cancer, this research is working to better understand how cancer clones evolve and to identify novel strategies for cancer treatment and predictors of response.

Dr. Aparicio’s research program encompasses the fields of cancer genomics, cancer evolution, single cell biology, mouse genetic models, high throughput screens, small molecule chemical probe development and translational breast cancer research. His work on the molecular taxonomy of breast cancer led to identification of new genes that could change the way breast cancer is diagnosed, and form the basis of next-generation treatments. This discovery was preceded by another breakthrough in decoding the genetic makeup of the most-deadly form of breast cancer, known as triple negative subtype (TNBC). Dr. Aparicio is also working to develop quantitative measures of clonal fitness in patients, including methods for single cell genome sequencing and PDX models of human cancer. He collaborates widely with other groups, with current projects including the genomic and biochemical analysis of lymphoma, ovarian cancer, and several rare pediatric cancers. He was a co-founder of Paradigm Therapeutics (now, Takeda Cambridge) and currently Canexia Health.

Academic
OpenClose

Academic Backgrounds

  • Royal College of Pathologists, MRC Pathology. May 2004
  • PhD, University of Cambridge, UK. 1995
  • MA, University of Cambridge, UK (Comparative gene regulation). 1988
  • BM BCh, University of Oxford, UK (Clinical Medicine). 1988
  • BA, University of Cambridge, UK (Natural and Medical Sciences). 1985

Awards & Recognition


Selected Publications

Publications: Link to PubMed

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

Dr. Aparicio’s research program encompasses the fields of cancer genomics, mouse genetic models, high throughput screens, small molecule chemical probes and translational breast cancer research. His most recent work on the molecular taxonomy of breast cancer led to identification of new genes that could change the way breast cancer is diagnosed, and form the basis of next-generation treatments. This discovery was preceded by another breakthrough in decoding the genetic makeup of the most-deadly form of breast cancer, known as triple negative subtype. Dr. Aparicio is also working to develop quantitative measures of clonal fitness in patients, including methods for single cell genome sequencing and PDX models of human cancer. He collaborates widely with other groups, with current projects including the genomic and biochemical analysis of lymphoma, ovarian cancer, and several rare pediatric cancers. He was a co-founder of Paradigm Therapeutics (now, Takeda Cambridge) and currently Contextual Genomics Ltd.

His contributions to academic research have been widely published in scientific and clinical journals such as Nature, Science, Cell and the New England Journal of Medicine. He is the recipient of numerous awards from academic as well as industrial institutions.

Teaching
OpenClose

Teaching

Sorensen, Poul

Portrait photo of Poul Sorensen

Dr.

Sorensen, Poul

MD, PhD

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

Department of Molecular Oncology, British Columbia Cancer Agency

Location:

BC Cancer Agency

Short Bio

Dr. Poul Sorensen is a board certified anatomic pathologist, specializing in the molecular pathology of pediatric cancers. He undertook his undergraduate, medical, and PhD degrees at the University of British Columbia (UBC) and McGill University, Montreal. He completed postdoctoral training at the University of Minnesota, Minneapolis and Children’s Hospital Los Angeles, University of Southern California, after his Pathology training. He then returned to Vancouver to start his own laboratory at Children’s and Women’s Hospital in Vancouver. Dr. Sorensen holds the Asa and Kashmir Johal Endowed Chair in Childhood Cancer Research, and he is Professor of Pathology and Laboratory Medicine at UBC. Dr. Sorensen’s research laboratory is located in the Department of Molecular Oncology at the BC Cancer Research Centre, where he is a senior scientist. His research focuses on targeting aberrant signaling pathways that are activated in childhood cancers and breast carcinoma.

Dr. Sorensen’s laboratory uses a combination of genetic and biochemical approaches to identify proteins that are specifically altered in human tumours. His laboratory has discovered many novel genetic alterations in childhood cancer and breast tumours, and these discoveries have been translated into new diagnostic tests for specific tumours, and have advanced our understanding of how the involved proteins transmit signals that cause cells to become cancerous. Such information then allows for the rapid implementation of strategies to target these proteins therapeutically. Dr. Sorensen is also the Chair of the Translational Research Committee of the Children’s Oncology Group (COG), the largest pediatric oncology clinical trials network in the world.

Academic
OpenClose

Academic Backgrounds

  • Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) – Anatomical Pathology. 1991
  • PhD, University of British Columbia, Canada. 1990
  • MD, University of British Columbia, Canada. 1984
  • BSc (Honours Chemistry /Biochemistry), McGill University, Montreal, Canada. 1980

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

The overall premise of my research is that a greater understanding of how childhood cancer cells respond to extra- or intracellular signals is necessary to identify tumour-specific pathways. Only then can these pathways be targeted therapeutically in a manner that minimizes effects on normal cells. This is especially important in childhood cancer to avoid toxic effects of treatments on the intellectual, physical, and emotional development of a growing child. An ongoing difficulty with this approach is how to find the relevant pathways to target. Over the years we have chosen to characterize recurrent genetic alterations in childhood tumours as a means to more efficiently identify novel cancer genes. This is part of our belief that analysis of primary tumours is preferable for initial identification of pathophysiologically relevant alterations in human malignancies. With the advent of next-generation sequencing, we are now extending this approach to whole genome sequencing of childhood cancers to better understand the mutational landscape of these tumours. Then, once the involved proteins have been identified, model systems can be invoked to further study their biology and how the pathways they are involved in become activated. We then use various biochemical approaches as well as high-throughput platforms such as RNA interference screening to rigorously characterize the involved proteins, their functional interactors, and the signal transduction pathways they participate in. This forms the basis for subsequent strategies to therapeutically target candidate proteins in childhood cancers.

Teaching
OpenClose

Teaching

Huntsman, David

Portrait photo of David Huntsman

Dr.

Huntsman, David

MD, FRCPC, FCCMG

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

BC Cancer Agency

Location:

BC Cancer Agency

Short Bio

Dr. David Huntsman is a Professor in the Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology at The University of British Columbia (UBC) and is the Dr. Chew Wei Memorial Professor of Gynaecologic Oncology. He is a a Staff Pathologist at the BC Cancer Agency (BCCA), and a Consulting Pathologist at the Vancouver General Hospital (VGH).

Dr. Huntsman is currently the Director of the BC multidisciplinary ovarian cancer research team (OvCaRe), Medical Director of the Centre for Translational and Applied Genomics (CTAG) at the BCCA, and co-Director of the Genetic Pathology Evaluation Centre (GPEC) at the Jack Bell Research Centre, VGH.

Dr. Huntsman research has led to development of predictive and prognostic tissue based cancer biomarkers for ovarian cancer and a wide variety of other tumour types. His team created a blueprint for subtype specific ovarian cancer control and have been leaders in the application of novel genomics technologies to ovarian cancer. As collaboration is critical in his field, Dr. Huntsman happily leads and engages in a wide number of multidisciplinary research groups. Most recently he has been working on the creation of broad based personalized medicine initiative for British Columbia.

Academic
OpenClose

Academic Backgrounds

  • FRCPC. 1995
  • MD – Memorial University Newfoundland, Canada. 1988

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • David Huntsman’s lab studies genetic predisposition to ovarian cancer. This research focuses on understanding the molecular differences between the different ovarian cancer subtypes, which will hopefully lead to more specific treatments. Recently, Dr. Huntsman headed the research group that discovered a new mutation in a gene called FOXL2, which appears to be responsible for the development of granulosa cell tumours of the ovary.
  • Dr. Huntsman has active research programs in the development of predictive and prognostic tissue based cancer biomarkers of hereditary gastric cancer and a wide variety of other tumor types. His team created a blueprint for subtype specific ovarian cancer control and have been leaders in the application of novel genomics technologies to ovarian cancer. Dr. Huntsman happily leads and engages in a wide number of multidisciplinary research groups. Most recently he has been working with Professor Pieter Cullis on the creation of broad based personalized medicine initiative for British Columbia.
Cancer
Teaching
OpenClose

Teaching

Lim, James

Portrait photo of James Chinten Lim

Dr.

Lim, James

PhD

Basic Info
OpenClose

Academic Rank:

Assistant Professor, Pediatrics

Affiliation(s):

BC Children’s Hospital Research Institute

Location:

BC Children’s Hospital Research Institute

Short Bio

My research is aimed at understanding the molecular mechanisms governing cell adhesion and motility, in particular those involving white blood cell function in normal as well as in pathologic outcomes.

Circulating white blood cells represent the immune system’s front-line defense against infection. The successful and accurate targeting of white blood cells to inflamed tissues is facilitated by cell adhesion receptor proteins expressed on the surface of these cells. However, aberrant function of these receptor proteins and the cellular signals that regulate them can lead to diseases of the immune system, including leukemia, lymphoma and autoimmunity.

My laboratory is focused on understanding the differences in cellular signalling between healthy and diseased cells in order to explore and evaluate novel signalling targets for therapeutic intervention in blood diseases. We employ a multi-disciplinary approach that encompasses cell biology, protein biochemistry, molecular biology and immunology.

Academic
OpenClose

Academic Backgrounds


Awards & Recognition

  • The Leukemia and Lymphoma Society of Canada (LLSC) OG (2010-2012)
  • CFI/BCKDF – Leaders Opportunity Fund (2010)
  • The Leukemia and Lymphoma Society (U.S.A.) – Fellow, Career Development Program (2004–07)
  • Canadian Institutes of Health Research (CIHR) – PhD Studentship (1997-2002)

Selected Publications

  • Weisser SB, Kozicky LK, Brugger HK, Ngoh EN, Cheung B, Jen R, Menzies SC, Samarakoon A, Murray PJ, Lim CJ, Johnson P, Boucher JL, van Rooijen N, amd Sly LM. 2014. Arginase activity in alternatively activated macrophages protects PI3Kp110delta deficient mice from dextran sodium sulfate induced intestinal inflammation. Eur J Immunol 44(11):3353-67. DOI: 10.1002/eji.201343981. PMID: 25124254
  • Khademolhosseini F, Liu CC, Lim CJ and Chiao M. 2015. Application of periodic loads on cells from magnetic micropillar arrays impedes cellular migration. Micro Electro Mechanical Systems (MEMS), 2015 28th IEEE International Conference on , vol., no., pp.624,627, 18-22 Jan. 2015. DOI: 10.1109/MEMSYS.2015.7051033
  • Leclair P, Lim CJ. CD47-Independent Effects Mediated by the TSP-Derived 4N1K Peptide*. PLoS ONE (2014) 9(5): e98358. PMID:24848268   *F1000 Recommended
  • Chen H, Mohan P, Jiang J, Nemirovsky O, He D, Fleisch MC, Niederacher D, Pilarski LM, Lim CJ, Maxwell CA. Spatial regulation of Aurora A activity during mitotic spindle assembly requires RHAMM to correctly localize TPX2. Cell Cycle (2014) 13(14):2248-61. PMID:24875404
  • Liu CC, Leclair P, Yap SQ, Lim CJ. The Membrane Proximal KxGFFKR Motif of α-Integrin Mediates Chemoresistance*. Molecular and Cellular Biology (2013) 33:4334-45. PMID:24001772  *MCB Spotlighted Article
  • Lee HS*, Anekal P*, Lim CJ*, Liu CC, Ginsberg MH. Two modes of integrin activation form a binary molecular switch in adhesion maturation#. Molecular Biology of the Cell (2013) 24:1354-62. PMID:23468527 *equal contribution #ASCB Highlighted
  • Sun G, Cheng SY, Chem M, Lim CJ, Pallen CJ. Protein tyrosine phosphatase α phosphotyrosyl-789 binds BCAR3 to position Cas for activation at integrin-mediated focal adhesions. Molecular and Cellular Biology (2012) 32:3776-3789. PMID:22801373
  • Lee HS*, Lim CJ*, Puzon-McLaughlin W, Shattil SJ, Ginsberg MH. RIAM Activates Integrins by Linking Talin to Ras GTPase Membrane-targeting Sequences. Journal of Biological Chemistry (2009) 284:5119-5127. PMID:19098287 *equal contribution
  • Lim CJ*, Kain KH*, Tkachenko E, Goldfinger LE, Gutierrez E, Allen MD, Groisman A, Zhang J, Ginsberg MH. Integrin-mediated protein kinase A activation at the leading edge of migrating cells. Molecular Biology of the Cell (2008) 19:4930-41. PMID:18784251*equal contribution
  • Lim CJ, Han J, Yousefi N, Ma Y, Amieux PS, McKnight GS, Taylor SS, Ginsberg MH. α4 Integrins are Type I cAMP-dependent protein kinase-anchoring proteins*. Nature Cell Biology (2007) 9:415-421. PMID:17369818   *Featured Article
  • Han J, Lim CJ, Watanabe N, Soriani A, Ratnikov B, Calderwood DA, Puzon-McLaughlin W, Lafuente EM, Boussiotis VA, Shattil SJ, Ginsberg MH. Reconstructing and Deconstructing Agonist-induced Activation of Integrin αIIbβ3 (Platelet GPIIb-IIIa)*. Current Biology (2006) 16:1796-1806. PMID:16979556   *Featured Article
  • Anthis NJ, Haling JR, Oxley CL, Memo M, Wegener KL, Lim CJ, Ginsberg MH and Campbell ID. Beta integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation. Journal of Biological Chemistry (2009) 284:36700-36710. PMID:19843520
  • Jones, CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC, Lim CJ, Chen H, Zhang Q, Schultz PG, Hayallah AM, Thomas KR, Famulok M, Zhang K, Ginsberg MH and Li DY. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nature Cell Biology (2009) 11:1325-1331. PMID:19855388
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Integrin dependent cell adhesion and migration
  • Mechanisms of chemotherapeutic resistance
  • Protein interactions and cell signaling
  • Tumour microenvironment
Teaching
OpenClose

Teaching

Vercauteren, Suzanne

Portrait photo of Suzanne Vercauteren

Dr.

Vercauteren, Suzanne

BSc, MSc, MD, PhD (University of Utrecht)

Basic Info
OpenClose

Academic Rank:

Clinical Associate Professor, Hematopathologist, BCCH

Affiliation(s):

BC Cancer Research Centre

Location:

Children’s & Women’s Health Centre of BC

Short Bio

Dr. Vercauteren is interested in the genetic events that lead to leukemia. At the moment, I am working on several projects including looking at mutations in microRNAs in a large number of AML patients. WE are also determining whether microRNA expression can be measured by flowcytometry. In addition, I am sequencing the RNA profile on two patients with a very rare type of leukemia, plasmacytoid dendritic cell leukemia to see if we can find a common genetic event that may cause this disease.

Academic
OpenClose

Academic Backgrounds

  • Certification in Hematological Pathology, Royal College of Physicians and Surgeons of Canada. 2008
  • Medical Council of Canada Qualifying Exam Part I, Medical Council of Canada. 2002
  • Medical Council of Canada Evaluating Exam, Medical Council of Canada. 2001
  • PhD, University of Utrecht. 2003
  • MD, University of Utrecht. 1999
  • MSc, University of Utrecht. 1997
  • BSc, University of Utrecht. 1977

Awards & Recognition


Selected Publications

  • Ubaka Ogbogu, Sarah Burningham, Adam Ollenberger, Kathryn Calder, Li Du, Khaled El Emam, Robyn Hyde-Lay, Rosario Isasi, Yann Joly, Ian Kerr, Bradley Malin, Michael McDonald, Steven Penney, Gayle Piat, Denis-Claude Roy, Jeremy Sugarman, Suzanne Vercauteren, Griet Verhenneman, Lori West and Timothy Caulfield: Policy recommendations for addressing privacy challenges associated with cell-based research and interventions, BMC Med Ethics. Feb 3;15:7, 2014.
  • Crystal D. Karakochuk, Kyly C. Whitfield, Susan I. Barr, Yvonne Lamers, Angela M. Devlin, Suzanne M. Vercauteren, Hou Kroeun, Aminuzzaman Talukder, Judy McLean, Timothy J. Green:Genetic hemoglobin disorders rather than iron deficiency are a major predictor of hemoglobin concentration in women of reproductive age in rural Cambodia, submitted.
    Li S, Vercauteren S: Nodular sclerosis Hodgkin lymphoma with classic Reed-Sternberg cells. Blood, in press. 2014
  • Crystal D. Karakochuk, Kyly C. Whitfield, Susan I. Barr, Suzanne M. Vercauteren, Hou Kroeun, Judy McLean, Timothy J. Green,: A method-comparison study of a hemoglobinometer and a hematology analyzer to measure hemoglobin concentration among women with hemoglobin E structural variants in Cambodia, submitted. 2014
  • Tamsin E. Tarling, Caron Strahlendorf, Kirk R. Schultz, Ruth Milner, and Suzanne M. Vercauteren: Verbal permission to obtain clinically urgent biospecimens for a pediatric BioBank, submitted. 2014
  • Stefanie Cheah, Sheila O’Donoghue, Helena Daudt, Simon Dee, Jodi LeBlanc, Rebecca Barnes, Suzanne Vercauteren, Robert Boone, and Peter H.Watson: Permission to Contact (PTC) – A strategy to enhance patient engagement in translational research. Biopreservation and Biobanking Aug 11 (4):245-252, 2013.
  • Dmitrienko S, Vercauteren S: Auer rods in mature granulocytes of a patient with mixed lineage leukemia. Blood. 2012 May 10; 119(19):4348.
  • Suzanne M. Vercauteren, Daniel T. Starczynowski, Sandy Sung, Kelly McNeil, Chris Salski, Clara-Lynn Jensen, Helene Bruyere, Wan L. Lam and Aly Karsan. T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone. British Journal of Haematology Volume 156, Issue 3, February 2012, Pages: 409-412.
  • Vawda A, Davis J, Vercauteren S. Leukemic transformation of anaplastic large-cell lymphoma. Blood. 2011 Oct 6;118(14):3763.
  • Suzanne Vercauteren, Sandy Sung, Daniel T. Starczynowski, Wan L. Lam, Helene Bruyere, Douglas E. Horsman, Peter Tsang, Heather Leitch and Aly Karsan. Array comparative genomic hybridization of peripheral blood granulocytes of patients with myelodysplastic syndromes detects karyotypic abnormalities. American Journal of Clinical Pathology, vol 134(1), p.119-26, 2010
  • Starczynowski DT, Vercauteren S, Sung S, Brooks-Wilson A, Lam WL, Karsan A. Copy number alterations at polymorphic loci may be acquired somatically in patients with myelodysplastic syndromes. Leuk Res. 2010 Aug 27.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Blood Research
  • Cancer
Teaching
OpenClose

Teaching

Bally, Marcel

Portrait photo of Marcel Bally

Dr.

Bally, Marcel

BSc, MSc (Texas), PhD (Brit. Col.)

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

BC Cancer Agency, Centre for Drug Research and Development

Location:

BC Cancer Research Centre

Short Bio

The research conducted in Dr. Bally’s laboratory focuses on developing improved protocols for the treatment of cancer. Clinicians have an arsenal of very potent drugs available for treatment of cancer. These drugs, however, lack specificity and often produce severe, life threatening, toxicities. Further, optimal therapeutic effects of any anticancer drug appear to be dependent on their use in a combination setting. Multi-agent therapy is the standard by which cancer is treated. Based on this understanding, research in the laboratory is designing methods and strategies for capturing the benefits of drug combination effects that are often first measured using cell based screening assays. Although basic research interests include evaluation of novel targeted anticancer drugs, Dr. Bally’s group is also comprehensively pursuing combinations of existing, already approved, cytotoxic agents. The latter studies will provide the proof of concept data needed to demonstrate the value of pursuing anticancer drug combination products. These products will be of particular interest when used with emerging targeted agents, but will also demonstrate the potential to develop new products that may consist of two or more targeted agents.

Academic
OpenClose

Academic Backgrounds

  • MRC Centennial Fellow, Biochemistry – U.B.C
  • MRC Postdoctoral Fellow, Terry Fox Laboratory – BC Cancer Agency
  • PhD (Biochemistry), UBC, 1984
  • MSc (Biol.), Texas A&M University, 1979
  • BSc (Biol.), Texas A&M University, 1977

Awards & Recognition


Selected Publications

  • Waterhouse DN, Sutherland S, Dos Santos N, Masin D, Osooly M, Strutt D, Ostlund C, Anantha M, Harasym N, Manisali I, Wehbe M, Bally MB and Webb M (2014) “Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities” (Accepted in June 2014, Investigation New Drugs).
  • Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, Yapp DT and Bally MB, Gorski SM (2014) “Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer” Clin Cancer Res. 2014 Jun 15;20(12):3159-73. Epub 2014 Apr 10. PMID:24721646.
  • Leung AW, Kalra J, Dos Santos ND, Bally MB and Anglesio MS (2014) “Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments” Nanomedicine (Lond). 2014 Mar;9(3):501-22. doi: 10.2217/nnm.13.220. PMID:24746193.
  • Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB (2013) “Topophore C: A liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer” Investigational New Drugs. 2013;31(1):46-58. PMID: 22615060.
  • Ho EA, Osooly M, Strutt D, Masin D, Yang Y, Yan H, Bally MB (2013) “Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor Model” Journal of Pharmaceutical Sciences. 2013;102(1):227-36. PMID: 23132529.
  • Patankar NA, Pritchard J, Van Grinsven MC, Osooly M, Bally MB (2013) “Topotecan and doxorubicin combination to treat recurrent ovarian cancer: The influence of drug exposure time and delivery systems to achieve optimum therapeutic activity” Clinical Cancer Research. 2013;19(4):865-77. PMID: 23303216.
  • Verreault M, Stegeman A, Warburton C, Strutt D, Masin D and Bally MB (2013) “Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model” PLoS One. 2013;8(3):e59597. PMID: 23555046.
  • Kalra J, Dragowska WH, Bally MB (2013) “Kinetics of early signaling following ILK inhibition in an in vivo model of breast cancer using digital quantification of stained tissue microarrays” Journal of Cancer Science & Therapy; 2013; 5:1-13.
  • Ahn RW, Barrett SL, Raja MR, Jozefik JK, Sapho L, Chen H, Bally MB, Mazar AP, Avram MJ, Winter JN, Gordon LI, Shea LD, O’Halloran TV, Woodruff TK. “Nano-encapsulation of arsenic trioxide enhances efficacy in a murine lymphoma model while minimizing chemotherapeutic fertoxicity in vitro and in vivo” PLoS One. 2013;8(3):e58491. PMID: 23526987.
  • Hare JI, Neijzen RW, Anantha M, Dos Santos N, Harasym N, Webb MS, Allen TM, Bally MB, Waterhouse DN. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore CTM) and 5-fluorouracil. PLoS One. 2013;8(4):e62349. PMID: 23626804.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

The research conducted in my laboratory focuses on developing improved protocols for the treatment of cancer. Clinicians have an arsenal of very potent drugs available for treatment of cancer. These drugs, however, lack specificity and often produce severe, life threatening, toxicities. Further, optimal therapeutic effects of any anticancer drug appear to be dependent on their use in a combination setting. Multi-agent therapy is the standard by which cancer is treated. Based on this understanding, research in my laboratory is designing methods and strategies for capturing the benefits of drug combination effects that are often first measured using cell based screening assays. Although basic research interests include evaluation of novel targeted anticancer drugs, my group is also comprehensively pursuing combinations of existing, already approved, cytotoxic agents. The latter studies will provide the proof of concept data needed to demonstrate the value of pursuing anticancer drug combination products. These products will be of particular interest when used with emerging targeted agents, but will also demonstrate the potential to develop new products that may consist of two or more targeted agents.

In order to achieve this, my research group embraces two fundamental principles: (i) drug combination products will be dependent on use of drug carrier technologies and (ii) drug combination products should achieve optimal therapeutic effects using better tolerated drug doses. I have extensive expertise on the use of liposome drug carriers for improving the specificity of anti-cancer drugs as well as enabling the use of some exciting new biologically active agents, such as therapeutically active antibodies, nucleic acid drugs (antisense oligonucleotides and siRNA) and therapeutically active peptides. In general terms, liposomes are small microscopic bags prepared from natural and synthetic lipids (fats). The therapeutic activity of conventional anti-cancer drugs can be improved, sometimes dramatically, when given intravenously trapped inside these lipid bags. Mechanistically, it has been suggested that liposomal drugs deliver more drug to tumors then conventional drug and development of this technology has been based on achieving improvements in drug delivery to sites of cancer growth. It is believed that delivery of liposomal drug carriers from the blood to interstitial sites within the tumor is due to characteristics of tumor blood vessels. In addition, my research clearly establishes that drug release from liposomes, whether in the blood compartment or within the tumor, can increase tumor cell exposure to anticancer drugs. Based on this understanding, my lab is now using drug carriers, such as liposomes, to provide the format to deliver combinations of drugs that are shown, via high content cell screening assays, to interact to achieve better than expect (synergistic) therapeutic activity.

Teaching
OpenClose

Teaching

Sadar, Marianne

Portrait photo of Marianne Sadar

Dr.

Sadar, Marianne

BSc, PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

BC Cancer Agency, Genome Science Centre

Location:

BC Cancer Agency

Short Bio

The major focus of Dr. Sadar’s research is to develop therapies that will delay or prevent tumour progression and emergence of hormone independence in prostate cancer.

  • Distinguished Scientist, Genome Sciences Centre, BC Cancer Agency
  • President, Society of Basic Urologic Research
  • Chief Scientific Officer, ESSA Pharma Inc
  • Professor, Pathology and Laboratory Medicine, University of British Columbia (UBC)

Academic
OpenClose

Academic Backgrounds

  • PhD, Biochemistry, University of Bradford, UK / University of Göteborg, Sweden.  1995
  • BSc, Biochemistry, Simon Fraser University. 1988

Awards & Recognition

  • SWIU/SBUR Award for Excellence in Urologic Research, First non-American to receive SWIU/SBUR Award for Excellence in Urologic Research, 2010
  • SFU Outstanding Alumni Award for Academic Achievement, Simon Fraser University, In recognition of significant achievements in cancer research, 2009
  • Terry Fox Young Investigator Award, National Cancer Instituate of Canada, 2008. The Terry Fox Young Investigator Award is a national award given annually to one investigator in the first 10 years of his/her career that is doing outstanding basic laboratory work in cancer.
  • Co-op recognition Award, University of British Columbia.  2003

Selected Publications

  • Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013 Jul 1;123(7):2948-60.
  • Yang YC, Meimetis LG, Tien AH, Mawji NR, Carr G, Wang J, Andersen RJ, Sadar MD. Spongian diterpenoids inhibit androgen receptor activity. Mol Cancer Ther. 2013 May;12(5):621-31.
  • Myung JK, Sadar MD. Large scale phosphoproteome analysis of LNCaP human prostate cancer cells. Mol Biosyst. 2012 Aug;8(8):2174-82.
  • Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, Park JJ, Tien AH, Fernandez JG, de Voogd NJ, Sadar MD, Andersen RJ. Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J Med Chem. 2012 Jan 12;55(1):503-14.
  • Haile S, Lal A, Myung JK, Sadar MD. FUS/TLS is a co-activator of androgen receptor in prostate cancer cells. PLoS One. 2011;6(9):e24197.
  • Sadar MD. Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. World J Urol. 2012 Jun;30(3):311-8.
  • Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci. 2011 Dec;68(24):3971-81.
  • Sadar MD. Small molecule inhibitors targeting the “achilles’ heel” of androgen receptor activity. Cancer Res. 2011 Feb 15;71(4):1208-13.
  • Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD. LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med Genomics. 2010 Sep 24;3:43.
  • Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW, Squire JA, Wang Y. Development of metastatic and non-metastatic tumor lines from a patient’s prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor. Prostate. 2010 Nov 1;70(15):1636-44.
  • Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Bañuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell. 2010 Jun 15;17(6):535-46.
  • Chiu HH, Yong TM, Wang J, Wang Y, Vessella RL, Ueda T, Wang YZ, Sadar MD. Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. Cancer Lett. 2010 Jun 28;292(2):176-85. doi: 10.1016/j.canlet.2009.11.023.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Steroid receptor biochemistry
  • Drug development
  • Prostate cancer research
Teaching
OpenClose

Teaching

Gilks, Blake

Portrait photo of Blake Gilks

Dr.

Gilks, Blake

MD, FRCPC

Basic Info
OpenClose

Academic Rank:

Professor Emeritus, UBC, Co-Founder, Ovarian Cancer Research

Affiliation(s):

VGH/VCHRI

Location:

VGH/VCHRI

Short Bio

Together with my colleagues in the Genetic Pathology Evaluation Center, we have taken advantage of the excellent patient outcome data available through the British Columbia Cancer Agency to create tissue microarrays (TMAs) that have allowed for examination of large numbers of cases of breast cancer, ovarian cancer, endometrial cancer and other cancer types, correlating immunostaining and FISH results with patient outcomes.

Starting with a presentation to the International Society of Gynecological Pathology annual meeting, and subsequently published in the society journal as a review article (Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol. 2004;23:200-5), I have advanced the hypothesis that ovarian cancer subtypes, recognizable based on histopathological examination, are distinct diseases, with different risk factors, genetic events during oncogenesis, precursor lesions, natural history, and response to chemotherapy. We founded a local ovarian carcinoma research group, OvCaRe, and have shown that these subtypes can be reproducibly diagnosed by surgical pathologists and are studying the subtype specific molecular abnormalities in these tumors. This has been my primary academic focus for the past 5 years. This is a subject of clinical import as we move towards subtype specific treatment of ovarian carcinoma. More recently the gynecological cancer focus has expanded to include uterine and vulvar cancers.

Academic
OpenClose

Academic Backgrounds

  • Fellow of the Royal College of Physicians and Surgeons of Canada (Anatomical Pathology)
  • MD cum laude, Dalhousie University, Medicine. 1982
  • BSc, University of New Brunswick. 1978

Awards & Recognition


Selected Publications

  • Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, Gilks CB, Huntsman DG. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015 Feb;125(2):338-45.
  • Kulic I, Robertson G, Chang L, Baker JH, Lockwood WW, Mok W, Fuller M, Fournier M, Wong N, Chou V, Robinson MD, Chun HJ, Gilks B, Kempkes B, Thomson TA, Hirst M, Minchinton AI, Lam WL, Jones S, Marra M, Karsan A. Loss of the Notch effector RBPJ promotes tumorigenesis. J Exp Med. 2015 Jan 12;212(1):37-52.
  • Torlakovic EE, Nielsen S, Francis G, Garratt J, Gilks B, Goldsmith JD, Hornick JL, Hyjek E, Ibrahim M, Miller K, Petcu E, Swanson PE, Zhou X, Taylor CR, Vyberg M. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):1-18.
  • So WK, Cheng JC, Fan Q, Wong AS, Huntsman DG, Gilks CB, Leung PC. Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion. FEBS Lett. 2015 Jan 30;589(3):302-9.
  • Chiang S, Staats PN, Senz J, Kommoss F, De Nictolis M, Huntsman DG, Gilks CB, Oliva E. FOXL2 Mutation is Absent in Uterine Tumors Resembling Ovarian Sex Cord Tumors. Am J Surg Pathol. 2015 Jan 9. [Epub ahead of print].
  • McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015 Jan 28. [Epub ahead of print].
  • Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assessment of a new system for primary site assignment in high-grade serous carcinoma of fallopian tube, ovary and peritoneum. Histopathology. 2015 Jan 14. [Epub ahead of print].
  • Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, Gilks B, Tinker AV, Clarke B, McAlpine JN, Huntsman D. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer. 2014 Dec 18;14:982.
  • Gilks CB, Irving J, Köbel M, Lee C, Singh N, Wilkinson N, McCluggage WG. Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases: Further Evidence for the Tubal Origin of High-grade Serous Carcinomas. Am J Surg Pathol. 2014 Dec 16. [Epub ahead of print].
  • Hanna WM, Barnes PJ, Chang MC, Gilks CB, Magliocco AM, Rees H, Quenneville L, Robertson SJ, SenGupta SK, Nofech-Mozes S. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study. J Clin Oncol. 2014 Dec 10;32(35):3967-73.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Breast and Gynecological Pathology
  • Teaching Pathology, Surgery and Obstetrics and Gynecology Residents
  • Development of Pathology labs for the GI/Nutrition block of the new medical school curriculum
  • Cancer
Teaching
OpenClose

Teaching

Nielsen, Torsten

Portrait photo of Torsten Nielsen

Dr.

Nielsen, Torsten

MD/PhD FRCPC

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, BC Cancer Agency

Location:

Vancouver General Hospital

Short Bio

I am a clinician-scientist in the  Department of Pathology and Laboratory Medicine and an affiliated member of the Department of Orthopaedics and the Department of Urologic Sciences at the University of British Columbia in Vancouver, Canada, recently promoted to the rank of full professor. I am based at Vancouver General Hospital and at the British Columbia Cancer Agency, working out of the Division of Anatomical Pathology, the Genetic Pathology Evaluation Centre, and the Centre for Translational and Applied Genomics.

I am also Associate Director of UBC’s combined MD/PhD program , where I help to organize our seminar series for clinician-scientists. I contribute to the correlative sciences planning around cancer clinical trials for the Canadian NCIC-Clinical Trials Group and the U.S.-based Alliance for Clinical Trials in Oncology — formerly CALGB.

25% of my time is devoted to clinical work: musculoskeletal pathology including diagnosis of connective tissue neoplasms in the province of British Columbia, weekly sarcoma treatment planning conferences, and teaching residents and medical students at UBC. The rest of my time is devoted to translational research into how molecular changes in cancer cells impact upon diagnosis, prognosis, and treatment response, and in developing new and clinically-practical molecular diagnostics and targeted therapies for human cancer (with a focus on breast cancer and sarcomas).

Academic
OpenClose

Academic Backgrounds


Awards & Recognition


Selected Publications

Here is my publications list

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include

Dr. Nielsen’s active projects are listed at: http://www.gpecdata.med.ubc.ca/torsten/Currproj.htm


Research

  • Translational research in breast cancer – developing clinically-practical predictive biomarkers using tissue microarray and Nanostring technology
  • Molecular oncology of sarcomas afflicting the AYA (adolescent and young adult) population – synovial sarcoma, myxoid liposarcoma, epithelioid sarcoma and related cancers
  • Correlative science support for clinical trials in breast cancer and sarcoma, in association with the Canadian Cancer Trials Group
Teaching
OpenClose

Teaching

Associate Director, UBC MD/PhD program: http://mdprogram.med.ubc.ca/mdphd/program-overview/

Karsan, Aly

Portrait photo of Aly Karsan

Dr.

Karsan, Aly

BA, MD (Queen’s)

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

BC Cancer Research Centre

Location:

BC Cancer Research Centre

Short Bio

  • Head, Clinical Diagnostic Genomics and Distinguished Scientist, Genome Sciences Centre, BC Cancer Agency
  • Medical Director, Cancer Genetics Lab, BC Cancer Agency
  • Hematopathologist, Pathology and Laboratory Medicine, BC Cancer Agency
  • Professor, Pathology and Laboratory Medicine, University of British Columbia (UBC)
  • Founding Member, Centre for Blood Research, University of British Columbia (UBC)
  • Member, Stem Cell Network

I make use of both, my clinical and research expertise in teaching. I teach Pathology and Internal Medicine residents and students clinical aspects of Hematology/Hematopathology. As well I give resident (Hematology/ Hematopathology, Oncology) seminars on tumor angiogenesis.

I teach graduate student courses using my expertise derived from my research interests in endothelial biology, apoptosis, angiogenesis and tumor biology, and stem cell differentiation. Currently much of my teaching time is spent on grad students, undergrads and high school students who are rotate through my laboratory.

My lab focuses on two major areas: (1) Understanding the molecular basis of the preleukemic bone marrow failure conditions called myelodysplastic syndromes (MDS); and (2) Determining the role of the endothelium in the development of the hematopoietic system. With respect to both areas we have been studying the role of two pathways: innate immune signaling as represented by the Toll-like receptor (TLR) pathways, and the Notch signaling pathway.

Academic
OpenClose

Academic Backgrounds

  • BA, Magna Cum Laude, Queen’s University, Kingston, ON, Life Sciences
  • University of St. Andrews, Scotland, Exchange scholarship (Queen’s University)
  • MD, Queen’s University, Faculty of Medicine, Medicine
  • Fellow of the Royal College of Physicians and Surgeons of Canada – Hematological Pathology

Awards & Recognition


Selected Publications

  • B.S. Sheffield MD, I.E. Bosdet PhD, R.H. Ali MD, S.S. Young PhD, B.K. McNeil BSc, C. Wong BSc, K. Dastur RT, A. Karsan MD, D.N. Ionescu MD. Relationship of TTF-1 to EGFR status in non-small cell lung cancer. Curr Oncol. 2014 Dec;21(6):305-8. doi: 10.3747/co.21.2148. PMID: 25489257.
  • Lai CK, Moon Y, Kuchenbauer F, Starzcynowski DT, Argiropoulos B, Yung E, Beer P, Schwarzer A, Sharma A, Park G, Leung M, Lin G, Vollett S, Fung S, Eaves CJ, Karsan A, Weng AP, Humphries RK, Heuser M. Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene. PLoS One. 2014 Nov 17;9(11):e112671. doi: 10.1371/journal.pone.0112671. eCollection 2014.
  • Wilson IM, Vucic EA, Enfield KSS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TPH, Selamat SA, Laird-Offringa IA, Liu P, Anderson M, You M, Tsao MS, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, and Lam WL. EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene. 2014 Sep 4;33(36):
  • Cutz JC, Craddock KJ, Torlakovic E, Brandao G, Carter RF, Bigras G, Deschenes J, Izevbaye I, Xu Z, Greer W, Yatabe Y, Ionescu D, Karsan A, Jung S, Fraser RF, Blumenkrantz M, Lavoie J, Fortin F, Bojarski A, Cote GB, van den Berghe JA, Rashid-Kolvear F, Trotter M, Sekhon HS, Albadine R, Tran-Thanh D, Gorska I, Knoll JHM, Xu J, Blencowe B, Iafrate AJ, Hwang DM,Pintilie M, Gaspo R, Couture C, and Tsao MS . Canadian Anaplastic Lymphoma Kinase (ALK) study: A model for multi-centre standardization and Sep 2014
  • Gerrie A, Huang S.J,T, Bruyere H, Chinmay D, Hrynchak M, Karsan A, Ramadan K.M, Smith A.C, Tyson C, Toze C.L, Gillian T.L. Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization. Cancer Genet. 2014 Jul-Aug;207(7-8):316-25. doi: 10.1016/j.cancergen.2014.08.006. Epub 2014 Aug 29. PMID: 25441686.
  • Patenaude A, Fuller M, Chang L, Wong F, Paliouras G, Shaw R, Kyle AH, Umlandt P, Baker JH, Diaz E, Tong J, Minchinton AI, Karsan A. Endothelial-specific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism. Cancer Res. 2014 May 1;74(9):2402-11. PMID:24599126.
  • Chang ACY, Garside VC, Fournier M, Smrz J, Vrljicak P, Umlandt P, Fuller M, Robertson G, Zhao Y, Tam A, Jones SJM,. Marra MA, Hoodless PA, Karsan A. A Notch-dependent transcriptional hierarchy promotes mesenchymal transdifferentiation in the cardiac cushion. Dev Dyn. 2014 Jul;243(7):894-905. doi: 10.1002/dvdy.24127. Epub 2014 Apr 17. PMID:24633789.
  • Mariano C, Bosdet I, Karsan A, Ionescu D, Murray N, Laskin JJ, Zhai Y, Melosky B, Sun S, Ho C. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease for consideration for publication in lung cancer. Lung Cancer. 2014 Jan;83(1):73-7. PMID:24192511.
  • Wilson IM, Vucic EA, Enfield KSS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TPH, Selamat SA, Laird-Offringa IA, Liu P, Anderson M, You M, Tsao MS, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, and Lam WL. EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene. 2013 Oct 7. doi: 1
  • El-Sehemy A, Chang A, Azad AK, Gupta N, Xu Z, Steed H, Karsan A, Fu YX. Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells. Cell Signal. 2013 Dec;25(12):2780-7.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Myelodysplastic syndromes and myeloid malignancies
  • Innate immune signaling in vascular and hematopoietic function
  • Genomics for clinical diagnostics
  •  My lab focuses on two major areas: (1) Understanding the molecular basis of the preleukemic bone marrow failure conditions called myelodysplastic syndromes (MDS); and (2) Determining the role of the endothelium in the development of the hematopoietic system. With respect to both areas we have been studying the role of two pathways: innate immune signaling as represented by the Toll-like receptor (TLR) pathways, and the Notch signaling pathway.
  • We have recently demonstrated that microRNAs that reside on the long arm of chromosome 5 act to regulate innate immune signaling. Deletion of chromosome arm 5q is the commonest structural anomaly seen in MDS, and our current work is centred around establishing the function of these microRNAs and deregulated innate immune signaling in the manifestations of MDS. We are using a variety of in vivo transplantation assays, in vitro cell biology and cell signaling studies as well as genomic approaches to answer these questions.
  • In other work related to innate immune signaling, we have identified a novel protein, Sash1, by differential proteomic analysis that appears to act as a scaffold protein in a MyD88-independent TLR signal transduction pathway. Expression analyses indicate that this molecule is highly expressed in the microvasculature. Molecular and cellular studies to elucidate the mechanisms of action of this protein are ongoing. As well we have generated a gene-targeted mouse model that demonstrates that loss of this protein results in perinatal death. Currently, we are generating a conditional gene-targeted mouse model to gain a better understanding of the physiologic role of Sash1.
  • My lab has also had a long-standing interest in the role of Notch signaling in the endothelium. We have generated a conditional, inducible mouse model in which we are able to regulate Notch signaling. Using this and other models we are studying how endothelial cells contribute to hematopoietic development both at the initial stages of intraembryonic hematopoiesis where hematopoietic stem cells are thought to derive from the endothelium, as well as during fetal liver and adult hematopoiesis, where the endothelium may act as a niche to regulate stem cell self renewal and/or differentiation.
  • Over the last few years my clinical interest has shifted to using genomics methodologies to deliver clinical diagnostic testing. We were the first clinical lab in Canada to use next-generation sequencing techniques to deliver clinical testing. We are currently developing various gene panels as well as genome-wide tests with the intention of taking these into the clinic.
Teaching
OpenClose

Teaching

Lam, Wan

Portrait photo of Wan Lam

Dr.

Lam, Wan

BSc, MSc, PhD, (Dalhousie Univ), MRC

Basic Info
OpenClose

Academic Rank:

Professor, Distinguished Scientist

Affiliation(s):

BC Cancer Agency, BC Cancer Research Centre

Location:

BC Cancer Agency

Short Bio

Dr. Lam received his graduate training in Biochemistry at Dalhousie University with Dr. W. Ford Doolittle. As a post-doctoral fellow, he trained with Nobel Laureate Dr. Walter Gilbert at Harvard University. Dr. Lam returned to Canada in 1998 as a Senior Scientist in Cancer Genetics and Developmental Biology at the British Columbia Cancer Agency. Currently, he is Professor of Pathology & Laboratory Medicine, and a faculty member of the Interdisciplinary Oncology Program, at the University of British Columbia.

Dr. Lam’s primary research interest is in understanding the events leading to cancer progression. Early detection and treatment is key to a favorable prognosis in cancer.   His laboratory has developed novel whole genome approaches for tracking genetic, epigenetic and gene expression changes in order to identify genes and pathways critical to cancer progression, and signatures for treatment response.

Current Appointments

  • Distinguished Scientist, Integrative Oncology, BC Cancer Agency
  • Deputy Head, Integrative Oncology Department, BC Cancer Agency
  • Professor, Pathology and Laboratory Medicine, University of British Columbia
  • Faculty Member, Interdisciplinary Oncology Program, University of British Columbia

Academic
OpenClose

Academic Backgrounds

  • Postdoctoral Research Associate (Molecular and Cellular Biology) Harvard University. 1994-1998
  • MRC Postdoctoral Fellow (Cellular and Developmental Biology) Harvard University. 1991-1994
  • PhD (Biochemistry) Dalhousie University. 1991
  • BSc and MSc (Microbiology), University of Alberta. 1983, 1986

Awards & Recognition


Selected Publications

  • Martinez VD, Becker-Santos DD, Lam S, Lam WL (2012) How should treatment differ for lung cancers caused by arsenic exposure? Lung Cancer Management 1: 243–246.
  • Hubaux R, Becker-Santos DD, Enfield KSS, Lam S, Lam WL, Martinez VD (2012) Arsenic, asbestos and radon: Emerging players in lung tumorigenesis. Environmental Health 11:89, 1-12.
  • McKee C, Xu D, Cao Y, Kabraji S, Allen D, Kearsman V, Beech J, Smart S, Hamdy F, Ishkanian A, Sykes J, Pintile M, Milosevic M, van der Kwast T, Zafarana G, Ramnarine VR, Jurisica I, Malloff C, Lam W, Bristow RG, Muschel R (2012) Protease Nexin 1 modulates prostate adenocarcinoma by regulating the Hedgehog pathway in humans and mice. Journal of Clinical Investigation 122: 4025-36.
  • Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, Lam S, Gazdar AF, Laird-Offringa IA (2012) Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Research 22:1197–1211.
  • Vucic, EA, Thu KL, Robison K, Rybaczyk L, Chari R, Alvarez CE, Lam WL (2012) Translating cancer omics to outcomes. Genome Research 22:188-95.
  • Hubaux R, Becker-Santos DD, Enfield KSS, Lam S, Lam WL, Martinez VD (2011) MicroRNAs as biomarkers for clinical features of lung cancer. Metabolomics 2:108, 1-11. 2012
  • Lockwood WW, Thu KL, Lin L, Pikor LA, Chari R., Lam WL*, Beer DG* (2012) Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clinical Cancer Research 18: 1936-46.
  • Lin L, Bass AJ, Lockwood WW, Wang Z, Silvers AL, Thomas DG, Li W, Chang AC, Orringer MB, Glover TW, Giordano TJ, Lam WL, Meyerson M, Beer DG (2012) Activation of GATA6 sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 109:4251-6.
  • Enfield KSS, Pikor LA, Martinez VD, Lam WL (2012) Mechanistic roles of non-coding RNAs in lung cancer biology and their clinical implications. Genetic Research International 2012: 737416, 1-16.
  • Martinez VD, Vucic EA, Lam S, Lam WL (2012) Arsenic and lung cancer in never smokers: Lessons from Chile. American Journal of Respiratory and Critical Care Medicine 185: 1131-2.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Cancer progression
  • Genome biology
  • Epigenetics
  • Molecular Systems Biology
  • Lung Cancer
  • Technology Development
  • Dr. Lam’s primary research interest is in understanding the events leading to cancer progression. Early detection and treatment is key to a favorable prognosis in cancer. His laboratory at the British Columbia Cancer Research Centre (http://www.bccrc.ca/dept/ic/genetics) has developed novel whole genome approaches for tracking genetic, epigenetic and gene expression changes in order to identify genes and pathways critical to cancer progression and signatures for treatment response.
Teaching
OpenClose

Teaching

MacAulay, Calum

Portrait photo of Calum MacAulay

Dr.

MacAulay, Calum

BSc, MSc (Dal.), PhD (Brit. Col.)

Basic Info
OpenClose

Academic Rank:

Clinical Associate Professor, Head, Integrative Oncology Department

Affiliation(s):

BC Cancer Research Centre

Location:

BC Cancer Agency

Short Bio

Dr. MacAulay’s lab focuses on early cancer detection and treatment in Lung, Oral, Colon, Cervix using advanced optical imaging techniques with and without molecular contrast agents. Computer assisted and fully automated quantitative cytology and histology systems for screening, diagnosis and prognosis.

Current Appointments:

  • Head – Integrative Oncology Department
  • Distinguished Scientist – Imaging Unit, Integrative Oncology Department
  • Clinical Associate Professor – Pathology and Laboratory Medicine, University of British Columbia

Academic
OpenClose

Academic Backgrounds

  • PhD (Physics), University of British Columbia. 1989
  • MSc (Physics), Dalhousie University. 1984
  • BSc (Eng.Phys.), Dalhousie University. 1982

Awards & Recognition


Selected Publications

  • Pahlevaninezhad H, Lee AMD, Shaipanich T, Raizada R, Cahill L, Hohert G, Yang VXD, Lam S, MacAulay C, Lane PM. A high-efficiency fiber-based imaging system for co-registered autofluorescence-optical coherence tomography (AF-OCT). Biomedical Optics Express. 2014 Aug 6. Vol. 5, Iss. 9, pp. 2978–2987.
  • MacLellan SA, MacAulay C, Lam S, Garnis C. Pre-profiling factors influencing serum microRNA levels. BMC Clin Pathol. 2014 Jun 21;14:27.
  • Lee AM, Kirby M, Ohtani K, CAndido T, Shalansky R, MacAulay C, English K, Finley R, Lam S, Coxson HO, Lane P. Validation of Airpway Wall Measurements by Optical Coherence Tomography in Porcine Airways. PLoS One. 2014 Jun 20; 9(6):e100145.
  • Lee AM, Pahlevaninezhad H, Yang VX, Lam S, MacAulay C, Lane P. Fiber-optic polarization diversity detection for rotary probe optical coherence tomography. Opt Lett. 2014 Jun 15;39(12):3638-41.
  • Baik J, Ye Q, Zhang L, Poh C, Rosin M, MacAulay C, Guillaud M. Automated classification of oral premalignant lesions using image cytometry and Random Forests-based algorithms. Cell Oncol (Dordr). 2014 Jun;37(3):193-202.
  • Wang L, Lee JS, Lane P, Atkinson EN, Zuluaga A, Follen M, MacAulay C, Cox DD. A statistical model for removing inter-device differences in spectroscopy. Opt Express. 2014 Apr 7;22(7):7617-24. doi: 10.1364/OE.22.007617.
  • Pahlevaninezhad H, Lee AM, Lam S, MacAulay C, Lane PM. Coregistered autofluorescence-optical coherence tomography imaging of human lung sections. J Biomed Opt. 2014 Mar;19(3):36022. doi: 10.1117/1.JBO.19.3.036022.
  • Arifler D, MacAaulay C, Follen M, Guillaud M. Numerical investigation of two-dimensional light scattering patterns of cervical cell nuclei to map dysplastic changes at different epithelial depths. Biomed Opt Express. 2014 Jan 15;5(2):485-98. doi: 10.1364/BOE.5.000485.
  • Li G, van Niekerk D, Miller D, Ehlen T, Garnis C, Follen M, Guillaud M, Macaulay C. Molecular fixative enables expression microarray analysis of microdissected clinical cervical specimens. Exp Mol Pathol. 2014 Jan 8. pii: S0014-4800(13)00153-6. doi: 10.1016/j.yexmp.2013.12.007. [Epub ahead of print].
  • Laronde DM, Williams PM, Hislop TG, Poh C, Ng S, Bajdik C, Zhang L, Macaulay C, Rosin MP. Influence of fluorescence on screening decisions for oral mucosal lesions in community dental practices. J Oral Pathol Med. J Oral Pathol Med. 2014 Jan;43(1):7-13. doi: 10.1111/jop.12090.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Automated image analysis of cell preparations
  • In vivo tissue imaging
  • Quantitative microscopy with digital micromirror devices
  • Lung cancer chemoprevention
  • Bioinformatics

 

My research focuses on the research and development of new means for the detection, grading, and treatment of early, non-invasive cancer and to see these means used clinically. It has long been, recognized that all cancer can be successfully treated at an early stage, including cancer of the lung, breast, cervix, colon and prostate. Towards this goal the multi-disciplinary in which I participate have developed several new devices employing solid state sensors and advanced light sources coupled with computer technology. These devices make previously invisible early cancers readily detectable. We developed a device called the Light Induced Fluorescence Endoscope (LIFE), enabling a more than 2X improvement in early lung cancer detection.

As part of NCI/NIH program grant I participate as part of a multi-disciplinary group to develop, apply and test new macroscopic and microscopic optical technologies for the detection and grading of preinvasive cervical interepithelial neoplasias (CIN).

Another system which we developed is a fully automated microscope which can scan microscope slides for the presence of cancerous cells. This device, too, has now been used in clinical trials for detection of early cervical cancer as well as in research for the lung and the breast and is currently being optimized for monolayer cervical smears. Subtle changes in cells, invisible to the human eye, can now be detected with the automated microscope which indicates the presence of cancerous growth, even in the absence of traditionally diagnostic cells. This effect is known as Malignancy Associated Changes (MAC). This is particularly useful in the quantitative screening of sputum cytology which is the only non-invasive method for detecting early non-invasive lung cancer. To better understand the development of normal tissue into invasive neoplasia we have developed and continue to develop tools to measure nuclear morphology and tissue architecture. The measurements from these tools are being used to quantify this development process and to understand the process through mathematical models.

As part of investigating these areas it became obvious that in the interpretation of biopsies much information was being lost in the translation from a three dimensional biopsy to a two dimensional section. To address this issue we are currently working on two new novel methods of DMD (digital micromirror device, TI) enabled three dimensional microscopic imaging (confocal and tomographic reconstruction microscopy). In addition we are also developing confocal in vivo endoscopic applications.

See Also: Lung Cancer: Lung Cancer Chemoprevention

Teaching
OpenClose

Teaching

Bennewith, Kevin

Portrait photo of Kevin Bennewith

Dr.

Bennewith, Kevin

PhD (UBC)

Basic Info
OpenClose

Academic Rank:

Associate Professor

Affiliation(s):

BC Cancer Agency

Location:

BC Cancer Research Centre

Short Bio

Dr. Kevin Bennewith obtained his PhD in Pathology and Laboratory Medicine at UBC in 2004 under the supervision of Dr. Ralph Durand at the BC Cancer Agency. During his PhD training, he studied solid tumour physiology with particular emphasis on quantifying poorly oxygenated (hypoxic) tumour cells. He then joined the laboratory of Dr. Amato Giaccia at Stanford University as a post-doctoral scholar, where he was involved in several projects investigating the role of hypoxia-induced secreted proteins in the growth and metastasis of solid tumours. His post-doctoral work included studying the role of connective tissue growth factor in pancreatic tumour growth and using an orthotopic pancreatic tumour model to study the efficacy of chemotherapeutics designed to target hypoxic tumour cells. He also helped to discover a central role for lysyl oxidase in breast cancer metastasis through promoting the recruitment of bone marrow-derived cells to metastatic target organs. Dr. Bennewith was recruited to the BC Cancer Agency in 2008, and since that time his work has been funded by a Terry Fox Foundation New Investigator Operating Grant, the Canadian Institutes of Health Research Institute of Cancer Research, the BC Cancer Foundation, and a Michael Smith Foundation for Health Research Career Investigator Award. Dr. Bennewith is currently a Scientist at the BC Cancer Agency and an Assistant Professor in Pathology and Laboratory Medicine at UBC.

Academic
OpenClose

Academic Backgrounds

  • PhD, The University of British Columbia,Pathology and Laboratory Medicine. 2004
  • BSc, The University of British Columbia, Chemistry. 1997

Awards & Recognition


Selected Publications

  • Ho VW, Hamilton MJ, Dang NH, Hsu BE, Adomat HH, Guns ES, Weljie A, Samudio I, Bennewith KL and Krystal G. A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. Carcinogenesis 2014 Jul 14. pii: bgu147.
  • Rowbotham D, Enfield KSS, Martinez VD, Thu KL, Vucic EA, Stewart GL, Bennewith KL and Lam WL. Multiple components of the VHL tumor suppressor complex are frequently affected by DNA copy number loss in pheochromocytoma. Int J Endocrinology (accepted) MA. 2014
  • Halvorsen EC, Mahmoud SM and Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev (accepted) SA. 2014
  • Hamilton MJ, Bosiljcic M, LePard NE, Halvorsen EC, Ho VW, Banáth JP, Krystal G and Bennewith KL. Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas. (in press, J Immunol) (Impact Factor 5.673). 2014
  • Wilson IM, Vucic EA, Enfield KSS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TPH, Selamat SA, Laird-Offringa IA, Liu P, Anderson M, You M, Tsao MS, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, and Lam WL. EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene. 2013 Oct 7. doi: 10
  • Hamilton MJ, Banáth JP, Lam V, LePard NE, Krystal G and Bennewith KL. Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice. Cancer Immunol Immunother, 61(5): 643-54, 2012.
  • Hamilton MJ, Antignano F, von Rossum A, Boucher JL, Bennewith KL, Krystal G. TLR agonists that induce IFN-beta abrogate resident macrophage suppression of T cells. J Immunol. 2010 Oct 15;185(8):4545-53. Epub 2010 Sep 15.
  • Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol. 2010 Apr;3(2):109-13.
  • Cairns RA, Bennewith KL, Graves EE, Giaccia AJ, Chang DT, Denko NC. Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104. Clin Cancer Res. 2009 Dec 1;15(23):7170-4. Epub 2009 Nov 17.
  • Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009 Sep 24;35(6):856-67.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Cancer research
  • Solid tumour microenvironment
  • Hypoxia
  • Metastasis research
  • Pre-metastatic niche
  • Targeting hypoxic tumour cells in therapy
  • Radiation biology
  • 2013-present, National Mentor, The Terry Fox Foundation Strategic Initiative for Excellence in Radiation Research for the 21st Century (EIRR21) at CIHR.
  • This integrated Radiation Medicine training program for graduate students and post-doctoral fellows is based out of the University of Toronto, with 32 “local” mentors from Toronto, 3 national mentors from across Canada, and 3 international mentors. I am the national mentor representing the province of British Columbia.
Cancer
Teaching
OpenClose

Teaching

Pallen, Catherine

Portrait photo of Catherine  Pallen

Dr.

Pallen, Catherine

PhD

Basic Info
OpenClose

Academic Rank:

Professor, Department of Pediatrics, Associate Member, Department of Pathology and Laboratory Medicine

Affiliation(s):

BC Children’s Hospital Research Institute

Location:

BC Children’s Hospital Research Institute

Short Bio

Reversible protein tyrosine phosphorylation is a prominent mechanism utilized in controlling these signalling pathways: protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) co-ordinately determine the tyrosine phosphorylation status and the function of a particular substrate protein. Perturbations of such signalling pathways underlie a variety of pathological conditions. Aberrant tyrosine phosphorylation due to malfunctioning PTKs is well established as the basis of several human diseases, in particular human cancers. It is becoming apparent that defective or deregulated PTPs are likewise critical in the development and progression of some human diseases such as cancer and diabetes. Consequently, PTPs are excellent targets for disease intervention.

Academic
OpenClose

Academic Backgrounds


Awards & Recognition

  • Outstanding University Researcher Award 1999/2000, National University of Singapore – 2001
  • MacMillan Distinguished Lecturer, Rutgers University – 2000
  • National Science Award, Singapore – 1995
  • Medical Research Council of Canada Postdoctoral Fellowship – 1986-88
  • Medical Research Council of Canada Studentship Award – 1982-85

Selected Publications

  • Cheng SY, Sun G, Schlaepfer DD, Pallen CJ. Grb2 Promotes Integrin-Induced Focal Adhesion Kinase (FAK) Autophosphorylation and Directs the Phosphorylation of Protein Tyrosine Phosphatase ¦Á by the Src-FAK Kinase Complex. Mol Cell Biol. 2014 Feb;34(3):348-61. doi: 10.1128/MCB.00825-13. Epub 2013 Nov 18. PubMed PMID: 24248601.
  • Meyer DS, Aceto N, Sausgruber N, Brinkhaus H, M¨¹ller U, Pallen CJ, Bentires-Alj M. Tyrosine phosphatase PTP¦Á contributes to HER2-evoked breast tumor initiation and maintenance. Oncogene. 2014 Jan 16;33(3):398-402. doi: 10.1038/onc.2012.585. Epub 2013 Jan 14. PubMed PMID: 23318421.
  • Fam HK, Walton C, Mitra SA, Chowdhury M, Osborne N, Choi K, Sun G, Wong PC, O’Sullivan MJ, Turashvili G, Aparicio S, Triche TJ, Bond M, Pallen CJ, Boerkoel CF. TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells. Mol Cancer Res. 2013 Oct;11(10):1179-92. doi: 10.1158/1541-7786.MCR-12-0575. Epub 2013 Aug 2. PubMed PMID: 23913164.
  • Samayawardhena LA, Pallen CJ.: Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. J Biol Chem. 2008 Oct 24;283(43):29175-85.
  • Bessette DC, Qiu D, Pallen CJ.: PRL PTPs: Mediators and markers of cancer progression. Cancer Metastasis Rev. 2008 Jun;27(2):231-52.
  • Ye H, Tan YJL, Ponniah S, Takeda Y, Wang SQ, Schachner M, Watanabe K, Pallen CJ, Xiao ZC. (2008) Neural recognition molecules CHL1 and NB-3 regulate apical dendrite orientation in the neocortex via PTPalpha. EMBO J. 27: 188-200.
  • Maksumova L, Wang Y, Wong NK, Le HT, Pallen CJ, Johnson P. (2007) Differential function of PTPalpha and PTPalpha Y789F in T cells and regulation of PTPalpha phosphorylation at Tyr789 by CD45. J Biol Chem. 282:20925-32.
  • Le HT, Maksumova L, Wang J, Pallen CJ. (2006) Reduced NMDA receptor tyrosine phosphorylation in PTPalpha-deficient mouse synaptosomes is accompanied by inhibition of four src family kinases and Pyk2: an upstream role for PTPalpha in NMDA receptor regulation. J Neurochem. 98:1798-809.
  • Chen M, Chen SC, Pallen CJ. (2006) Integrin-induced tyrosine phosphorylation of protein-tyrosine phosphatase-alpha is required for cytoskeletal reorganization and cell migration. J Biol Chem. 281:11972-80.
  • Maksumova L, Le HT, Muratkhodjaev F, Davidson D, Veillette A, Pallen CJ. (2005) Protein tyrosine phosphatase alpha regulates Fyn activity and Cbp/PAG phosphorylation in thymocyte lipid rafts.  J Immunol. 175:7947-56.
  • Le HT, Ponniah S, Pallen CJ.  (2004) Insulin signalling and glucose homeostasis in mice lacking protein tyrosine phosphatase alpha.  Biochem Biophys Res Commun. 6;314(2):321-9.
  • Skelton MR, Ponniah S, Wang DZ, Doetschman T, Vorhees CV, Pallen CJ. (2003) Protein tyrosine phosphatase alpha (PTP alpha) knockout mice show deficits in Morris water maze learning, decreased locomotor activity, and decreases in anxiety. Brain Res. 984: 1-10.
  • Zeng L, Si X, Yu WP, Le TH, Ng KP, Teng RMH, Ryan K, Wang DZM, Ponniah S, Pallen CJ. (2003) PTPalpha regulates integrin-stimulated FAK autophosphorylaiton and cytoskeletal rearrangement in cell spreading and migration. J. Cell. Biol. 160:137-46.
  • Pallen CJ. (2003) Protein tyrosine phosphatase alpha (PTPalpha): A src family kinase activator and mediator of multiple biological effects. Curr. Top. Med. Chem. 7:821-35.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Childhood Cancer & Blood Research
  • Protein tyrosine phosphatases in cell signalling, health, and disease
Teaching
OpenClose

Teaching

Schultz, Kirk

Portrait photo of Kirk Schultz

Dr.

Schultz, Kirk

MD

Basic Info
OpenClose

Academic Rank:

Head, Childhood Cancer & Blood Research cluster, CFRI, Senior Clinician Scientist, CFRI, Professor, Division of Hematology and Oncology, Department of Pediatrics

Affiliation(s):

BC Children’s Hospital Research Institute

Location:

BC Children’s Hospital Research Institute

Short Bio

Dr. Schultz’s lab is attempting to harness the immune system to cure child leukemia and to use blood-derived stem cells to cure other life threatening childhood diseases. Currently, blood and marrow transplantation (BMT) is the only successful form of immune therapy for childhood leukemia. Dr. Schultz’s research group focuses on harnessing the immune forces unleashed by BMT to improve immune therapy for childhood leukemia. By increasing their understanding of these important immune forces, they hope to also improve the ability to provide safe tissue transplants when needed. Lastly, the group is focused on developing approaches to extend the ability to use blood-derived stem cells to regenerate damaged tissues, correct the immune system, and save children and adolescents from life threatening childhood diseases.

Academic
OpenClose

Academic Backgrounds


Awards & Recognition

  • Election to Fellowship in the Canadian Academy of Health Sciences (CAHS) – 2014
  • Canadian National Transplant Research Program, CIHR and Genome BC – 2013
  • Geoffrey L. Hammond Lectureship Award, CFRI Member Recognition Awards – 2013
  • NIH/NIAID – U54 grant – 2009-2014
  • CIHR Biomarkers in Chronic GVHD grant – 2009-2014
  • St. Baldrick’s Foundation Grant – 2009-2011
  • NIHLBI/NIC Grant – 2006-2011
  • CIHR/Wyeth Clinical Research Chair in Transplantation – 2003-2008

Selected Publications

  • Suttorp M, Yaniv I, Schultz KR. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S115-22.
  • Goyal RK, Lin Y, Schultz KR, Ferrell RE, Kim Y, Fairfull L, Livote E, Yanik G, Atlas M. Tumor necrosis factor-alpha gene polymorphisms are associated with severity of acute graft-versus-host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study. Biol Blood Marrow Transplant. 2010 Jul;16(7):927-936.e1. Epub 2010 Jan 25.
  • Pulsipher MA, Horwitz EM, Haight AE, Kadota R, Chen AR, Frangoul H, Cooper LJ, Jacobsohn DA, Goyal RK, Mitchell D, Nieder ML, Yanik G, Cowan MJ, Soni S, Gardner S, Shenoy S, Taylor D, Cairo M, Schultz KR. Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2010 Sep;16(9):1212-21. Epub 2010 Jan 14. Review.
  • Schultz KR, Prestidge T, Camitta B.Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. Expert Rev Hematol. 2010 Dec;3(6):731-42.
  • Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA, Heemskerk MB, Horan J, Kamani N, Kasow KA, Chan KW, Lee SJ, Leung WH, Lewis VA, Miklos D, Oudshoorn M, Petersdorf EW, Ringdén O, Sanders J, Schultz KR, Seber A, Setterholm M, Wall DA, Yu L, Pulsipher MA.Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood. 2010 Nov 11;116(19):4007-15. Epub 2010 Jul 29.
  • Rolf N, Kariminia A, Ivison S, Schultz KR. Therapeutic Potential for Toll-Like-Receptor 2 Agonists in Pediatric Acute Lymphoblastic Leukemia (pre-B ALL): Induction of Apoptosis and Anti-ALL Immunogenicity. (ASH Travel Award) 52. Annual Meeting of the American Society of Hematology, Dec.3-7, 2010, Orlando/FL, USA, Blood 116, 21: 381 (2010).
  • Rolf N, Kariminia A, Ivison S, Schultz KR. In Vitro Studies On The Impact Of TLR2 Agonists On The Cytotoxic Potential Of Chemotherapy And Immune Responses In pre-B Acute Lymphoblastic Leukemia (ALL). 2nd International Conference on Immunotherapy in Pediatric Oncology, Oct.11-12, 2010 Houston/TX, USA.
  • Woodard P, Carpenter PA, Davies SM, Gross TG, He W, Zhang MJ, Horn BN, Margolis DA, Perentesis JP, Sanders JE, Schultz KR, Seber A, Woods WG, Eapen M. Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children. Biol Blood Marrow Transplant. 2010 Aug 30.
  • Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010 Aug 10;28(23):3730-8. Epub 2010 Jul 12.
  • Schultz KR. Haploidentical transplantation in children. Blood. 2010 Apr 29;115(17):3420-1
  • Baird K, Cooke K, Schultz KR. Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am. 2010 Feb;57(1):297-322. Review.
  • Cuvelier GD, Kariminia A, Fujii H, Aslanian S, Wall D, Goldman F, Grupp SA, Dunn SE, Krailo M, Shapiro LH, Gilman A, Schultz KR. Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children’s Oncology Groups Study, ASCT0031. Bone Marrow Transplant. 2010 Nov;45(11):1653-7. Epub 2010 Mar 1.
  • Lehman AM, Schultz KR, Poskitt K, Bjornson B, Keyes R, Waters PJ, Clarke LA, Everett R, McConnell D, Stockler S. Intracranial calcification after cord blood neonatal transplantation for krabbe disease. Neuropediatrics. 2009 Aug;40(4):189-91. Epub 2010 Feb 4.
  • Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL, Matherly LH, Schultz KR, Pflumio F, You MJ, Weng AP. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood. 2010 Feb 11;115(6):1175-84. Epub 2009 Dec 11.
  • Reid, GDS, Grupp, S, Schultz KR.: Tumor Immunology and Immunotherapy In: Carroll W and Finlay J, eds. Cancer in Children and Adolescents Jones & Bartlett Publishers, Sudbury Mass; 2009. Chap 4.
  • Schultz KR.: Pathophysiology Of Chronic GVHD In: Vogelsang G, Pavletic S, eds. Chronic Graft Versus Host Disease: Principles And Practice Of Interdisciplinary Management Cambridge Press; 2009.Chap 3,p17-45.
  • Cuvelier GD, Schultz KR, Davis J, Hirschfeld AF, Junker AK, Tan R, Turvey SE.: Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency. Clin Immunol. 2009 May;131(2):179-88.
  • Griffith LM, Pavletic SZ, Lee SJ, Martin PJ, Schultz KR, Vogelsang GB.: Chronic Graft-versus-Host Disease–implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. Biol Blood Marrow Transplant. 2008 Apr;14(4):379-84.
  • Hunger SP, Loh KM, Baker KS, Schultz KR.: Controversies of and unique issues in hematopoietic cell transplantation for infant leukemia. Biol Blood Transplant. 2008 Jan;15(1 Supp):79-83.
  • Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Use of G-CSF in Matched Sibling Donor Pediatric Allogeneic Transplantation: A Consensus Statement from the Children’s Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer. 2006 Apr;46(4):414-21.
  • Schultz KR, Miklos DB, Fowler D, Cooke K,  Shizuru J, Emmanuel E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers MED, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB15, Pavletic SZ Towards Biomarkers For Chronic Graft Versus Host Disease: NIH Consensus Development Project On Criteria For Clinical Trials In Chronic Graft-Versus-Host Disease: III Biomarker Working Group Report  Biol Blood Marrow Transplant 2006 Feb;12(2):126-137.
  • Jastaniah WA, Alessandri AJ, Reid GSD, Schultz KR HLA-DM expression is elevated in ETV6-AML1 translocation positive pediatric acute lymphoblastic leukemia Leukemia Res 2005 Sep 24.
  • Reid GS, She K, Terrett L, Food MR, Trudeau JD, Schultz KR. CpG stimulation of precursor B lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells towards a Th1 response. Blood. 2005 105:3641-7.
  • Shier LR, Schultz KR, Imren S, Regan J, Issekutz A, Sadek I, Gilman A, Panzarella T, Eaves CJ, Couban S. Differential Effects of G-CSF on Marrow and Blood-Derived Hematopoietic and Immune Cell Populations in Healthy Human Donors. Biol Blood Marrow Transplantation St ;10(9):624-34,2004.
  • Schultz KR, Reid G. The Unique Biology and Characteristics of TEL-AML1 (ETV6-CBFA2) Acute Lymphoblastic Leukemia: Potential Therapeutic Approaches. ASCO Educational Book (In press), 2004.
  • Reid GSD, Terrett L, Allessandri A, Grubb S, Stork L, Seibel N, Gaynon P, Schultz KR. Altered Patterns of T Cell Cytokine Production Induced by Relapsed Pre-B ALL Cells/ :eil Res 2-3’27(12):1135-42.
  • Schultz KR, Su WN, Hsiao C-C, Jevon G, Bader S, Gilman AL. Chloroquine Prevention Of Murine MHC Disparate Acute Graft-Versus-Host Disease Correlates With Inhibition Of Spleenic Response To CpG Oligodeoxynucleotides And Alterations In T Cell Cytokine Production, Biol Blood Marrow Transplant 8(12):648-55, 2002.
  • Alessandri AJ, Reid GS, Bader SA, Massing BG, Sorensen PH, Schultz KR. ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. Br J Haematol. 116:266-72, 2002.
  • Reid G, Bharya S and Schultz KR. Phosphoinositide-dependent and -independent natural cell killing of pre-B acute lymphoblastic leukemia cells by IL-2 activated NK cells and NK-92ci Clin Exp Immunol. 129:265-271, 2002.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Childhood Diseases
  • Immune system
  • Childhood leukemia
  • Blood and marrow transplantation
  • Tumour immunology
Teaching
OpenClose

Teaching

Lockwood, William

Portrait photo of William Lockwood

Dr.

Lockwood, William

PhD

Basic Info
OpenClose

Academic Rank:

Associate Professor, Pathology and Laboratory Medicine, Scientist, Integrative Oncology, British Columbia Cancer Agency

Affiliation(s):

BC Cancer Agency

Location:

BC Cancer Agency

Short Bio

Born and raised in Kamloops, BC, Dr. Lockwood obtained his Ph.D. from the University of British Columbia and trained with the lung cancer research group at BC Cancer Research Centre where he worked on characterizing the genetic mechanisms underlying the development of different lung cancer subtypes. He pursued postdoctoral studies as a CIHR Jean-Francois St. Dennis Fellow in Cancer Research in the laboratory of Nobel laureate Dr. Harold Varmus, first at Memorial Sloan-Kettering Cancer Center, New York, and later at the National Human Genome Research Institute in Bethesda. There, he focused on utilizing mouse models of lung cancer to study mechanism of lung cancer initiation, progression and response to therapy and identifying novel therapeutics for lung cancer treatment. Dr. Lockwood returned to the BC Cancer Agency to begin his own research group in 2014 with a focus on understanding lung cancer biology using integrative genomics approaches and is currently a Michael Smith Foundation for Health Research Scholar and Scientist in the Integrative Oncology Department.

Academic
OpenClose

Academic Backgrounds

  • Post-Doctoral Fellow (Cancer Genetics), with Harold Varmus, National Human Genome Research Institute, 2010-2014
  • Post-Doctoral Fellow (Cancer Biology and Genetics), with Harold Varmus, Memorial Sloan-Kettering Cancer Center, 2009-2010
  • PhD (Pathology and Laboratory Medicine), University of British Columbia, 2009
  • BSc (Microbiology and Immunology), University of British Columbia, 2004

Awards & Recognition


Selected Publications

  • Lockwood WW†, Zejnullahu K, Bradner JE, Varmus H (2012) Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 109:19408-13. †Corresponding author. Highlighted in Nature Reviews Cancer (Dec. 2012) Recommended as an article of special significance by F1000.
  • Lockwood WW†, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, Solis LM, Nunez MI, Behrens C, Yee J, English J, Murray N, Tsao MS, Minna J, Gazdar AF, Wistuba II, MacAulay CE, Lam S, Lam WL (2012) Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One. 7(5):e37775. †Corresponding author.
  • Lockwood WW*,†, Thu KL*, Lin L, Pikor LA, Chari R, Lam WL, Beer DG (2012) Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clinical Cancer Research. 18:1936-46. [*co-first authorship] †Corresponding author.
  • Beverly LJ, Lockwood WW, Erdjument-Bromage H, Varmus HE (2012) Ubiquitination, localization and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci U S A. 109:E119-26.
  • Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, DePinho RA, Kemp CJ, Varmus HE, Hanash SM (2011) Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 20:289-99.
  • Lockwood WW†, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, Campbell J, Williams AC, Hwang D, Buys TPH, Yee J, English JC, MacAulay C, Tsao MS, Gazdar AF, Minna JD, Lam S, Lam WL (2010) Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Medicine. 7(7):e1000315. †Corresponding author.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Lung Cancer
  • Cancer Biology
  • Genomics
  • Gene Discovery
  • Mouse Models
  • Targeted Therapies, Biomarkers

Lung cancer is the leading cause of cancer mortality worldwide, suffering from a late stage of disease at the time of diagnosis and a paucity of effective therapeutic strategies to treat advanced tumours. However, with our increasing understanding of lung cancer biology has come the advent of targeted therapies to combat this devastating disease. These therapies target mutated components of key cellular pathways on which tumours have become dependent on for survival, yielding drastic initial response rates without the major side effects of traditional chemotherapies. Despite these successes two major problems remain: first, the majority of lung cancer patients have tumours without mutations in targetable genes and; second, all patients eventually develop resistance to treatment with these targeted agents. In addition, since lung tumours commonly have hundreds of mutated genes, it is difficult to pinpoint those that are responsible for tumour growth and resistance to therapy, creating a clear bottleneck in the translation of laboratory findings to a clinical setting.

Dr. Lockwood’s lab utilizes an integrative strategy to address these issues. Through analysis of the genomic profiles of human lung tumours, he aims to identify novel genes and pathways that are altered during lung cancer development. Furthermore, by combining this information with the characterization of mice genetically engineered to develop lung tumours, he attempts to elucidate the key genes driving lung cancer initiation, progression and response to therapy. Lastly, by screening libraries of chemical compounds across lung cancer cells, he aims to characterize novel inhibitors of these identified genes and their corresponding pathways that show promise for use as targeted therapies. Together, this work will further our understanding of lung cancer biology and create insight toward the development of new approaches to diagnose and treat patients suffering from this disease.

Teaching
OpenClose

Teaching

Lange, Philipp

Portrait photo of Philipp Lange

Dr.

Lange, Philipp

PhD, MSc

Basic Info
OpenClose

Academic Rank:

Assistant Professor, UBC, Investigator, Michael Cuccione Childhood Cancer

Affiliation(s):

BC Children’s Hospital Research Institute

Location:

BC Children’s Hospital Research Institute

Short Bio

Currently there are still no cures for one in every six children suffering from cancer.

Dr. Philipp Lange, Canada Research Chair in ‘Translational Proteomics of Pediatric Malignancies’, develops new diagnostic and therapeutic approaches to detect and treat children suffering from cancer earlier, better and with reduced impact on their life.

His research focuses on the aberrant cellular signaling pathways that are involved in select pediatric cancers. He applies and develops proteomics technologies to detect all proteins in a cell and he monitors how they are changed by post-translational modification (PTM). Such PTM can fundamentally alter the function of a protein. He then explores the role of these PTMs in cancer using cell biology as well as biochemistry and attempts to find new ways of using this knowledge to improve diagnosis and treatment of cancer in children.

Dr. Philipp Lange complements his experimental work with bioinformatics. He focuses on the development of algorithms for the prediction of protein function and the development of new biological knowledgebases to improve the functional analysis of genomics and proteomics data and guide personalized treatment decisions.

Academic
OpenClose

Academic Backgrounds

  • Free University of Berlin, PhD, Biochemistry. 2008
  • University of Hamburg, MSc, Molecular Biology, Microbiology and Computer science. 2004

Awards & Recognition


Selected Publications

  • Pitter F Huesgen, Philipp F Lange , Lindsay D Rogers, Nestor Solis, Ulrich Eckhard, Oded Kleifeld, Theodoros Goulas, F Xavier Gomis-Rüth & Christopher M Overall (2014). LysargiNase mirrors trypsin for protein C-terminal and methylation-site identification Nature Methods 12, 55–58 (2015)
  • Nikolaus Fortelny, Jennifer Cox, Reinhild Kappfelhoff, Amanda E. Starr, Philipp F. Lange, Paul Pavlidis, Christopher M. Overall (2014). Network Analyses Reveal Pervasive Functional Regulation Between Proteases in the Human Protease Web PLoS Biology, 12(5):e1001869. PMID: 24865846.
  • Philipp F Lange*, Pitter F Huesgen*, Karen Nguyen, Christopher M Overall (2014) Annotating N termini for the Human Proteome Project: N termini differentiate stable processed protein species from degradation remnants in the human erythrocyte proteome. Journal of Proteome Research13 (4), 2028-2044 (* joint first authors)
  • Huesgen PF*, Lange PF*, Overall CM (2014) Ensembles of protein termini are sensitive and specific proteolytic signature biomarkers of disease, Proteomics – Clinical Applications (* joint first authors)
  • Lange PF, Overall CM (2013) Protein TAILS: When termini tell tales of proteolysis and function. Current Opinion in Chemical Biology 17(1):73-82
  • Philipp F. Lange, Pitter F. Huesgen, Christopher M. Overall (2012). TopFIND 2.0—linking protein termini with proteolytic processing and modifications altering protein functionNucleic acids research. 40(D1): D351-D361.
  • Philipp F. Lange & Christopher M. Overall (2011). TopFIND, a knowledgebase linking protein termini with functionNature Methods 8: 703–704.
  • auf dem Keller U, Bellac CL, Li Y, Lou Y, Lange PF, Ting R, Harwig C, Kappelhoff R, Dedhar S, Adam MJ, Ruth TJ, Bénard F, Perrin DM, Overall CM (2010). Novel matrix metalloproteinase inhibitor [18F]marimastat-­‐aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancerCancer Research 1;70(19):7562-­9.
  • Philipp F. Lange, Lena Wartosch, Thomas J. Jentsch, Jens C. Fuhrmann (2006). ClC–7 requires Ostm1 as a β–subunit to support bone resorption and lysosomal functionNature 440: 220–223.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

Common Expertise:
Antibody development; Biochemistry; Bioinformatics; Cell biology; Cell culture; Confocal microscopy; Genetics; Histology; Informatics; Immunocytochemistry & immunohistochemistry; Mass spectrometry; Microarrays; Molecular biology; Neurobiology; Physiology; Proteomics; Systems biology

Specialties:

  • Research Areas: Human disease; Ion channels; Post‐translational protein modifications; Protease biology; Protein interaction; Protein termini
  • Genetics: Genetic screenings of autosomal dominant and recessive osteoporosis (ADO, ARO)
  • Proteomics: Enrichment & identification of protein termini (N‐TAILS, C‐TAILS); Mass spectrometric analysis of protease cleavage site specificities (PICS); Multiple reaction monitoring (MRM) of functional protein states (PSP‐ STEP); Phosphoproteomics;
  • Protease substrate identification; Protein databases; Protein quantitation (MS, MS/MS); Protein search engines; Shot‐gun proteomics; Selective protein enrichment;
  • Computational: Clustering; Co‐expression analysis; Confidence calculations; Database development; Data mining; Enrichment analysis; Machine learning; Probabilistic networks; Web application development
  • Cell Culture: Bacterial cultures; Cancer cell Lines; 3D cell culture; Co‐culture systems; Primary cell culture: Fibroblasts;
  • Hepatocytes; Neurons, Osteoclasts
  • Microscopy: Life cell imaging; Fluorescence lifetime microscopy (FLIM) of vesicular chloride; Fluorescence resonance energy transfer (FRET) imaging (membrane protein–‐protein interactions); Ratio metric ion imaging

Animal Models:
In vivo protein endocytosis and degradation essays; Knock‐out mouse models of chloride transporters and subunits; Syngeneic murine breast cancer models

Human Diseases:
Cancer; Neuronal ceroid lipofuscinosis (NCL); Osteopetrosis; Osteoporosis

Teaching
OpenClose

Teaching

Rennie, Paul

Basic Info
OpenClose

Academic Rank:

Honorary Professor

Affiliation(s):

Vancouver Prostate Centre

Location:

Vancouver Prostate Centre

Short Bio

Dr. Rennie is a PhD research scientist. His current research is aimed at determining how androgens regulate gene transcription and how to use this knowledge to prevent progression to androgen independence in prostate cancers. He is also studying prostate-specific elements of gene promoters and working to develop lenti and herpes virus-based vectors as a targeting vehicle for delivery and prostate-specific expression of genes that can control or kill prostate tumour cells.

Academic
OpenClose

Academic Backgrounds

  • BSc (Western Ontario)
  • PhD (Alberta)

Awards & Recognition


Selected Publications

Dr. Rennie’s PubMed record

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Prostate Cancer
Teaching
OpenClose

Teaching

Scott, Mark

Basic Info
OpenClose

Academic Rank:

Clinical Professor, Associate Director, Intellectual Property Senior Scientist

Affiliation(s):

Centre for Blood Research

Location:

Centre for Blood Research, Life Sciences Centre

Short Bio

Dr. Scott’s laboratory is primarily focused on three primary areas of research: 1) investigation of the potential therapeutic use of “immunocamouflaged” cells/tissues in transfusion and transplantation medicine; 2) prevention of viral invasion via viral inactivasion and target cell modification via immunocamouflage; and 3) examining whether the intraerythrocytic chelation and redox-inactivation of the hemoglobin-derived heme and iron present in the sickle and thalassemic RBC can slow/prevent premature red cell destruction.

Academic
OpenClose

Academic Backgrounds

  • PhD, University of Minnesota, Pathobiology (pathology and Laboratory Medicine). 1988
  • MA, Western State College, Gunnison, CO, Science. 1984
  • BA, Western State College, Gunnison, CO, Biology / Psychology. 1979

Awards & Recognition


Selected Publications

  • Chapanian R, Constantinescu I, Medvedev N, Scott MD, Brooks DE, Kizhakkedathu JN. Therapeutic cells via functional modification: influence of molecular properties of polymer grafts on in vivo circulation, clearance, immunogenicity, and antigen protection. Biomacromolecules. 2013 Jun 10;14(6):2052-62.
  • Kwan JM, Guo Q, Kyluik-Price DL, Ma H, Scott MD. Microfluidic analysis of cellular deformability of normal and oxidatively damaged red blood cells. Am J Hematol. 2013 Aug;88(8):682-9.
  • Chapanian R, Constantinescu I, Brooks DE, Scott MD, Kizhakkedathu J. Antigens protected functional red blood cells by the membrane grafting of compact hyperbranched polyglycerols. J Vis Exp. 2013 Jan 2;(71).
  • Chapanian R, Constantinescu I, Rossi NA, Medvedev N, Brooks DE, Scott MD, Kizhakkedathu JN. Influence of polymer architecture on antigens camouflage, CD47 protection and complement mediated lysis of surface grafted red blood cells. Biomaterials. 2012 Nov;33(31):7871-83.
  • Le Y, Li L, Wang D, Scott MD. Immunocamouflage of latex surfaces by grafted methoxypoly(ethylene glycol) (mPEG): proteomic analysis of plasma protein adsorption. Sci China Life Sci. 2012 Mar;55(3):191-201.
  • Wang D, Toyofuku WM, Scott MD. The potential utility of methoxypoly(ethylene glycol)-mediated prevention of rhesus blood group antigen RhD recognition in transfusion medicine. Biomaterials. 2012 Apr;33(10):3002-12.
  • Chapanian R, Constantinescu I, Brooks DE, Scott MD, Kizhakkedathu JN. In vivo circulation, clearance, and biodistribution of polyglycerol grafted functional red blood cells. Biomaterials. 2012 Apr;33(10):3047-57.
  • Wang D, Toyofuku WM, Chen AM, Scott MD. Induction of immunotolerance via mPEG grafting to allogeneic leukocytes. Biomaterials. 2011 Dec;32(35):9494-503.
  • Wang D, Kyluik DL, Murad KL, Toyofuku WM, Scott MD. Polymer-mediated immunocamouflage of red blood cells: effects of polymer size on antigenic and immunogenic recognition of allogeneic donor blood cells. Sci China Life Sci. 2011 Jul;54(7):589-98.
  • Rossi NA, Constantinescu I, Kainthan RK, Brooks DE, Scott MD, Kizhakkedathu JN. Red blood cell membrane grafting of multi-functional hyperbranched polyglycerols. Biomaterials. 2010 May;31(14):4167-78.
  • Rossi NA, Constantinescu I, Brooks DE, Scott MD, Kizhakkedathu JN. Enhanced cell surface polymer grafting in concentrated and nonreactive aqueous polymer solutions. J Am Chem Soc. 2010 Mar 17;132(10):3423-30.
  • Sutton TC, Scott MD. The effect of grafted methoxypoly(ethylene glycol) chain length on the inhibition of respiratory syncytial virus (RSV) infection and proliferation. Biomaterials. 2010 May;31(14):4223-30.
  • Le Y, Scott MD. Immunocamouflage: the biophysical basis of immunoprotection by grafted methoxypoly(ethylene glycol) (mPEG). Acta Biomater. 2010 Jul;6(7):2631-41.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Hematology and Immunology
  • Immunocamouflage of Blood Cells – Red Blood Cells, Leukocytes, and Platelets
  • Redox-Mediated Erythrocyte Injury
  • Anti-Viral Prophylaxis
  • Iron Chelators

 

Dr. Scott’s laboratory is primarily focused on three primary areas of research: 1) investigation of the potential therapeutic use of “immunocamouflaged” cells/tissues in transfusion and transplantation medicine; 2) prevention of viral invasion via viral inactivation and target cell modification via immunocamouflage; and 3) examining whether the intraerythrocytic chelation and redox-inactivation of the hemoglobin-derived heme and iron present in the sickle and thalassemic RBC can slow/prevent premature red cell destruction.

Immunocamouflage of foreign cells and tissues is accomplished via the covalent modification of the cell membrane with nonimmunogenic materials such as methoxypoly(ethylene glycol). This nonimmunogenic barrier prevents the recognition of antigenic sites on the cell membrane by preexisting antibodies –hence preventing immunological rejection – and significantly diminishes the immunogenicity of the foreign cellular epitopes. Ongoing projects within the laboratory include the modification of red blood cells to prevent alloimmunization in the chronically transfused (e.g., sickle cell, thalassemic, autoimmune hemolytic anemia) patient; the prevention of graft versus host disease via lymphocyte modification; and the modification of pancreatic islets for tissue transplantation in diabetes.

Immunocamouflage also has application in the inactivation of viruses and/or prevention of viral infections. Studies in Dr. Scott’s laboratory have demonstrated the utility of the immunocamouflage technique in inactivation viruses contained in blood products by preventing normal cellular invasion. Similarly, the immunocamouflage of the target cells of viruses has also proven effective in preventing viral invasion and infection. The utility of this technology towards blood borne and respiratory (e.g., Rhinoviruses) viruses are actively under investigation.

Additional research in Dr. Scott’s laboratory is directed towards determining whether the intraerythrocytic chelation and redox-inactivation of the hemoglobin-derived heme and iron present in the sickle and thalassemic RBC may significantly delay its premature destruction. Previous studies by this laboratory have demonstrated that the basic pathophysiology of the sickle and thalassemic RBC is mediated by a self-propagating, self-amplifying redox reaction initiated by the initial autoxidation of the sickle hemoglobin or unpaired alpha and beta hemoglobin chains. Subsequent glutathione-driven, iron-mediated, oxidative events degrade additional hemoglobin (releasing more heme/Fe) as well as other cellular components leading to significant functional and structural changes. It is hypothesized that a modest prolongation of the life span of the thalassemic erythrocyte may improve the “effective” erythropoiesis (i.e., hematocrit, reticulocyte count) such that the need for transfusion therapy may be obviated in a significant segment of the thalassemic population.

Teaching
OpenClose

Teaching

Kizhakkedathu, Jay

Basic Info
OpenClose

Academic Rank:

Professor, UBC, Associate Member, Dept of Chemistry, UBC

Affiliation(s):

Centre for Blood Research

Location:

Centre for Blood Research, Life Sciences Centre

Short Bio

My laboratory at Centre for Blood Research (www.cbr.ubc.ca) has interests in various aspects of biomaterial research for applications involving blood and polymers.

My research focuses on:

  1. Macromolecular Therapeutics
    • High molecular weight Iron chelators for Chelation therapy
    • Polymeric Antidotes to reverse the clotting effects of anticoagulants
  2. Polymer Cell Derivatization Technology (Universal blood donor cells and Cell based therapeutic carriers
  3. Development of Blood Compatible Surface Coatings
  4. Development of Polymeric Reagents for Proteomic Applications

Academic
OpenClose

Academic Backgrounds

  • PhD (Chemistry), Indian Institute of Chemical Technology. 2000
  • MSc (Chemistry), Mahatma Gandhi University, India. 1994
  • BSc (Chemistry), Mahatma Gandhi University, India. 1992

Awards & Recognition


Selected Publications

  • Du, Caigan; Mendelson, Asher A.; Guan, Qiunong; Chapanian, Rafi; Chafeeva, Irina; da Roza, Gerald; Kizhakkedathu, JN.* (2014) The size-dependent efficacy and biocompatibility of hyperbranched polyglycerol in peritoneal dialysis. Biomaterials, 35(5), 1378-1389.
  • Yu, X; Yang, X; Horte, S; Kizhakkedathu, JN.; Brooks, DE. (2014) A pH and thermosensitive choline phosphate-based delivery platform targeted to the acidic tumor microenvironment. Biomaterials 35(1), 278-286.
  • Shahinian, H; Loessner, D; Biniossek, ML.; Kizhakkedathu, JN.; Clements, JA.; Magdolen, V; Schilling, O (2014). Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.   Molecular Oncology 8(1):68-82.
  • Tholen, S.; Biniossek, ML.; Gansz, M.; Ahrens, TD.; Schlimpert, M.; Kizhakkedathu, JN.; Reinheckel, T; Schilling, O. (2014) Double deficiency of cathepsins B and L results in massive secretome alterations and suggests a degradative cathepsin-MMP axis. Cellular and Molecular Life Sciences 71(5):899-916.
  • Yu, X; Yang, X; Horte, S; Kizhakkedathu, JN.; Brooks, DE. (2014) A Thermoreversible Poly(Choline Phosphate) Based Universal Biomembrane Adhesive. Macromolecular Bioscience 14(3):334-9.
  • Schlage P, Egli FE, Nanni P, Wang LW, Kizhakkedathu JN, Apte SS, Auf dem Keller U. (2014)Time-resolved analysis of the matrix metalloproteinase 10 substrate degradome. Mol Cell Proteomics. 13(2):580-93.
  • Lai, B. F. L.; Zou, Yuquan; Yang, X; Yu, X; Kizhakkedathu, JN.* (2014) Abnormal blood clot formation induced by temperature responsive polymers by altered fibrin polymerization and platelet binding. Biomaterials 35(8), 2518-2528.
  • Hadjesfandiari, N; Yu, K; Mei, Y; Kizhakkedathu, JN.* (2014) Polymer brush-based approaches for the development of infection-resistant surfaces. Journal of Materials Chemistry B: Materials for Biology and Medicine 2(31), 4968-4978. (Invited Highlights for the Journal)
    (IF-6.504; Citations: ).
  • Imran ul-haq, M; Lai, Benjamin F. L.; Kizhakkedathu, JN.* (2014) Hybrid Polyglycerols with Long Blood Circulation: Synthesis, Biocompatibility, and Biodistribution. Macromolecular Bioscience (2014), Ahead of Print.
  • Chapanian, R., Kwan, DH, Constantinescu, I., Shaikh, F., Rossi, NAA., Withers, SG*. and Kizhakkedathu, JN* (2014) “Enhancement of biological reactions on cell surface via Macromolecular Crowding.” Nature Communications 5:4683.
Research
OpenClose

Current Openings & Opportunities

We are looking for talented graduate students and postdoctoral fellows. Please send your CV.


Current Projects In My Lab include


Research

Major thrust of my research program is to understand molecular level interactions of tailored synthetic polymers with biological systems in the design of novel biomaterials. We take an integrative and interdisciplinary approach with an understanding of the pathophysiology of diseases: advanced polymer synthesis in combination with well designed biological assays and animal models for the discovery of novel polymers and technologies to address unmet clinical needs.

    MACROMOLECULAR THERAPEUTICS:

  • A) Modular Design of  Macromolecular  Iron sequesters: Fundamental studies are directed towards the development of blood compatible long acting Iron chelators which could bind Iron inside the human body and excrete it through kidney. It is estimated that 300,000 babies are born annually with severely low amounts of normal red blood cells (anemia) and many of them require repeated blood transfusions. Unfortunately the blood transfusion will result the build-up of toxic iron in the body. This innovative approach will lead to long circulating and non-toxic iron chelators for the treatment for transfusion associated iron overload (e.g. sickle-cell anaemia, beta-thalessimia, myelodysplastic syndromes) and cancer.
  • B) Antidotes for Anticoagulants to Address Bleeding Complications: Anticoagulation is one of the commonly used clinical interventions in modern medicine.  Parenteral anticoagulants, namely unfractionated heparins (UFH), low molecular weight heparins (LWMHs) and the synthetic heparin pentasaccharide, fondaparinux, are used universally for the prevention of blood coagulation in surgical procedures and and have vital roles in the prophylaxis, and treatment of cardiovascular diseases such as venous and arterial thromboembolism. We are developing novel polymeric systems which reverse the activity of all heparin based anticoagulants.
    POLYMER CELL DERIVATIZATION TECHNOLOGY (Universal blood donor cells and Cell based therapeutic carriers):

  • Our focus is on the development of polymeric cell derivatization technology for the creation of universal blood donor cells and cell surface binding polymers. We are developing novel polymers and techniques to conjugate polymers on to erythrocytes and other cells towards this purpose. We are also extending the application of this technology for converting red cells as a carrier for homeostatic and antithrombotic drugs.
    III. DEVELOPMENT OF ANTITHROMBOTIC AND ANTIMICROBIAL SURFACES:

  • Over the years, we have been working on the development of surface modification methods for various surfaces for enhancing biocompatibility.  Our goal is to understand the various processes when blood comes in contact with a polymeric surface using using a variety of surface analytical techniques, calorimetry, proteomics, blood interaction studies, antibacterial assays and cell-adhesion studies. Novel polymer modification techniques being developed to manipulate its surface interaction with blood, other biological fluids, bacteria and cells. Major interests are in the development of specialty surface coatings for various implants (orthopedic, coronary stents), storage containers for blood and bio-sensors and antimicrobial coatings for implants.
    DEVELOPMENT OF POLYMERIC REAGENTS FOR PROTEOMIC APPLICATIONS: 

  • Proteomics relies upon high efficiency mass spectrometry (MS) analysis of tryptic peptides of up to thousands of proteins present in biological compartments. MS based functional proteomics has emerged as a powerful tool in quantifying and analyzing proteome modifications submitted to different treatments. However, the complexity and high dynamic range of proteins in living organisms and the fact that interesting proteins/protein modifications are often found in low abundance jeopardize functional proteomic analysis. We are developing highly functional, soluble polymeric supports which can be used for selective enrichment of peptides before MS analysis.
Teaching
OpenClose

Teaching

Pryzdial, Edward

Basic Info
OpenClose

Academic Rank:

Clinical Professor, Centre for Blood Research | Department of Pathology and Laboratory Medicine, University of British Columbia, Senior Scientist, Medical Affairs and Innovation, Canadian Blood Services

Affiliation(s):

Centre for Blood Research, Canadian Blood Service – Centre for Innovation

Location:

UBC Life Sciences Centre

Short Bio

Dr. Pryzdial’s doctoral work was on the physical biochemistry of complement protein interactions at the University of Toronto. Although staying in blood protein research, postdoctoral training at the NIH Specialized Centre of Research in Thrombosis, University of Vermont shifted his interests to blood clotting biochemistry. Joining Canadian Blood Services (at that time part of the Red Cross Society) and University of Ottawa in 1990/91, he transferred his laboratory in 2001 to become a member of the UBC Centre for Blood Research. Dr. Pryzdial’s lab members investigate: the regulation of clot formation and how it dissolves; how viruses exploit blood proteins to enhance cellular infection; and the molecular basis of patients with clotting protein deficiency. Particular emphasis is placed on novel applications of plasma proteins to transfusion science and advancing our understanding of heart disease. (www.blood.ca, www.cbr.ubc.ca)

Academic
OpenClose

Academic Backgrounds

  • PhD, University of Toronto, Biochemistry. 1987
  • BSc, University of Toronto, Biology (Major), Chemistry (Minor), Biochemistry, Specialist. 1981

Awards & Recognition


Selected Publications

  • Martínez-Gutierrez F, Thi EP, Silverman JM, de Oliveira CC, Svensson SL, Vanden Hoek A, Sánchez EM, Reiner NE, Gaynor EC, Pryzdial EL, Conway EM, Orrantia E, Ruiz F, Av-Gay Y, Bach H. Antibacterial activity, inflammatory response, coagulation and cytotoxicity effects of silver nanoparticles. Nanomedicine. 2011 Jun 27.
  • Talbot K, Song J, Hewitt J, Serrano K, Ho M, Carter CJ, MacGillivray RT, Pryzdial EL. A novel compensating mechanism for homozygous coagulation factor V deficiency suggested by enhanced activated partial thromboplastin time after reconstitution with normal factor V. Br J Haematol. 2010 Oct;151(2):198-200.
  • Gershom ES, Sutherland MR, Lollar P, Pryzdial EL. Involvement of the contact phase and intrinsic pathway in herpes simplex virus-initiated plasma coagulation. J Thromb Haemost. 2010 May;8(5):1037-43. Epub 2010 Jan 30.
  • Talbot K, Meixner SC, Pryzdial EL. Enhanced fibrinolysis by proteolysed coagulation factor Xa. Biochim Biophys Acta. 2010 Apr;1804(4):723-30.
  • Song J, Talbot K, Hewitt J, MacGillivray RT, Pryzdial EL. Differential contributions of Glu96, Asp102 and Asp111 to coagulation factor V/Va metal ion binding and subunit stability. Biochem J. 2009 Aug 13;422(2):257-64.
  • Churg A, Wang X, Wang RD, Meixner SC, Pryzdial EL, Wright JL. Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol. 2007 Aug;37(2):144-51.
  • Sutherland MR, Friedman HM, Pryzdial EL. Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1. J Thromb Haemost. 2007 May;5(5):1055-61.
  • Grundy JE, Hancock MA, Meixner SC, Mackenzie RC, Koschinsky ML, Pryzdial EL. Plasminogen binds to plasmin-modulated factor Xa by Ca (2+) – and C-terminal lysine-dependent and -independent interactions. Thromb Haemost. 2007 Jan;97(1):38-44.
  • Derry MC, Sutherland MR, Restall CM, Waisman DM, Pryzdial EL. Annexin 2-mediated enhancement of cytomegalovirus infection opposes inhibition by annexin 1 or annexin 5. J Gen Virol. 2007 Jan;88(Pt 1):19-27.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Blood Proteins
  • Coagulation and Fibrinolysis
  • Role of Blood Proteins in Viral Infection

 

The general expertise in our laboratory is the function of blood proteins and there novel application. By combining biochemistry and molecular engineering, we have discovered new functions of several proteins with possible therapeutic or diagnostic applications to heart disease and virus infection. Our long-range goal is to understand how these findings may impact on other blood protein functions and thereby contribute to optimizing the value derived from blood constituents and their substitutes.

Communication Between Clot-Forming and Clot-Dissolving Proteins

Clot generation (coagulation) and subsequent clearance (fibrinolysis) are fundamental biological processes. A high degree of communication between these opposing pathways is necessary to ensure that clots form and dissolve sequentially, and only when needed. The biological effector of coagulation, thrombin, is activated by an enzyme complex consisting of the protease factor Xa (FXa) and its cofactor Va (FVa). In recent work, Dr. Pryzdial’s group identified a previously unknown mechanism of communication between these clotting factors and the fibrinolysis pathway. The data revealed that FXa and FVa accelerate the clot-buster, tissue plasminogen activator (tPA), which is used as an important therapeutic. These studies suggest that the current fibrinolysis dogma must be revised to include auxiliary tPA cofactors, such as FXa and FVa, in the vicinity of the clot to further understand vascular health and pathology.

Blood Proteins Exploited by Viruses

For decades many viruses have been linked to heart disease. To understand the molecular basis of the clinical correlation, Dr. Pryzdial’s group found that at least herpes simplex virus type 1 and type 2, and cytomegalovirus can directly assemble clotting protein complexes on their surfaces to generate thrombin. This bypasses the normally strict regulation of coagulation imposed by cells. Virus initiated clot formation not only contributes to heart disease, but enhances the susceptibility of host cell infection through protease activated receptors and possibly annexins. Dr. Pryzdial and his lab members are further dissecting the specific host- and virus-derived proteins on the virus surface that trigger coagulation and their role in virus propagation.

Teaching
OpenClose

Teaching

Devine, Dana

Basic Info
OpenClose

Academic Rank:

Professor, Pathology and Laboratory Medicine, Medicine

Affiliation(s):

Centre for Blood Research

Location:

Centre for Blood Research, Life Sciences Centre

Short Bio

Current Positions

  • Director, Centre for Blood Research
  • Chief Medical & Scientific Officer, Canadian Blood Services
  • Professor, Pathology and Laboratory Medicine, Medicine
  • Associate Member, Biochemistry and Molecular Biology, Medicine
  • President, Association for the Advancement of Blood and Biotherapies (AABB)

Academic
OpenClose

Academic Backgrounds

  • PhD (Immunology), Duke University, 1986
  • MA (Biology), Boston University, 1981
  • BA (Biology), Boston University, 1978

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

The general subject areas of research expertise of this laboratory are platelet biology, complement biochemistry and blood coagulation. Our particular experimental focus in transfusion medicine is in the area of blood product processing and storage. Ongoing research projects include studies of the storage lesion of platelet concentrates and methods to improve the quality of stored platelet concentrates. Most recently, we have sought to apply leading edge technology to these research questions, in particular through the application of proteomics technology to investigations of blood products.

The research in the laboratory also includes a significant component of applied development work with projects related to practical solutions to issues arising in the manufacture of blood products including process control and quality enhancement through modification of production processes or through understanding more about the significance of the variability of donor characteristics. We have ongoing collaborations with other scientists in all of these areas as well as collaborations with companies working in the blood transfusion business.

Teaching
OpenClose

Teaching

Luo, Honglin

Portrait photo of Honglin Luo

Dr.

Luo, Honglin

MS, MD (Chongqing)

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

Institute for Heart + Lung Health

Location:

James Hogg Research Centre

Short Bio

Dr. Luo received her MD and MSc in Biomedical Engineering in China. She then pursued a postdoctoral training in Cardiovascular research with a focus on signal transduction at the University of Washington. Dr. Luo started her faculty appointment as an Assistant Professor in 2003 at the University of British Columbia. She was a CIHR New Investigator and a MSFHR Scholar. Her research was supported by CIHR, NSERC, CFI, Heart & Stroke Foundation of Canada, ALS Canada, BC Lung, Mitacs, and St. Paul’s Hospital Foundation. Dr. Luo has published 108 peer-reviewed papers (H-index 39 and i10-index 74). Most of these publications have been appeared in leading journals, including Circulation, Nature Medicine, Autophagy, Cell Reports, Journal of Virology, PNAS, Cell Death and Differentiation, Cell Host and Microbe, and Cell Research.

Academic
OpenClose

Academic Backgrounds

  • MD, Chongqing Medical University, China, Medicine. 1986
  • MS, West China University of Medical Sciences, China, Hemodynamics. 1989

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

The focus of Dr. Luo’s research program is to define the molecular and pathogenetic determinants of virus-host interactions in enterovirus-induced cardiac and neurodegenerative diseases. The ongoing research projects include: (1) Understanding molecular mechanisms of impaired cardiac function in enteroviral myocarditis. This research focuses on the protein quality control system, which includes molecular chaperones and protein degradation pathways (i.e., the ubiquitin-proteasome system and autophagy) with the long-term goal to design effective molecular therapies for this disease; (2) Determining the possible role of enteroviral infection in the development of amyotrophic lateral sclerosis (ALS). Dr. Luo’s laboratory recently made an exciting discovery that enteroviral infection results in the hallmark molecular and pathological features of ALS. The current project aims to establish and understand the contribution of enteroviral infection in the pathogenesis of ALS and to test whether application of anti-enterovirus drugs can lessen the progression of ALS; and (3) Developing coxsackievirus B3 (CVB3) as an oncolytis virus for lung cancer treatment. Using cell and mouse models, Dr. Luo’s group recently found that CVB3 is an extremely potent anti-tumor virus, destroying various types of lung cancer cells, with limited effects on normal cells. The present research is to genetically engineer CVB3 to further enhance its safety and anti-tumor potency for the treatment of lung cancer.

Teaching
OpenClose

Teaching

Yang, Decheng

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

James Hogg Research Centre, Institute for Heart + Lung Health, and PROOF Centre

Location:

St. Paul’s Hospital

Short Bio

Dr. Decheng Yang received his BSc in microbiology from Nankai University. He conducted his graduate studies at the University of Illinois at Urbana-Champaign, where he received his MSc in Plant Pathology and a PhD in Molecular Microbiology. He also received his postdoctoral training at the University of Illinois. In 1995, Dr. Yang began his academic appointment as an Assistant Professor at the James Hogg Research Centre, Department of Pathology and Laboratory Medicine, University of British Columbia. He was promoted to Associate Professor in 2001 and then to Professor in 2006, respectively. His research is supported mainly by Canada Institute of Health Research, National Sciences and Engineering Research Council of Canada and Heart and Stroke Foundation of Canada.

Academic
OpenClose

Academic Backgrounds

  • University of Illinois Postdoc. Molecular Microbiology 1989
  • University of Illinois PhD Molecular Microbiology 1986
  • University of Illinois MS Plant Pathology 1982
  • Nankai University BSc Microbiology 1978

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

Dr. Decheng Yang’s research programs focus on the molecular biology and pathogenesis of coxsackievirus B3 (CVB3)-induced myocarditis. Ongoing research projects include:

  • molecular mechanism of CVB3 replication, specifically focusing on the identification of cellular 5’TOP (Terminal oligopyrimidine tract) RNA, a group of cellular mRNAs encoding various components of the translation apparatus, in regulation of CVB3 transcription and translation.
  • Epigenetic analysis of N6-Methyladenosine (m6A) methylation profile of viral and cellular mRNAs in determining viral replication efficiency and pathogenesis of viral myocarditis.

By using genetically modified human iPSC-derived cardiomyocytes and inducible heart-specific gene knockout mice as models, Dr. Yang’s group studies host-viral interaction, particularly the roles of viral and cellular proteases in the pathogenesis of virus-induced heart diseases. These studies are aimed to identify key genes involved in signal transduction pathways leading to cardiomyocyte hypertrophy or injury/death. The identified novel genes may serve as potential targets to design nucleic acid-based therapeutics (siRNA, artificial miRNA) for the treatment of the disease.

Teaching
OpenClose

Teaching

McManus, Bruce M

Portrait photo of Bruce M McManus

Dr.

McManus, Bruce M

MD, PhD, FRSC, FCAHS, FRCPC, FCAP, FACC

Basic Info
OpenClose

Academic Rank:

Professor Emeritus

Affiliation(s):

Centre for Heart Lung Innovation, Prevention of Organ Failure Centre of Excellence (PROOF Centre)

Location:

St. Paul’s Hospital

Short Bio

I have entered my 27th year as faculty at the University of British Columbia. In the focused scientific sense, I have remained intent on answering worthwhile questions about heart allograft rejection, its mechanisms, detection and monitoring, and on issues related to enteroviral damage of myocardium as one pathway to heart failure. I have had the privilege of working with many colleagues and in mentoring numerous trainees in science and clinics regarding heart health, disease and relevant biology. I have enjoyed participation in many organizations locally and globally in this learning journey. It is a pleasure to continue.

Academic
OpenClose

Academic Backgrounds

  • BA – University of Saskatchewan, 1967
  • MSc – Pennsylvania State University, 1969
  • PhD – University of Toledo, 1972
  • PDF – University of California Santa Barbara, 1973
  • MD – University of Saskatchewan, 1977
  • Residency – Harvard University/Peter Bent Brigham Hospital, 1980
  • PDF – National Heart, Lung and Blood Institute, NIH, 1982

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Mechanisms of acute immune rejection of heart allografts
  • Mechanisms of chronic immune rejection of heart allografts
  • Detection of acute cellular rejection of heart allografts
  • Mechanisms of viral heart disease and cardiomyopathies
  • Means for preventing myocardial damage in cardiomyopathies
  • Elephant cardiovascular system
Teaching
OpenClose

Teaching

Granville, David

Portrait photo of David Granville

Dr.

Granville, David

PhD (Brit. Col.)

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

Centre for Heart Lung Innovation UBC, St. Paul’s Hospital

Location:

ICORD

Short Bio

Dr. David Granville is a Professor and Associate Dean, Research in the UBC Faculty of Medicine. He is also the Executive Director of the Vancouver Coastal Health Research Institute, the largest hospital-based research institute in Western Canada. He is a Principal Investigator at the ICORD Centre, the UBC Centre for Heart Lung Innovation and is the Director of the BC Professional Firefighters’ Burn and Wound Healing Research Group. Dr. Granville previously worked at QLT, Inc. (1994-2001) where his R&D studies supported the approval of Visudyne® to be used as the first treatment for macular degeneration, the leading cause of blindness in the elderly. In 1999 Visudyne® was approved by the FDA resulting in the largest ophthalmic product release in history. Dr. Granville’s research is referred to on the drug label for Visudyne®. In 2001, Dr. Granville moved to Scripps where he discovered a novel therapeutic target for attenuating ischemic heart injury related to myocardial infarction and transplantation, which led to the formation of Radical Therapeutix (San Diego, CA). He was recruited back to UBC as an Assistant Professor, Canada Research Chair and MSFHR Scholar to work at the UBC Centre for Heart Lung Innovation (2003-2016). In 2016 he relocated to the ICORD Centre/VCHRI/UBC. Dr. Granville has received numerous awards including a Michael Smith Foundation for Health Research Scholar Award, Canada Research Chair, Canada Top 40 Under 40 Award, Business in Vancouver Top Forty Under 40, Canadian Association of Pathology Scientist Award, UBC Outstanding Young Alumnus Award, SFU Academic Alumnus Award, and was a runner-up for the American Heart Association Louis and Arnold Katz Basic Science Prize. He is also a Scholar of the Royal Society of Canada and a Fellow of the American Heart Association. His current research is focused on mechanisms of tissue injury, inflammation and repair and how aging and dysregulated inflammation affect tissue integrity, repair and remodelling. His recent research has led to the formation of the UBC-spin-off company, viDA Therapeutics of which he is a co-Founder and Chief Scientific Officer.

  • Executive Director, Vancouver Coastal Health Research Institute (VCHRI)
  • Associate Dean, Research – VCHRI, Faculty of Medicine, UBC
  • Associate Director, BC Professional Firefighters’ Burn and Wound Healing Research Laboratory, Division of Plastic Surgery, Department of Surgery, UBC
  • Principal Investigator, UBC ICORD
  • Principal Investigator, UBC Centre for Heart Lung Innovation, St. Paul’s Hospital
  • Associate Member, Department of Surgery, UBC
  • Affiliated Member, CIHR Skin Research Training Centre, UBC
  • Adjunct Professor, Institute of Molecular Biology and Biochemistry, Simon Fraser University
  • Co-Founder and Chief Scientific Officer, viDA Therapeutics Inc.

Academic
OpenClose

Academic Backgrounds

  • PDF, The Scripps Research Institute, Molecular and Experimental Medicine. 2003
  • PhD, The University of British Columbia, Pathology and Laboratory Medicine. 2001
  • BSc, Simon Fraser University, Biological Sciences. 1994

Awards & Recognition

Some of Dr. Granville’s major awards and accomplishments include:

  • Tier II Canada Research Chair
  • Michael Smith Foundation for Health Research Scholar
  • Young Investigator Award, Canadian Society of Transplantation
  • Wilbert J. Keon Award for Basic Science Finalist
  • Canada Top 40 Under 40 Award
  • Outstanding Young Alumnus Award, University of British Columbia
  • American Heart Association – Louis N and Arnold M Katz Basic Science Research Prize Finalist
  • Outstanding Alumni Award for Academic Achievement, Simon Fraser University
  • Canadian Association of Pathologists Junior Scientist Award
  • Business in Vancouver Forty Under 40 Award
  • Fellow of the American Heart Association
  • Scholar of the College of New Scholars, Artists and Scientists of the Royal Society of Canada

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Although his laboratory is quite full at the moment, Dr. Granville is always on the lookout for talented, energetic and bright graduate students and post-doctoral fellows to join his team if funding is available. Please contact Dr. Granville with inquiries.


Current Projects In My Lab include


Research

Aging; Cardiovascular health; dermatology; extracellular matrix; Granzymes; inflammation; proteases; Pulmonary health; remodelling; Repair; Tissue injury; Wound healing

Over the past 20 years, Dr. Granville’s research program has focused on identifying mechanisms that underlie tissue injury and therapeutic targets that can be exploited to reduce injury and/or promote healing. His research is presently centered on how aging and immobility affect tissue injury, inflammation, and repair in different types of tissues. Dr. Granville’s research team is investigating a family of immune cell-secreted proteases known as granzymes (granule-secreted enzymes) and their role in aging and chronic inflammation. Dr. Granville identified that granzymes are elevated and contribute to the pathogenesis of conditions associated with impaired healing and inflammation, including skin injuries, autoimmune skin diseases, and cardiovascular and pulmonary diseases. In order to study granzymes in a diverse set of indications, Dr. Granville collaborates with a network of expert clinical and scientific collaborators. Dr. Granville is currently translating his discoveries into the development and commercialization of novel, first-in-class therapeutics.

At ICORD, Dr. Granville’s team is expanding on their discoveries in tissue injury, inflammation, and repair, and applying their expertise to spinal cord injury, pressure injury, dermatological conditions, and aging-related disorders. Dr. Granville also continues to lead an established research program examining the role of granzymes in cardiovascular and pulmonary diseases. Dr. Granville’s team is currently one of few groups in the world studying granzyme K in inflammation and disease.

Teaching
OpenClose

Teaching

Hill, John

Portrait photo of John Hill

Dr.

Hill, John

PhD

Basic Info
OpenClose

Academic Rank:

Adjunct Professor

Affiliation(s):

James Hogg Research Centre

Location:

James Hogg Research Centre

Short Bio

Dr. John Hill received his undergraduate (BMLSc) and graduate training (MSc, PhD) at UBC in the Faculty of Medicine within the Department of Pathology and Laboratory Medicine ending in 1994. He completed a three-year postdoctoral fellowship in the Lipid Research Laboratory at UCLA in Los Angeles before beginning his appointment at UBC in the Department of Pathology and Laboratory Medicine in January 1998.

Dr. Hill was the Director of the Atherosclerosis Specialty Laboratory of the Healthy Heart Program at St. Paul’s Hospital from 2000-2013. His research program was concerned with lipid and lipoprotein research and its relationship with coronary artery disease.

Currently, Dr. Hill is an Adjunct Professor providing lecture and educational support for a variety of activities at UBC.

Academic
OpenClose

Academic Backgrounds

  • Post-doctoral Fellow, UCLA, Los Angeles, CA. 1997
  • PhD, University of British Columbia, Pathology Lab Medicine. 1994
  • MSc, University of British Columbia, Pathology Lab Medicine. 1990
  • BMLSc, University of British Columbia, Pathology Lab Medicine. 1988

Awards & Recognition


Selected Publications

  • Nurit Fox, Najib Ayas, Julie E. Park, John Fleetham, C. Frank Ryan, Scott A. Lear, Alan Mulgrew, Sammy Chan, John Hill, G. B. John Mancini, Graham C. Wong. Carotid Intima Media Thickness in Patients with Obstructive Sleep Apnea: Comparison with a Community-Based Cohort. Lung. 2014 (in press).
  • Yang, Peng, Belikova, Natalia, Billheimer, Jeff, Rader, Daniel J, Hill, John S, Subbaiah, Papasani V. Inhibition of endothelial lipase activity by sphingomyelin in the lipoproteins. Lipids. 2014 (in press).
  • Dominik Domanski, Andrew J. Percy, Juncong Yang, Andrew G. Chambers, John S. Hill, Gabriela V. Cohen Freue, and Christoph H. Borchers. MRM-based Multiplexed Quantitation of 67 Putative Biomarkers of Cardiovascular Disease in Human Plasma. 2012. Proteomics 12: 1222-43.
  • Claire L Heslop, Scott J Tebbutt, Mohua Podder, Jian Ruan, and John S Hill. Combined polymorphisms in oxidative stress genes predict coronary artery disease and oxidative stress in coronary angiography patients. American Journal of Human Genetics. 2012, 76:435-447.
  • Eliane Picard-Deland, Charles Lavigne, Julie Marois, Julie Bisson, S. John Weisnagel, Andre Marette, Bruce Holub, Eugene Chu, Jiri Frohlich, John S. Hill, and Helene Jacques. Dietary supplementation with fish gelatin modifies nutrient intake and leads to sex-dependent responses in plasma triglyceride concentrations of insulin-resistant subjects. Journal of Nutritional Science. 2012 1:e15.
  • Eugene M. Chu, Daven C. Tai, Jennifer L. Beer, and John S. Hill . Macrophage heterogeneity and cholesterol homeostasis: Classically-activated macrophages are associated with reduced cholesterol accumulation following treatment with oxidized LDL. Biochmica et Biophysica Acta: Molecular and Cell Biology of Lipids. 2012, 1831: 378-386.
  • Hill JS, Heslop C, Man SFP, Frohlich J, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. Eur Heart J 2011 32:1918-25
  • Edelstein C, Pfaffinger D, Yang M, Hill JS, Scanu AM. Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts. Biochim Biophys Acta. 2010 Jul;1801(7):738-45. Epub 2010 Mar 24.
  • Heslop C, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol. 2010 Mar 16;55(11):1102-9.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Blood Research
  • Cardiovascular & Pulmonary
  • Biochemistry and molecular biology of lipids and lipoprotein metabolism, macrophage biology, cardiovascular biomarkers and atherosclerosis
  • Discovery of novel biomarkers for cardiovascular disease
  • Study of the macrophage as a therapeutic target for atherosclerosis
  • Lipid and lipoprotein metabolism in the normal population and in individuals with inherited genetic defects
Teaching
OpenClose

Teaching

Seow, Chun

Portrait photo of Chun Seow

Dr.

Seow, Chun

BSc (Manitoba), PhD (Manitoba)

Basic Info
OpenClose

Academic Rank:

Professor, Affiliated with Institute for Heart + Lung Health

Affiliation(s):

Centre for Heart Lung Innovation (HLI)

Location:

St. Paul’s Hospital

Short Bio

Dr. Seow specializes in smooth and skeletal muscle cell biology/physiology. His current research focus is on the mechanical function, ultrastructure and biochemistry of airway smooth muscle, in health and disease. His current research program is supported by 1 NSERC and 2 CIHR grants research program.  There are two major branches in his research program, one focuses on the basic mechanism of contraction in smooth muscle, the other focuses on airway hyperresponsiveness related to dysfunction of airway smooth muscle. His other research interests include skeletal muscle mechanics, ATPase cycle associated with the crossbridge cycle, visualization of protein-protein interaction, and mathematical modeling of muscle function.

Academic
OpenClose

Academic Backgrounds

  • University of Manitoba B.Sc. Mechanical Engineering, 1984
  • University of Manitoba Ph.D. Physiology, 1989
  • University of Chicago Post-doctoral Fellowship, 1989-1992
  • Special Professional Qualifications: Mechanical Engineer
  • University of Chicago Research Associate, 1992-1996
  • Indiana University Research Associate, July 1996- Sept. 1996

Awards & Recognition


Selected Publications

  • Pascoe CD, Seow CY, Paré PD, Bossé Y. Decrease of airway smooth muscle contractility induced by simulated breathing maneuvers is not simply proportional to strain. J Appl Physiol. 2013 Feb;114(3):335-43.
  • Seow CY. Passive stiffness of airway smooth muscle: the next target for improving airway distensibility and treatment for asthma? Pulm Pharmacol Ther. 2013 Feb;26(1):37-41.
  • Pascoe C, Jiao Y, Seow CY, Paré PD, Bossé Y. Force oscillations simulating breathing maneuvers do not prevent force adaptation. Am J Respir Cell Mol Biol. 2012 Jul;47(1):44-9.
  • Chin LY, Bossé Y, Pascoe C, Hackett TL, Seow CY, Paré PD. Mechanical properties of asthmatic airway smooth muscle. Eur Respir J. 2012 Jul;40(1):45-54.
  • Raqeeb A, Jiao Y, Syyong HT, Paré PD, Seow CY. Regulatable stiffness in relaxed airway smooth muscle: a target for asthma treatment? J Appl Physiol. 2012 Feb;112(3):337-46.
  • Syyong HT, Raqeeb A, Paré PD, Seow CY. Time course of isotonic shortening and the underlying contraction mechanism in airway smooth muscle. J Appl Physiol. 2011 Sep;111(3):642-56.
  • Seow CY, Fredberg JJ. Emergence of airway smooth muscle functions related to structural malleability. J Appl Physiol. 2011 Apr;110(4):1130-5.
  • Raqeeb A, Solomon D, Paré PD, Seow CY. Length oscillation mimicking periodic individual deep inspirations during tidal breathing attenuates force recovery and adaptation in airway smooth muscle. J Appl Physiol. 2010 Nov;109(5):1476-82.
  • Zhang J, Herrera AM, Paré PD, Seow CY. Dense-body aggregates as plastic structures supporting tension in smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2010 Nov;299(5):L631-8.
  • Bossé Y, Solomon D, Chin LY, Lian K, Paré PD, Seow CY. Increase in passive stiffness at reduced airway smooth muscle length: potential impact on airway responsiveness. Am J Physiol Lung Cell Mol Physiol. 2010 Mar;298(3):L277-87.
  • Chin LY, Bossé Y, Jiao Y, Solomon D, Hackett TL, Paré PD, Seow CY. Human airway smooth muscle is structurally and mechanically similar to that of other species. Eur Respir J. 2010 Jul;36(1):170-7.
  • Bossé Y, Chin LY, Paré PD, Seow CY. Chronic activation in shortened airway smooth muscle: a synergistic combination underlying airway hyperresponsiveness? Am J Respir Cell Mol Biol. 2010 Mar;42(3):341-8.
  • Sobieszek A, Sarg B, Lindner H, Seow CY. Phosphorylation of caldesmon by myosin light chain kinase increases its binding affinity for phosphorylated myosin filaments. Biological Chemistry 391(9):1091-1104, 2010.
  • Chin L, Yue P, Feng JJ, and Seow CY. Mathematical simulation of muscle crossbridge cycle and force-velocity relationship.  Biophys J. 91(10):3653-3663, 2006.
  • Seow CY.  Invited Perspective in Cell Physiology: Myosin filament assembly in an ever-changing myofilament lattice of smooth muscle. Am. J. Physiol. Cell Physiol.  289: C1363-C1368, 2005.
  • Seow CY. Biophysics: Fashionable cells.  Nature, 435: 1172-1173, 2005.
  • Herrera AM, McParland BE, Bienkowska A, Tait R, Pare PD, and Seow CY.  “Sarcomeres” of smooth muscle: functional characteristics and ultrastructural evidence.  J. Cell Sci. 118: 2381-2392, 2005.
  • Kuo KH, and Seow CY.  Contractile filament architecture and force transmission in swine airway smooth muscle.  J Cell Sci. 117(Pt 8):1503-1511, 2004.
Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Airway smooth muscle
  • Asthma
  • Respiratory System
  • Muscle mechanics
  • Muscle biochemistry
  • Muscle ultrastructure

 

Dr. Seow specializes in smooth and skeletal muscle cell biology/physiology. His current research focus is on the mechanical function, ultrastructure, and biochemistry of airway smooth muscle in health and disease. There are two main components of his current CIHR and NSERC funded research programs. One focuses on the basic mechanism of contraction in smooth muscle, the other on airway hyperresponsiveness related to dysfunction of human asthmatic airway smooth muscle. His other research interests include skeletal muscle mechanics, ATPase cycle associated with the myosin cross-bridge cycle, and mathematical modeling of muscle function. The main research tools include dynamic myography for muscle mechanics, electron microscope, and atomic force microscope. He collaborates with Dr. Peter Paré at the James Hogg Research Centre and many investigators from UBC and other institutions around the world.

Teaching
OpenClose

Teaching

Ziltener, Hermann

Portrait photo of Hermann Ziltener

Dr.

Ziltener, Hermann

Bioch, PhD (Freiburg, Switzerland)

Basic Info
OpenClose

Academic Rank:

Professor, Dept of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia (retired)

Affiliation(s):

UBC Biomedical Research Center

Location:

UBC Biomedical Research Center

Short Bio

Sugar molecules attached to proteins expressed at the cell surface are increasingly recognized as playing an important role in the control of cell-cell interaction. Specific oligosaccharides can be recognized by sugar binding proteins (so called lectins) and this interaction has the potential to control how a cell interacts with other cells.  Dr. Ziltener is studying the enzymes, “glycosyltransferases” that allow formation of oligosaccharide groups made from sugars such as sialic acid, fucose, galactose and N-acetylglucosamine to form ligands for selectins. Expression of selectin ligands for instance on cells of the immune system is required for these cells to migrate to a site of inflammation, leave the blood vessel and migrate into the tissue where they then participate in the immune response to e.g. a pathogen. Understanding the mechanisms that control the activities of glycosyltransferases that lead to formation of selectin ligands will thus lead to a better understanding of processes that control migration of cells of the immune system to sites of inflammation.

Academic
OpenClose

Academic Backgrounds

  • Postdoctoral Fellow, The Walter and Eliza Hall Institute of Medical Research, Melbourne. 1984-1987
  • PhD, University of Freiburg, Switzerland, Biochemistry. 1977-1983
  • Diploma, University of Freiburg, Switzerland. 1971-1976

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

Research in our laboratory is focused on the role of leukocyte mucin family glycoproteins in both steady state hemopoiesis and inflammation. Leukocyte mucins are heavily glycosylated cell surface molecules that are abundantly expressed; they can have anti-adhesive properties, so-called “molecular Teflon” as well as pro-adhesive properties whereby mucin expressed sugar groups bind selectins or other cell derived lectins such as galectins or sialoadhesins. Given that leukocyte mucins can interact with a range of sugar binding lectins, focus is also on study of the glycosyltransferases that generate the lectin-binding sites on mucin family members.

Teaching
OpenClose

Teaching

Quandt, Jacqueline

Portrait photo of Jacqueline Quandt

Dr.

Quandt, Jacqueline

BSc, PhD (UBC)

Lab Website

Basic Info
OpenClose

Academic Rank:

Assistant Professor, Dept of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia

Affiliation(s):

Centre for Brain Health

Location:

UBC Hospital

Short Bio

Dr. Jacqueline Quandt is the Associate Director of the UBC MS Research Group at UBC and leads the Neuroinflammation Lab at the Djavad Mowafaghian Centre for Brain Health and the Department of Pathology in the Faculty of Medicine. Her research is focused on understanding the role of the immune system in both damage and repair of the brain and spinal cord as a result of neurodegenerative diseases, such as Multiple Sclerosis. Using cell-based and more complex disease models, researchers in the Quandt Lab study the relationships between inflammation and neuronal death.

Academic
OpenClose

Academic Backgrounds

  • BSc (Microbiology and Immunology), University of British Columbia. 1990-1994
  • PhD (Pathology, Section of Neuropathology), University of British Columbia. 1994-1999
  • Post doctoral fellowship (Neuroimmunology Branch), National Institutes of Health, Bethesda, MD. 1999-2005
  • Staff Scientist – Animal Models Unit (Neuroimmunology Branch), National Institutes of Health, Bethesda, MD. 2005-2009

Awards & Recognition


Selected Publications

View Dr. Verchere’s PubMed record here

Research
OpenClose

Current Openings & Opportunities

The Laboratory currently has openings for a graduate student and a post doctoral fellow to pursue independent projects in the areas of neuroinflammation and models of disease. Interested candidates should send their CV and statement of research interests directly to Dr. Quandt.


Current Projects In My Lab include


Research

  • Brain Injury & Repair
  • Sensory/Motor Systems & Movement Disorders

The Quandt lab’s current projects are diverse, but most apply molecular and cellular techniques in cell and disease models to study the way that inflammatory cells contribute to disease development. Having made significant contributions to MS research, the lab is now pursuing discovery in a range of neurodegenerative diseases.

Teaching
OpenClose

Teaching

Kollman, Tobias R

Portrait photo of Tobias R. Kollman

Dr.

Kollman, Tobias R

MD, PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Affiliate Professor, Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, University of British Columbia

Affiliation(s):

BC Children’s Hospital Research Institute

Location:

BC Children’s Hospital Research Institute

Short Bio

As you read this paragraph, two infants in the world will have died from an infection for which there is an effective vaccine. Worldwide we could save 5 million infants every year—if only we could immunize them on time. There appear to be many reasons—none of them insurmountable—why the world fails to save the lives of these children. The work in our lab focuses on part of the science to help solve this problem: we are developing a vaccine system that with only one immunization given at birth will protect from a wide range of specific infectious diseases, as well as from allergies, autoimmune diseases and malignancies, for the entire life. We are systematically analyzing the human neonatal and infant response to danger signals (e.g. TLR-ligands) and vaccines. This way, we will learn what aspects of the newborn’s immune system work well. With that knowledge, we hope to identify immune modulators or adjuvants that would aid in their immune response to vaccines and help protect them from disease. This work is done in close collaboration with several national and international research centres through large clinical trials. Our lab uses state-of-the-art technology (high-throughput flow cytometry, multiplex ELISA, real-time PCR, SNP genotyping, microarrays, etc.) to get the most information from very small samples. Part of this also requires a solid investment into development of optimal bioinformatics tools, and we are part of an international group focused on this important task. Parallel to the human descriptive studies, we are developing a vaccine platform in mice on which we can test our vaccines and define the exact molecular mechanisms at work. For example, we use genetically altered strains of Listeria monocytogenes to target our vaccines to only those cells we want to infect, to then deliver its vaccine antigen, induce the desired immune response, and disappear—all without causing any harm to the newborn. Our preliminary data gives us great hope that our final goal is within reach.

Academic
OpenClose

Academic Backgrounds

  • MD and PhD (Microbiology and Immunology), Albert Einstein College of Medicine (Bronx, New York)
  • Fellowship, Pediatric Infectious Disease, University of Washington

Awards & Recognition

  • Michael Smith Foundation for Health Research Career Investigator Award
  • Canadian Child Health Clinician Scientist Career Development Award
  • Burroughs Wellcome Career Award in the Biomedical Sciences
  • Pfizer Postdoctoral Fellowship in Infectious Diseases
  • Alpha Omega Alpha (National Honour Medical Society)

Selected Publications

View Dr. Verchere’s PubMed record here

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Immunology and immunological diseases
  • Developmental immunology/ neonatal immunology
  • Infectious disease
  • Vaccines

Our lab uses state-of-the-art wet-lab technology and bioinformatic approaches (systems biology) to get the most information out of the smallest samples from newborns and infants around the world. Parallel to these obervational human cohort studies, we are developing in vitro (culture) and in vivo (animal) models where we establish concrete cause & effect of the relationships identified in our systems biological studies. This combined approach allows us to systematically dissect the key cellular and molecular mechanisms important in the human neonatal and infant response to infection or vaccination. Based on that knowledge, we are identifying immune modulators that help protect newborns from disease, and aid in their immune response to vaccines important for global health. This work is done in close collaboration with several large national (e.g. CHILD) and international research groups from Africa and Asia, to Europe, Australia and North America.

Teaching
OpenClose

Teaching

Verchere, Bruce

Portrait photo of Bruce Verchere

Dr.

Verchere, Bruce

BSc, MSc, PhD (Brit. Col.)

Basic Info
OpenClose

Academic Rank:

Professor, Department of Pathology and Laboratory Medicine, Professor, Department of Surgery, Faculty of Medicine, University of British Columbia

Affiliation(s):

BC Children’s Hospital Research Institute

Location:

BC Children’s Hospital Research Institute

Short Bio

  • Investigator, BC Children’s Hospital; Director, Centre for Molecular Medicine and Therapeutics
  • Childhood Diabetes Laboratories, BC Children’s Hospital
  • Irving K Barber Chair in Diabetes Research

Bruce Verchere, PhD, is a Professor in the Departments of Pathology & Laboratory Medicine and Surgery at the University of British Columbia (UBC), head of the Diabetes Research Program at the Child & Family Research Institute (CFRI) at BC Children’s Hospital, and the Irving K Barber Chair in Diabetes Research. His research aims to develop therapeutic approaches for enhancing beta cell survival and function in diabetes and islet transplants and he has published over 100 manuscripts in the field of islet biology and diabetes. Dr. Verchere was awarded the UBC Outstanding Young Alumnus award in 2000, the Canadian Diabetes Association Young Scientist award in 2006, and in 2012 received a Queen Elizabeth II Diamond Jubilee Medal for diabetes research and service. His research is funded by the Canadian Institutes of Health Research (CIHR), Canadian Diabetes Association (CDA), and JDRF. Currently, Dr. Verchere is chair of the CIHR Diabetes Obesity Lipid and Lipoprotein Disorders and JDRF Islet Biology & Transplantation Training and Innovative grant review panels, and a member of the national research council and national board of directors of the Canadian Diabetes Association He has served on the editorial boards of Diabetes and the Canadian Journal of Diabetes and is currently on the editorial board of Endocrinology, and associate editor of the journal Islets.

Academic
OpenClose

Academic Backgrounds

  • Post-doctoral fellow (Molecular Biology), University of Geneva, Geneva, Switzerland. 1997
  • Post-doctoral fellow (Medicine), Veterans Affairs Medical Center, Seattle, Washington Department of Medicine, Seattle, WA. 1996
  • PhD, University of British Columbia, Physiology. 1991
  • MSc, University of British Columbia, Physiology. 1987
  • BSc, University of British Columbia, Cell Biology. 1983

Awards & Recognition


Selected Publications

View Dr. Verchere’s PubMed record here

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Insulin-producing beta cell of the pancreatic islet. The beta cell synthesizes and secretes the precise amount of insulin into the blood so that glucose and other nutrients can be stored as energy in tissue. In persons with diabetes, beta cells are dysfunctional or are destroyed, resulting in a deficiency of insulin secretion, which in turn leads to high blood glucose levels. In type 1 (juvenile onset) diabetes, the beta cells are killed by the patient’s own immune system. In type 2 (adult onset) diabetes, there is a decreased sensitivity of the peripheral tissues to insulin, and the beta cells cannot secrete sufficient insulin to compensate for this demand. Eventually, insulin secretion declines, probably due to loss of beta cells because of the toxic effects of prolonged hyperglycemia and the accumulation of islet amyloid deposits. We are trying to understand how beta cells are killed in both type 1 and type 2 diabetes. In the long term, we hope to devise new ways to protect beta cells from dying, thereby slowing or preventing the onset of the disease.
  • Type 1 diabetes and type 2 diabetes
  • Beta cell biology, islet amyloid, amylin, insulin, prohormone processing, apoptosis, hormone secretion, transgenic mice, islet transplantation, autoantigens, histology
Teaching
OpenClose

Teaching

Côté, Hélène

Portrait photo of Hélène Côté

Dr.

Côté, Hélène

BSc (Laval University ), PhD (University of British Columbia)

Basic Info
OpenClose

Academic Rank:

Professor

Affiliation(s):

Centre for Blood Research, Women’s Health Research Institute

Location:

UBC Hospital, Room G136

Short Bio

Dr. Cote’s research concentrates on the mitochondrial toxicity of drugs, primarily antiretroviral drugs used in HIV therapy. HIV combination therapy has significantly decreased mortality in the HIV infected population. However, treatment is life-long and as HIV infected individuals survive longer, the toxicity of the drugs and the serious side effects associated can cause of morbidity, non-adherence to prescribed therapy and mortality. HIV drugs can increase mitochondrial DNA (mtDNA) depletion/mutation/deletion through pressure on polymerase gamma, the enzyme responsible for mtDNA replication. In addition, some HIV drugs can inhibit telomerase, the enzyme complex elongating telomeric DNA. MtDNA damage and telomere shortening have been associated with diseases and aging.

Academic
OpenClose

Academic Backgrounds

  • BSc, Biochemistry, Laval University. 1987
  • PhD, Biochemistry, University of British Columbia. 1993
  • Post-doctoral Fellow, Biochemistry, University of British Columbia. 1994
  • Post-doctoral Fellow, Biochemistry, University of Washington. 1995-1998
  • Research Associate II, British Columbia Centre for Excellence in HIV/AIDS. 1998-2004
  • Research Scholar B.C. Foundation for Health Research (MSFHR)/St.Paul’s Hospital Foundation Joint Scholarship. 1999-2003
  • Michael Smith Foundation for Health Research Scholar. 2004-2009
  • CIHR New Investigator. 2007-2012

Awards & Recognition


Selected Publications

  • Srinivasa S, Fitch KV, Petrow E, Burdo TH, Williams KC, Lo J, Cote HCF, Grinspoon SK. Soluble CD163 is assoiated with shortened telomere length in HIV-infected patients. J Acquir Immune Defic Syndr 2014 Sep 5. [Epub ahead of print].
  • Ngoma MS, Hunter JA, Harper JA, Church PT, Mumba S, Chandwe M, Côté HC, Albert AY, Smith ML, Selemani C, Sandstrom PA, Bandenduck L, Ndlovu U, Khan S, Roa L, Silverman MS. Cognitive and language outcomes in HIV-uninfected infants exposed to combined antiretroviral therapy in utero and through extended breast-feeding. AIDS. 2014 Jul;28 Suppl 3:S323-30.
  • Zanet DL, Thorne A, Singer J, Maan E, Sattha A Le Campion, Soudeyns H, B, Pick N, Murray M, Money DM, Côté HCF for the CIHR Emerging Team in HIV Therapy and Aging: CARMA. Association between short leukocyte telomere length and HIV infection in a cohort study: No evidence of a relationship with antiretroviral therapy. Clin Infect Dis. 2014 May;58(9):1322-32 (SA).
  • Kalyan S, Huebbe P, Esatbeyoglu T, Niklowitz P, Côté HC, Rimbach G, Kabelitz D. Nitrogen-bisphosphonate therapy is linked to compromised coenzyme Q10 and vitamin E status in postmenopausal women. J Clin Endocrinol Metab. 2014 Apr;99(4):1307-13. (CA).
  • Giesbrecht CJ, Thornton AE, Hall-Patch C, Maan EJ, Cote HCF, Money DM, Murray M, Pick N, and the CIHR team in HIV therapy and Aging. Select neurocognitive impairment in HIV-infected women: Associations with HIV plasma viral load, hepatitis C virus, and depression, but not leukocyte telomere length. PLoS One 2014 Mar; 9(3):e89556 (CA).
  • MacDonald HM, Chu J, Nettlefold L, Maan EJ, Forbes JC, Cote HCF, Alimenti A, and the CIHR Emerging Team Grant on HIV Therapy and Aging (CARMA). Bone geometry and strength are adapted to muscle force in perinatally HIV-infected children and adolescents. J Musculoskelet Neuronal Interact. 2013 Mar;13(1):53-65. (CA).
  • Wagner TA, Lin CH, Tobin NH, Côté HC, Sloan DD, Jerome KR, Frenkel LM. Quantification of mitochondrial toxicity in HIV-infected individuals by quantitative PCR compared to flow cytometry. Cytometry B Clin Cytom. 2013 Jan;84(1):55-8.
  • Zanet, D, Saberi S, Oliveira L, Sattha B, Gadawski I, Côté HCF. Blood telomere length measurement by qPCR: assay considerations. PLoS ONE 2013;8(2):e57787.
  • Stringer HAJ, Sohi GK, Maguire JA, Cote HCF. Decreased Skeletal Muscle Mitochondrial DNA in Patients with Statin–Induced Myopathy. J Neurol Sci. Jan 10 doi:pii: S0022-510X(12)00648-X. 10.1016/j.jns.2012.12.023. [Epub ahead of print].
  • Imam T, Jitratkosol MH, Soudeyns H, Sattha B, Gadawski I, Maan E, Forbes JC, Alimenti A, Lapointe N, Lamarre V, Money DM, Côté HC; the CIHR Emerging Team Grant on HIV Therapy and Aging: CARMA. Leukocyte Telomere Length in HIV-Infected Pregnant Women Treated With Antiretroviral Drugs During Pregnancy and Their Uninfected Infants. J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):495-502.
Research
OpenClose

Current Openings & Opportunities

Currently recruiting Graduate Students.


Current Projects In My Lab include

  • Mitochondrial and telomere toxicity in HIV pregnant women and infants born to HIV-infected mothers. (Leader of 5-year $2.5 million CIHR team grant: Cellular aging and HIV comorbidities in women and children)
  • Mitochondrial and telomere toxicity in HIV and hepatitis C virus (HCV) infections.
  • Development of quantitative assays to measure mitochondrial DNA alterations.
  • Statin-induced mitochondrial toxicity
  • Inherited and acquired mitochondrial disease

 

I am recruiting graduate students. If interested, please send a letter of interest, CV, transcripts, and English proficiency test (GRE, TOEFL) scores if applicable to helene.cote@ubc.ca.

Research

  • HIV infection, antiretroviral therapy and aging
  • Drug mitochondrial toxicity
  • Markers of biological aging
  • Blood Research
  • Infectious Diseases

My research concentrates on the mitochondrial and telomere toxicity of drugs, primarily antiretroviral drugs used in HIV therapy. The use of combination antiretroviral therapy has significantly decreased mortality in the HIV infected population, However, HIV therapy is not a cure and treatment is life-long. As HIV infected individuals survive longer, the effects of chronic HIV infection and the toxicity of antiretroviral drugs can be associated with significant co-morbidities. In addition, HIV antiretroviral therapy in pregnancy prevents mother-to-child HIV transmission but the long-term effects of in utero exposure to HIV and antiretroviral agents remain incompletely understood.

HIV infection can cause chronic immune activation and inflammation that can affect cellular aging, while antiretroviral drugs can lead to oxidative stress, affect mitochondrial and telomeric DNA through a variety of potential mechanisms. As mitochondrial dysfunction and telomere shortening are markers of cellular aging, our research aims to better understand how viral infections and antiretroviral medications may affect aging processes in HIV-infected and affected populations, particularly women and children.

My translational research includes both basic and clinical studies, among them a large cohort study of HIV-infected and uninfected adults (and pregnant women) and children, including HIV-exposed uninfected children: the CARMA cohort.

Infectious Diseases
Teaching
OpenClose

Teaching

Wellington, Cheryl

Portrait photo of Cheryl Wellington

Dr.

Wellington, Cheryl

BSc (U of Alberta), PhD (Brit. Col.)

Basic Info
OpenClose

Academic Rank:

Professor, Department of Pathology and Laboratory Medicine, Faculty of Medicine, UBC

Affiliation(s):

Centre for Brain Health

Location:

Djavad Mowafaghian Centre for Brain Health

Short Bio

Dr. Wellington is a basic research scientist whose research interests focus on three common genetic and environmental risk factors for dementia, including apolipoprotein E (apoE) metabolism, history of traumatic brain injury (TBI), and cerebrovascular dysfunction.

Dr. Wellington holds leadership positions in both the dementia and neurotrauma communities, including the Canadian Traumatic Brain Injury Research Consortium, the International Traumatic Brain Injury Research Consortium, the Canadian Consortium for Neurodegeneration in Aging, and the AstraZeneca ApoE Alzheimer Disease Academic Alliance.

Academic
OpenClose

Academic Backgrounds

  • PhD, University of British Columbia, Microbiology. 1991
  • BSc, University of Alberta, Microbiology (1st Class Honors). 1985

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Brain Injury & Repair
  • Learning/Memory & Dementias
  • Dr. Wellington is internationally recognized for her work on lipid and lipoprotein metabolism in the brain, and her group has made key contributions to the understanding of the role of apolipoprotein E (apoE) in Alzheimer’s Disease. ApoE is the major cholesterol carrier in the brain and the best established genetic risk factor for typical late-onset Alzheimer’s Disease. ApoE also plays a critical role in repair of damaged neurons after TBI. Dr. Wellington’s program also is closely linked with initiatives exploring the contributions of the vascular system and metabolic disease to dementia.

    Additionally, Dr. Wellington’s group has recently developed an entirely novel, non-surgical animal model of concussion that for the first time, accurately mimics the biomechanics and the neuropathology of human head injury. Her current research projects include drug discovery efforts to increase apolipoprotein function in the brain for application to both Alzheimer’s Disease and TBI, understanding how movement of the head and brain after TBI correlate with behavioural and neuropathological outcomes, and tissue engineering approaches to investigate cerebrovascular function in health and disease.

    Dr. Wellington’s research interests are highly multipdisciplinary with major efforts in the fields of Alzheimer’s Disease (AD) and Traumatic Brain Injury (TBI). With respect to both AD and TBI programs, her laboratory is the leading Canadian site for research on blood biomarkers using the Simoa platform, as she is the first in Canada to operationalize the Quanterix Simoa HD-1 Analyser. Her lab’s first paper using this platform to study serum tau as a biomarker in pediatric TBI was published online in June 2019 in Lancet Child and Adolescent Health. Dr. Wellington’s work on AD focuses mainly on how lipoproteins affect AD pathogenesis, with major programs focused on apolipoprotein E (apoE) and apoA-I, which is the major lipoprotein found on circulating high-density lipoprotein (HDL; the good cholesterol). For the AD program, her team uses a combination of animal models and in vitro platforms, including pioneering a human-based 3D tissue engineered model of perfusable cerebral vessels surrounded by astrocytes and, now, neurons. Along with Dr. Peter Cripton, a Mechanical Engineer, her laboratory developed the CHIMERA (Closed Head Model of Engineered Rotational Acceleration) animal model of TBI that is currently operational for mice, rats and ferrets. Thus far, this program has produced 9 peer-reviewed primary papers with 4 additional manuscripts under review. Importantly, the Wellington lab is committed to facilitating the dissemination of this platform to both academia and industry through licensing agreements. To date, they have completed 15 licensing agreements, which include building a CHIMERA device for the client, shipping, and traveling to the client’s facility to install CHIMERA and train new users on this platform.

Teaching
OpenClose

Teaching

Rajcan-Separovic, Evica

Portrait photo of Evica Rajcan-Separovic

Dr.

Rajcan-Separovic, Evica

MSc, PhD (Molecular Cytogenetics), FCCMG

Basic Info
OpenClose

Academic Rank:

Clinical Professor, Department of Pathology and Laboratory Medicine, Affiliate Investigator, BC Children’s Hospita

Affiliation(s):

BC Children’s Hospital Research Institute

Location:

BC Children’s Hospital Research Institute

Short Bio

My laboratory studies genomic abnormalities as the cause of human diseases. We use genomic microarrays to detect tiny chromosomal microdeletions and microduplications in patients with intellectual disability, autism or reproductive disorders. Most recently, we started using next generation sequencing to identify even smaller abnormalities in the DNA from our patients. Our current interest includes finding the functional consequences of gene copy number or sequence changes in patient cells and in animal models (e.g. zebrafish or C.elegans). Our ultimate goal is to understand better the connection between the phenotypic abnormalities in our patients and the defects in their genes.

Academic
OpenClose

Academic Backgrounds

  • Michael Smith Foundation of Health Research Scholar, 2008-2014
  • CIHR Clinical Investigatorship, 2005-2009
  • Fellow of the Canadian College of Medical Genetics, subspecialty cytogenetics, 1998-present
  • CCMG Postdoctoral Fellowship (Clinical Cytogenetics), Children’s Hospital of Eastern Ontario, 1995-1997
  • Postdoctoral Fellow (Genetics) University of Ottawa, Ontario, 1993-1995
  • NSERC Visiting Fellowship, Agriculture Canada, Ottawa, 1991-1993
  • PhD, University of Belgrade, Yugoslavia, Molecular Cytogenetics. 1989
  • MSc, University of Belgrade, Yugoslavia, Cytogenetics. 1985
  • BSc, University of Novi Sad, Yugoslavia, Biology. 1983

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Genomic changes in human miscarriages and their functional consequences
  • Genomics of intellectual disability
Teaching
OpenClose

Teaching

Devlin, Angela

Portrait photo of Angela Devlin

Dr.

Devlin, Angela

BSc, PhD

Basic Info
OpenClose

Academic Rank:

Professor, Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, University of British Columbia

Affiliation(s):

BC Children’s Hospital Research Institute

Location:

BC Children’s Hospital Research Institute

Short Bio

Recent evidence suggests that a mother’s diet during pregnancy can influence the development of cardiovascular disease (CVD) risk factors in their adult children. Currently my research focuses on determining how this occurs. I speculate that maternal diet during pregnancy can influence gene expression in children through epigenetic processes, defined as heritable changes in gene expression that occur without a change in the DNA sequence of the gene. I’m conducting studies in mice to determine the roles of prenatal and early postnatal diet and the role of epigenetic processes in the development of CVD, and am addressing the questions: if diet during adult life can change epigenetic processes, what happens to offspring exposed early in development to a similar nutrient insult, and are there consequences later in life? Overall determining how diet and epigenetic processes contribute to CVD will aid in the development of early screening tools for at-risk children, and novel therapeutic targets for prevention and treatment of CVD.

Academic
OpenClose

Academic Backgrounds


Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Diet, epigenetics, cardiovascular disease
  • Nutrigenomics: gene-nutrient interactions, nutrient regulation of gene experssion, metabolic effects of genetic polymophisms and how these contribute to chronic disease
  • Metabolism & Epigenomics: impact of metabolism on epigenetic processes such as DNA methylation
Teaching
OpenClose

Teaching

Sinclair, Graham

Portrait photo of Graham  Sinclair

Dr.

Sinclair, Graham

PhD, FCCMG

Basic Info
OpenClose

Academic Rank:

Clinical Professor, Dept of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia

Affiliation(s):

BC Children’s Hospital Research Institute

Location:

Children’s & Women’s Health Centre of BC

Short Bio

Newborn screening is designed to identify infants with treatable rare disorders at birth in order to start therapies before the infants get sick. These disorders can lead to developmental disability, growth failure, liver disease, seizures, and even death if untreated. The investigation of potential new candidate disorders for screening, evaluation of new screening tests or improvement of existing methods, and the measurement of the long-term effectiveness of screening to improve health are all active aspects of my research.

We have a focus on disorders affecting the use of fats as an energy source and a variant of one of these disorders that is common to coastal BC First Nations. This variant is associated with an increased risk of infant death, but may also have benefits related to traditional diets.. Investigation of this variant will lead to a better understanding of its clinical impact and help to identify effective interventions.

Academic
OpenClose

Academic Backgrounds

  • Fellowship (CCMG, Biochemical) University of British Columbia.  2007
  • Postdoctoral Research Fellow, University of British Columbia.  2004
  • PhD (Molecular Biology), University of Victoria. 2001
  • Bachelor of Science (Genetics), University of British Columbia. 1995

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Biochemical Genetics, Inborn errors of metabolism, Newborn screening
  • Fatty Acid Oxidation Disorders: Disorders of fatty acid oxidation are a rare but treatable group inborn errors of metabolism. We are investigating a mild variant of a fatty acid oxidation disorder (CPTI, P479L) that appears to be common to coastal BC First Nations and is associated with an increased risk of sudden death in infancy. Using a combination of biochemical, genetic, and linked-population health approaches, we are working with the affected communities to better define the natural history, clinical risks, and appropriate interventions for this variant.
  • Clinical Applications of Mass Spectrometry: We have a number of investigations underway to apply tandem mass spectrometry-based small molecule analysis to the diagnosis of inborn errors of metabolism, and as a replacement for routine clinical tests currently utilizing radio-isotopes for analysis.
  • Newborn Screening: Ongoing evaluation of health outcomes associated with disorders on the current BC Newborn Screening test panel and investigation of novel testing methodologies and new disorders as potential candidates for the further improvement/ expansion of the newborn screening program.
  • Clinical: Neonatal screening, Inborn errors of metabolism Laboratory:Mass spectrometry
Teaching
OpenClose

Teaching

Heather Cheadle

Portrait photo of Heather Cheadle

Heather Cheadle

Basic Info
OpenClose

Academic Rank:

Affiliation(s):

Location:

UBC Point Grey Campus

Short Bio

Academic
OpenClose

Academic Backgrounds

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Teaching
OpenClose

Teaching

Guilaine Boyce

Portrait photo of Guilaine Boyce

Guilaine Boyce

Degree Program:

PhD

Date of Entry:

2012-09-04

e-mail:

Basic Info
OpenClose

Academic Rank:

Affiliation(s):

Location:

The University of British Columbia

Supervisor:

Cheryl Wellington

Short Bio

Academic
OpenClose

Academic Backgrounds

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Teaching
OpenClose

Teaching

Laule, Cornelia

Portrait photo of Cornelia Laule

Dr.

Laule, Cornelia

BSc, MSc, PhD

Basic Info
OpenClose

Academic Rank:

Associate Professor, Department of Radiology and Pathology & Laboratory Medicine, Faculty of Medicine, UBC, MR Physicist, Blusson Spinal Cord Centre/ICORD and DMCBH

Affiliation(s):

Blusson Spinal Cord Centre / ICORD and DMCBH

Location:

Blusson Spinal Cord Centre

Short Bio

Dr. Cornelia (Corree) Laule is a physicist and has been involved with nuclear magnetic resonance and magnetic resonance imaging (MRI) research for 22 years. She completed a post-doctoral fellowship with Dr. Wayne Moore in the Department of Pathology & Laboratory Medicine where her research focused on MRI pathology correlation studies in multiple sclerosis (MS) brain tissue. Dr. Laule was appointed as an Assistant Professor in the Faculty of Medicine in January 2013 and promoted with tenure in July 2019.

Academic
OpenClose

Academic Backgrounds

  • BSc (Major: Physics, Minor: German), University of British Columbia (1994-1999)
  • MSc (Physics), University of British Columbia (1999-2001)
  • PhD (Physics), University of British Columbia (2001-2005)
  • Research Associate, Department of Radiology, University of British Columbia (2005-2010)
  • Post doctoral fellowship, Department of Pathology & Laboratory Medicine, University of British Columbia (2010-2012)

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • MRI
  • brain & spinal cord
  • myelin
  • T1 and T2 relaxation
  • multiple sclerosis
  • CNS diseases
  • myelin water imaging
  • histology-MRI correlation
Teaching
OpenClose

Teaching

DeMarco, Mari

Portrait photo of Mari DeMarco

Dr.

DeMarco, Mari

PhD, DABCC

Basic Info
OpenClose

Academic Rank:

Clinical Associate Professor , Clinical Chemist, Providence Health Care

Affiliation(s):

The Centre for Heart Lung Innovation

Location:

St. Paul’s Hospital

Short Bio

Dr. DeMarco is a Clinical Chemist for St. Paul’s Hospital, Providence Health Care, a Clinical Associate Professor at the UBC Department of Pathology and Laboratory Medicine, and a Principal Investigator at the Centre for Heart Lung Innovation.

Her lab’s overall focus is on impacting patient care through the development of new and/or improved biofluid tests for peptide and protein biomarkers, and the translation of these tests into routine care. Dr. DeMarco was named as a Michael Smith Foundation for Health Research Scholar for her work developing biofluid diagnostic tests for Alzheimer’s disease and related forms of dementia.

Dr. DeMarco is an active member of her research and professional communities, for example, participating in guideline development for clinical laboratory standards for mass spectrometry assays, serving on the board of editors for the leading journal in laboratory medicine, and taking leadership roles in professional organizations such as the American Association for Clinical Chemistry, Mass Spectrometry: Applications to the Clinical Lab and the BC Association of Clinical Scientists.

Academic
OpenClose

Academic Backgrounds

  • BSc, Honors Biochemistry (major), Mathematics (minor), Computational Chemistry (concentration), Mercyhurst University
  • PhD, Medicinal Chemistry, Biomolecular Structure and Design Program, University of Washington
  • Diplomate of the American Board of Clinical Chemistry
  • Fellow of the Canadian Academy of Clinical Biochemistry

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

With a strong interest in bridging basic biomedical science, analytical chemistry, and laboratory medicine, Dr. DeMarco’s research group specializes in new methodological approaches for identification and quantitation of protein biomarkers of health and disease. A particular focus is advancing clinical diagnostics for neurodegenerative disorders, such as Alzheimer’s disease and frontotemporal dementia. Another area of focus is the development of streamlined proteomic workflows suitable for implementation of clinical mass spectrometric assays in hospital laboratories. The work to translate new biomedical discoveries into patient care is accomplished in collaboration with clinicians and scientists at the UBC Centre for Brain Health, the Clinic for Alzheimer’s Disease and Related Disorders and HLI.

Teaching
OpenClose

Teaching

Moore,Wayne GR

Portrait photo of G R Wayne Moore

Dr.

Moore,Wayne GR

BSc (Nfld.), MD(McG.), FRCPC

Basic Info
OpenClose

Academic Rank:

Clinical Professor, Dept of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia

Affiliation(s):

ICORD

Location:

Vancouver General Hospital

Short Bio

Sugar molecules attached to proteins expressed at the cell surface are increasingly recognized as playing an important role in the control of cell-cell interaction. Specific oligosaccharides can be recognized by sugar binding proteins (so called lectins) and this interaction has the potential to control how a cell interacts with other cells.  Dr. Ziltener is studying the enzymes, “glycosyltransferases” that allow formation of oligosaccharide groups made from sugars such as sialic acid, fucose, galactose and N-acetylglucosamine to form ligands for selectins. Expression of selectin ligands for instance on cells of the immune system is required for these cells to migrate to a site of inflammation, leave the blood vessel and migrate into the tissue where they then participate in the immune response to e.g. a pathogen. Understanding the mechanisms that control the activities of glycosyltransferases that lead to formation of selectin ligands will thus lead to a better understanding of processes that control migration of cells of the immune system to sites of inflammation.

Academic
OpenClose

Academic Backgrounds

  • Fellow of the Royal College of Pathologists (UK). 2007
  • Certification in Neuropathology by the Royal College of Physicians and Surgeons of Canada. 1980
  • Certification in Neurology by the Royal College of Physicians and Surgeons of Canada. 1978
  • MD, CM, McGill University, Montreal, QC. 1972
  • BSc, Memorial University of Newfoundland, St. John’s, NL. 1968

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities

Please contact Dr. Moore with inquiries.


Current Projects In My Lab include


Research

  • Multiple Sclerosis
  • spinal cord injury

Dr. Moore conducts research on the pathology of multiple sclerosis (MS) and spinal cord injury. Dr. Moore is a Principal Investigator at ICORD and a Clinical Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. He completed his B.Sc. at Memorial University of Newfoundland, and his M.D. at McGill University.

Teaching
OpenClose

Teaching

Priatel, John

Portrait photo of John Priatel

Dr.

Priatel, John

PhD

Basic Info
OpenClose

Academic Rank:

Honorary Assistant Professor, UBC; Chief Research Officer at ME Therapeutics Inc.

Affiliation(s):

ME Therapeutics Inc.

Location:

ME Therapeutics Inc.

Short Bio

Academic
OpenClose

Academic Backgrounds

  • PhD, University of British Columbia, Biomedical Research Centre ) then moved with advisor to Howard Hughes Medical Institute, University of California San Diego, (Genetics Program). 1990 – 1997
  • BSc, University of British Columbia, (Microbiology & Immunology). 1985 – 1989

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

My primary research is focused at investigating the genetic and physiological bases of immune system functioning and how it relays to immunological tolerance. The ability to discriminate self- from foreign-antigens is essential for both generating efficacious immune responses and avoiding the ravages of autoimmunity. My lab’s scientific themes will center on investigating immune functions in both human and mouse cells as a means of discovering novel therapies for autoimmune type 1 diabetes (T1D) and other forms of autoimmunity. A greater understanding of the immune system will lead to improved care for patients with primary Immunodeficiencies, autoimmune diseases and cancers. My work has been published in high impact journals such as Immunity, Blood and The Journal of Immunology and has been supported by the Canadian Institute of Health Research and the Juvenile Diabetes Research Foundation.

Teaching
OpenClose

Teaching

Steidl, Christian

Portrait photo of Christian Steidl

Dr.

Steidl, Christian

MD, PhD

Basic Info
OpenClose

Academic Rank:

Professor, UBC, Associate Vice President Research at BC Cancer Research Centre, Head, Department of Lymphoid Cancer Research, Research Director of Centre for Lymphoid Cancer

Affiliation(s):

BC Cancer Research Centre

Location:

BCCA/BCCRC

Short Bio

Dr. Steidl is the Research Director of the Centre for Lymphoid Cancer at BC Cancer and Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. He has specific expertise in clinical malignant hematology, molecular pathology, genomics and lymphoma biology. Dr Steidl’s translational research group focuses on the pathogenesis of B cell lymphomas, tumor microenvironment biology and applied genomics.

Dr. Steidl contributed to the discovery of novel somatic gene mutations in B cell lymphomas using next generation sequencing, and established microenvironment composition, and tumor-associated macrophages and normal B cells in particular, as novel biomarkers for outcome prediction in Hodgkin lymphoma. These seminal studies have led to multiple high-impact publications with him as the first or senior author including publications in the New England Journal of Medicine, Nature, Nature Genetics, Cancer Discovery, the Journal of Clinical Oncology and Blood. His leading role in the Centre for Lymphoid Cancer, associated membership to BCC’s Lymphoma Tumor Group as well as active collaborations with scientific consortia (Leukemia and Lymphoma Molecular Profiling Project, Interlymph Hodgkin lymphoma group) and clinical trials groups (Canadian Cancer Trials Group, Eastern Clinical Oncology Group, Children’s Oncology Group) enable the use of primary biopsy material as the start and end points of discovery and biomarker studies in his lymphoma program promoting precision oncology. The Steidl lab is ideally positioned to perform next generation sequencing experiments, downstream data analysis and biological/clinical interpretation of large datasets. With specific relevance to the feasibility of the experiments in the current proposal, the Steidl lab has produced single-cell RNAseq data in primary cell suspension of Hodgkin lymphoma and follicular lymphoma to characterize microenvironment composition and functional state at unprecedented resolution. Single-cell sequencing methodologies will form the basis of novel and detailed genetic and phenotypic investigations into the crosstalk of malignant cells with their microenvironment as proposed in this grant application in the context of ovarian cancer.

Dr. Steidl holds a CIHR Foundation grant investigating the biological underpinnings of cellular crosstalk in lymphoma and is lead investigator of a team grant on treatment failure in lymphoid cancers funded by the Terry Fox Research Institute (TFRI). He is also project leader of a Genome Canada Large-Scale Applied Research Project (LSARP) to advance personalized treatments of lymphoid cancer patients. Dr Steidl is a member of the Scientific Advisory Board of the Lymphoma Research Foundation, past Chair of the American Society of Hematology Scientific Committee on Lymphoid Neoplasia and Member of the Leukemia and Lymphoma Society of Canada Medical and Scientific Advisory Committee. In 2017, he was inducted as a member of the Royal Society of Canada, College for New Scholars, Artists and Scientists.

Academic
OpenClose

Academic Backgrounds

  • PhD equivalent, Universitat Witten / Herdecke, Germany. 2003
  • MD, University of Muenster Medical School, Germany. 2001

Awards & Recognition

  • Career Investigator of the Michael Smith Foundation for Health Research (MSFHR)
  • Canadian Institutes of Health Research (CIHR) New Investigator Award

Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

The research of the Steidl laboratory focuses on the molecular characterization of lymphoid cancers and biomarker discovery in a variety of Hodgkin and Non-Hodgkin lymphoma subtypes. Our translational lymphoma research group uses a variety of state-of-the-art genome-wide discovery tools including array-based and digital gene expression profiling, single-nucleotide polymorphisms analysis and massively parallel sequencing techniques. A main research goal of the lab is to identify and functionally study underlying genetic mechanisms of immune privilege in lymphoid cancers. In previous work using next generation sequencing, we identified several driver mutations and gene fusions, in particular, that have been shown to arise from specific chromosomal rearrangements in Hodgkin lymphoma and primary mediastinal large B cell lymphoma. Most of the identified genes (e.g. CIITA, CD274, PDCD1LG2) feature prominently in immune cell function impacting non-neoplastic cells in the tumour microenvironment. The discovery of these changes across a wide spectrum of lymphomas will likely reinforced the paradigm that immune privilege is a critical component of cancer phenotypes.

Another focus of the laboratory is on the specific composition of the tumour microenvironment in Hodgkin lymphoma. Using gene expression profiling and immunohistochemistry we have identified that the number of tumour-associated macrophages in lymph node biopsies is linked to unfavourable treatment outcome. However, many questions remain regarding the molecular mechanisms underlying the interaction of the malignant cells with infiltrating macrophages and immune cells in the microenvironment in general. Recently, CSF1R has been identified as a key molecule expressed on Hodgkin Reed Sternberg (HRS) cells and tumour-associated macrophages in Hodgkin lymphoma. We now seek to better describe the phenotype of tumour-associated macrophages found in lymphoma biopsies to shed more light on this tumour-microenvironment interaction and to test if this cross-talk can be targeted by small molecule inhibitors in-vitro.

Lymphoma relapse and progression is still one of the major clinical challenges in clinical care and our knowledge about the underlying biology of relapse is still rudimentary. Our preliminary data indicate that certain gene findings have developed during treatment and might be characteristic of this relapse biology. Therefore, we specifically focus in ongoing translational studies on lymphoma relapse biopsies using highly-annotated clinical data sets. By collaboration with our clinical colleagues we are working on solutions how to develop better outcome predictors and predictive biomarkers that inform on individualized treatment options. These studies encompass biomarker evaluation in Hodgkin lymphoma, follicular lymphoma, large B cell lymphomas, and mantle cell lymphoma.

Teaching
OpenClose

Teaching

Takei, Fumio

Portrait photo of Fumio Takei

Dr.

Takei, Fumio

BSc, PhD

e-mail:

Basic Info
OpenClose

Academic Rank:

Professor, UBC, Distinguished Scientist

Affiliation(s):

BC Cancer Agency

Location:

Terry Fox Laboratory

Short Bio

Dr. Takei received his PhD from the University of British Columbia (UBC) and completed postdoctoral training in Cambridge, England. He then returned to UBC to lead his own laboratory. He has been working on innate lymphocytes for over 30 years. From 1990 to 2010, he mainly worked on natural killer (NK) cell receptors for MHC class I and regulation of NK cell functions and development. In 2010, he found a unique lymphocyte population, which is now termed group 2 innate lymphoid cell (ILC2), in mouse lungs. He showed that lung ILC2s play a key role in allergic lung inflammation. He is currently investigating the regulation of ILC2 functions and functional and developmental relationship between ILC2s and other lymphocytes.

Academic
OpenClose

Academic Backgrounds

  • BSc, University of Tokyo, Tokyo, Japan, Biochemistry. 1968
  • PhD, University of British Columbia, Vancouver, BC, Immunology. 1976
  • Postdoctoral Fellow, University of British Columbia, Microbiology, 1977
  • Postdoctoral Fellow, MRC Laboratory of Molecular Biology, Cambridge, England. 1979

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

Our current researches focus on innate lymphoid cells in mouse lungs. We are investigating the regulation of group 2 innate lymphoid cell functions, their interaction with other cells and their role in allergic lung inflammation.

Dr. Takei received his PhD from the University of British Columbia (UBC) and completed postdoctoral training in Cambridge, England. He then returned to UBC to lead his own laboratory. He has been working on innate lymphocytes for over 30 years. From 1990 to 2010, he mainly worked on natural killer (NK) cell receptors for MHC class I and regulation of NK cell functions and development. In 2010, he found a unique lymphocyte population, which is now termed group 2 innate lymphoid cell (ILC2), in mouse lungs. He showed that lung ILC2s play a key role in allergic lung inflammation. He is currently investigating the regulation of ILC2 functions and functional and developmental relationship between ILC2s and other lymphocytes.

Teaching
OpenClose

Teaching

Yip, Stephen

Portrait photo of Stephen Yip

Dr.

Yip, Stephen

MD, PhD, FRCPC

Basic Info
OpenClose

Academic Rank:

Associate Professor, UBC, Clinician-Scientist/Consultant Neuropathologist, BCCA, Associate Member at Canada’s Michael Smith Genome Sciences Centre, Neuropathologist, VGH

Affiliation(s):

BC Cancer Agency

Location:

VGH/VCHRI

Short Bio

I completed my fellowship training at the Massachusetts General Hospital (MGH) under the supervision of Drs. David Louis and John Iafrate which resulted in a key publication on the mechanism of treatment failure in glioblastoma. Also, ongoing active collaboration with MGH has resulted in additional publications in advanced diagnostics and precision medicine. I am also a contributor to several chapters of the 2016 WHO Classification of Tumours of the Central Nervous System, edited by Dr Louis. Key local collaborators includes Dr Marco Marra, who is also my mentor and with whom I have published over 10 papers in the past six years. We are actively collaborating on elucidating the molecular pathogenesis of glioma, particularly of CIC in oligodendroglioma. In 2012, we had discovered recurrent mutations in this gene in a majority of 1p19q-codeleted, IDH mutated oligodendroglioma. This result was later confirmed in multiple other studies including the TCGA Low Grade Glioma project. I am also collaborating with Dr Marra in the Personalized OncoGenomics (POG) program of which I am leading the pathology effort which is also branching out to involve large scale epigenomics and proteomic investigations. I lead the initial panel sequencing in which I implemented the Ion Torrent AmpliSeq Cancer panel pipeline for the first 120 cases in POG. I was intimately involved in optimizing and improving the assay as well as in the analyzing the data. Results were correlated and validated against whole genome data in each POG case. I also work very closely with Dr David Huntsman and co- authored numerous papers on molecular pathology. We share a strong belief that molecular profiling has an important role in elucidating the mechanism of disease. My qualification as a board- certified neuropathologist with postdoctoral training in molecular experimental neuro-oncology and fellowship training in molecular genetic pathology allows me to contribute in a meaningful way to this grant application. Also, my ongoing involvement with the POG program also gives me a unique perspective on the challenges and promises of genomic- based profiling of pathology tissue particularly in the cost/benefit of panel vs exome vs whole genome sequencing.

Academic
OpenClose

Academic Backgrounds

  • HMS – Molecular Genetic Pathology fellowship. 2009
  • MGH – Molecular neuro-oncology research fellowship (FRCPC certification – CIP). 2008
  • VGH – Neuropathology residency (FRCPC certification). 2006
  • VGH – Neurosurgery residency (year 1-4). 2003
  • BC – MD-PhD (Microbiology & Immunology). 1999
  • UBC – BSc (Microbiology & Immunology). 1991

Awards & Recognition


Selected Publications

Research
OpenClose

Current Openings & Opportunities


Current Projects In My Lab include


Research

  • Brain
  • Brain Cancer
Teaching
OpenClose

Teaching

Jack Calder

Portrait photo of Jack Calder

Jack Calder

Degree Program:

MSc

Date of Entry:

2015-01-05

Basic Info
OpenClose

Academic Rank:

Affiliation(s):

Location:

Vancouver General Hospital (BCCRC)

Supervisor:

Will Lockwood

Short Bio

Academic
OpenClose

Academic Backgrounds

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Teaching
OpenClose

Teaching

Ada Young

Portrait photo of Ada Young

Ada Young

Degree Program:

MSc

Date of Entry:

2014-09-02

e-mail:

Basic Info
OpenClose

Academic Rank:

Affiliation(s):

Location:

Vancouver General Hospital (BCCRC)

Supervisor:

Kevin Bennewith

Short Bio

Academic
OpenClose

Academic Backgrounds

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Teaching
OpenClose

Teaching

Jenna Collier

Portrait photo of Jenna Collier

Jenna Collier

Degree Program:

MSc

Date of Entry:

2015-09-08

Basic Info
OpenClose

Academic Rank:

Affiliation(s):

Location:

Vancouver General Hospital (BCCRC)

Supervisor:

Kevin Bennewith

Short Bio

Academic
OpenClose

Academic Backgrounds

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Teaching
OpenClose

Teaching

Sarah Fernando

Portrait photo of Sarah Fernando

Sarah Fernando

Degree Program:

PhD

Date of Entry:

2012-09-04

e-mail:

Basic Info
OpenClose

Academic Rank:

Affiliation(s):

Location:

UBC Hospital (CBR)

Supervisor:

Neil Cashman

Short Bio

Academic
OpenClose

Academic Backgrounds

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Teaching
OpenClose

Teaching

Sara Saberi

Portrait photo of Sara Saberi

Sara Saberi

Degree Program:

PhD

Date of Entry:

2011-09-06

e-mail:

Basic Info
OpenClose

Academic Rank:

Affiliation(s):

Location:

UBC Hospital

Supervisor:

Helene Cote

Short Bio

Academic
OpenClose

Academic Backgrounds

  • Master of Science in Food Science (Biotechnology), University of British Columbia, 2011
  • Master of Food Science (MFS program), University of British Columbia, 2008
  • Honours BSc in Agricultural Engineering-Food Science and Technology, Azad University, Science and Research Branch, Tehran, Iran, 2006

Awards & Recognition

  • Graduate Student Entrance Scholarship, University of British Columbia. 2011-2012
  • International Partial Tuition Research Award, University of British Columbia, 2008-2011
  • Just Desserts Award , University of British Columbia, 2011
  • First place team member at 2010 CIFST Student Challenge Competition, CIFST, 2010
  • W.D. Powrie Scholarship in Food Science Research, University of British Columbia, 2009
  • Ulrich Freybe Memorial Graduate Prize in Food Science, University of British Columbia, 2009
  • CBR Internal Collaborative Training Awards, Centre for Blood Research, 2012-2013

Selected Publications

Peer-reviewed publications:

  • Saberi S, Cliff MA and Van Vuuren HJJ. Impact of mixed S. cerevisiae strains on the production of volatiles and estimated sensory profiles of Chardonnay wines. Food Research International. Accepted for publication, available online as of June 16th, 2012 http://www.sciencedirect.com/science/journal/aip/09639969

Submitted Manuscript:

  • S. Saberi, M. A. Cliff, & H. J. J. van Vuuren . Impact of mixed S. cerevisiae strains on the production of volatiles and estimated sensory profiles of Chardonnay wines. Submitted to Food Research International.

Published thesis:

  • Saberi, S. Effect of mixed Saccharomyces cerevisiae strains on Chardonnay wine composition. Food, Nutrition and Health Department, UBC, July 2011. (Supervisor: Hennie J.J. Van Vuuren)

Conference Poster:

  • Saberi S, Cliff M, and Van Vuuren, HJJ. Effect of mixed Saccharomyces cerevisiae strains on Chardonnay wine composition. 12th Annual Enology & Viticulture Conference, Penticton, BC, July 2011.
  • Saberi S, Money DM and Côté HCF. Leukocyte telomere length during pregnancy and postpartum in HIV-infected women upon initiation or interruption of HIV antiretroviral therapy, VCH Research Institute Annual Research and Networking Event, Vancouver, BC, May 2012
  • Saberi S, Money DM and Côté HCF. Leukocyte telomere length during pregnancy and postpartum in HIV-infected women upon initiation or interruption of HIV antiretroviral therapy, Pathology Day, UBC, Vancouver, BC, May 2012

Manuscript in preparation:

  • Saberi S, Cliff MA, and Van Vuuren HJJ. Comparison of enological properties of new and existing strains of S. cerevisiae. Prepared for submission to American Journal of Enology and viticulture
Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Teaching
OpenClose

Teaching

Chris Wang

Portrait photo of Chris Wang

Chris Wang

Degree Program:

PhD

Date of Entry:

2015-09-08

Basic Info
OpenClose

Academic Rank:

Affiliation(s):

Location:

Vancouver General Hospital

Supervisor:

Mads Daugaard

Short Bio

Academic
OpenClose

Academic Backgrounds

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Teaching
OpenClose

Teaching

Cederberg, Rachel

Portrait photo of Rachel Cederberg

Cederberg, Rachel

Degree Program:

PhD

Date of Entry:

2017-09-01

e-mail:

Basic Info
OpenClose

Location:

Vancouver General Hospital (BCCRC)

Supervisor:

Kevin Bennewith

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Forgrave, Lauren

Portrait photo of Lauren Forgrave

Forgrave, Lauren

Degree Program:

PhD

Date of Entry:

2017-09-01

e-mail:

Basic Info
OpenClose

Location:

St. Paul’s Hospital

Supervisor:

Mari DeMarco

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Greening, Kendall

Portrait photo of Kendall Greening

Greening, Kendall

Degree Program:

MSc

Date of Entry:

2017-09-01

e-mail:

Basic Info
OpenClose

Location:

Vancouver General Hospital (BCCRC)

Supervisor:

David Huntsman

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Islamzada, Emel

Portrait photo of Emel Islamzada

Islamzada, Emel

Degree Program:

PhD

Date of Entry:

2017-01-01

e-mail:

Basic Info
OpenClose

Location:

UBC Hospital

Supervisor:

Hongshen Ma, Mark Scott

Short Bio
Academic
OpenClose
Academic Backgrounds
Awards & Recognition
Selected Publications
Research
OpenClose
Research

Anam Liu

Portrait photo of Anam Liu

Anam Liu

Degree Program:

MSc

Date of Entry:

2017-09-01

e-mail:

Basic Info
OpenClose

Academic Rank:

Affiliation(s):

Location:

Vancouver General Hospital (BCCRC)

Supervisor:

Andrew Minchinton, Helene Cote

Short Bio

Academic
OpenClose

Academic Backgrounds

Awards & Recognition

Selected Publications

Research
OpenClose

Current Openings & Opportunities

Current Projects In My Lab include

Research

Teaching
OpenClose

Teaching